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ABSTRACT 
 
The temporomandibular joint (TMJ), associated with everyday activities, such 
as chewing, yawning, talking, and laughing, is one of the most complex but least 
studied joints in the musculoskeletal system. Patients suffering from TMJ disorders 
(TMDs) may experience a variety of agonizing symptoms, such as earaches, 
headaches, neck pain, and difficulty opening the mouth, while current treatments are 
inefficacious owing to a poor understanding of TMJ disorder pathologies. Prior to this 
thesis, human umbilical cord mesenchymal stromal cells (hUCMSCs), identified as 
multipotent cells only in this decade, had not yet been used for TMJ tissue 
engineering. Hence, this thesis proposed a revolutionary tissue engineering approach 
in which hUCMSCs and mature hyaline cartilage cells, scaffolds, and growth factors 
were integrated to create TMJ condylar bone and cartilage in vitro to substitute for 
deteriorated native tissues. hUCMSCs were successfully differentiated along 
chondrogenic and osteogenic lineages in a 3D biomaterial-based environment, 
supporting the feasibility of using these cells for TMJ cartilage and bone tissue 
engineering. In TMJ cartilage regeneration, hUCMSCs demonstrated significant 
advantages over both mature TMJ cells and human bone marrow mesenchymal 
stromal cells (hBMSCs), with faster cell proliferation and superior biosynthesis. As 
an additional alternative, hyaline cartilage cells also surpassed TMJ cells in that they 
produced considerably more extracellular matrix. Following the initial efforts, the cell 
culture environment was refined, including cell seeding densities and signaling 
strategies. Higher cell seeding densities (>25 million cells/ml) were recommended for 
 iii
both cartilage and bone tissue engineering, mainly due to their benefits to 
differentiation and biosynthesis. Insulin-like growth factor I (IGF-I) enhanced the 
chondrogenesis of pre-differentiated hUCMSCs while having no effect on 
osteogenically induced hUCMSCs. Therefore, the work on the successful 
differentiation of hUCMSCs in 3D biomaterials has been pioneering, and the culture 
parameters for in vitro TMJ tissue engineering have been refined. Moreover, this 
innovative work has tremendous implications for a broader area (e.g., 
musculoskeletal tissue engineering). 
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CHAPTER 1: Introduction 
 
Temporomandibular joint disorders (TMDs) are a multifactorial and complex 
set of dysfunctional conditions in the area of the jaw joint, with various symptoms 
including headaches, neck pain, and difficulty in daily activities such as eating, 
talking, and yawning. The pathology of TMDs is poorly understood and current 
treatments are inefficient. Tissue engineering, aiming to create a substitute in vitro to 
replace deteriorated temporomandibular joint (TMJ) structures, is an ideal solution to 
these problems. Human umbilical cord mesenchymal stromal cells (hUCMSCs) are a 
multipotent and primitive stromal population with numerous advantages over adult 
stem cells and mature TMJ cells, including inexpensive and painless collection, 
extensive availability, no ethical controversy, no donor site morbidity, and great in 
vitro expansion ability. The overall objective of this strategy was thus to tissue 
engineer cartilage and bone in the TMJ condyle in vitro using hUCMSCs. To achieve 
this goal, three specific aims were designed: 
1) To identify suitable cell sources for engineering the TMJ condylar cartilage: 
To achieve this aim, a comparison was conducted among porcine TMJ condylar 
cartilage cells, porcine hyaline cartilage cells, human bone marrow stromal cells 
(hBMSCs), and hUCMSCs. The hypothesis was that hUCMSCs would outperform 
mature TMJ condylar cartilage cells as a mesenchymal stromal cell (MSC) 
source and that hyaline cartilage cells would outperform TMJ cells as a mature 
autologous cell source.  
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2) To refine culture parameters for engineering the TMJ condylar cartilage using 
hUCMSCs: 
Endeavoring to attain this goal, parameters were refined for cartilage tissue 
engineering in two phases: cell seeding density and growth factor selection. The 
first phase was to select an initial cell seeding density in the scaffolds. The second 
phase was to identify the effects of insulin-like growth factor-I (IGF-I) added after 
the initial chondrogenic differentiation of hUCMSCs using the seeding density 
selected during the first phase. The hypothesis was that a higher seeding density 
(50 million cells/ml), coupled with IGF-I (100 ng/ml), would promote cell 
proliferation and differentiation and extracellular matrix synthesis better than a 
lower density without IGF-I incorporation. 
3) To refine culture parameters for engineering the TMJ condylar bone using 
hUCMSCs: 
Using the osteogenic media for bone tissue engineering, the experimental design 
of Aim 3 was analogous to Aim 2. The hypothesis was that the combination of a 
higher seeding density and a higher IGF-I concentration would enhance 
extracellular matrix synthesis to a greater extent. 
The remaining chapters are organized as follows: 
Chapters 2 − 3 serve as a comprehensive review, providing background 
information for subsequent chapters. In Chapter 2, the recent progress in TMJ 
condyle biology is documented, and the three main factors in TMJ tissue engineering 
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are described: cell sources, growth factors, and scaffolds. In Chapter 3, the biology of 
hUCMSCs and their application in tissue engineering and regenerative medicine are 
discussed, and the rationale for using hUCMSCs for TMJ tissue engineering in this 
thesis is explained.  
In Chapters 4 − 7, the first above-mentioned goal, that is, to select cell sources 
for TMJ condylar cartilage tissue engineering, is fulfilled. Chapter 4 serves as a cell 
biology study, screening different growth factors and glucosamine sulfate with TMJ 
condylar and hyaline cartilage cells in a 2D monolayer environment for the following 
tissue engineering studies. As the criterion, biochemical contents, including cell 
number, glycosaminoglycans (GAGs), and collagen, were evaluated during the 3-
week culture period. Chapter 5 is a side-by-side comparison of TMJ and hyaline 
cartilage cells, with the stimulation of bioactive signals selected from Chapter 4, in a 
3D biomaterial-based environment for TMJ tissue engineering. Biochemical assays 
and immunohistochemical techniques were used to access cell proliferation, matrix 
synthesis, and aggrecan and collagen distribution. Chapter 6 is a comparison of TMJ 
cells and hUCMSCs and serves as the introduction of hUCMSCs to musculoskeletal 
tissue engineering, demonstrating that TMJ cells themselves may be not the best 
option for TMJ tissue engineering. In Chapter 7, hUCMSCs were further compared to 
hBMSCs, the current “gold standard” in musculoskeletal tissue engineering, to 
illustrate that hUCMSCs may be a viable alternative to hBMSCs based on cell 
proliferation, matrix synthesis, and chondrogenic differentiation ability. 
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Chapters 8 − 9 delineate the second above-mentioned goal. In the first phase, 
Chapter 8 investigated the effects of three different seeding densities, 5, 25, and 50 
million cells per ml of scaffolds on hUCMSCs, which provided the critical parameter 
for Chapter 9. Except for the evaluation of biochemical contents and differentiation, a 
compressive mechanical test was used to determine Young’s elastic modulus and the 
relaxation modulus of tissue-engineered constructs. In the second phase, an optimal 
seeding density, determined from Chapter 8, was used to seed hUCMSCs in 
scaffolds, and then a sequential signaling of transforming growth factor beta3 (TGF-
β3) and IGF-I on hUCMSCs was applied. hUCMSCs were exposed to a 
differentiation medium containing TGF-β3 for 3 weeks to induce chondrogenesis and 
then exposed to an anabolic medium containing IGF-I for another 3 weeks to promote 
cell proliferation and matrix synthesis. In addition to biochemical and 
immunohistochemical assays, a real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) was used to evaluate chondrogenic differentiation at a gene level. 
Chapters 10 − 11 focus on the third goal, for which the experimental design 
was analogous to Aim 2. The difference is that osteogenic differentiation of 
hUCMSCs, in place of chondrogenic differentiation in Aim 2, was induced in Aim 3 
for bone tissue engineering. Biochemical assays were used to examine cell number, 
collagen and calcium contents, and alkaline phosphatase (ALP) activity. Histology, 
including Alizarin red S staining and von Kossa staining, was used to visualize the 
mineralization during osteogenesis of hUCMSCs. RT-PCR was used to quantify the 
relative gene expression level of bone-specific markers. The significance of these two 
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studies in Aim 3 was to first demonstrate osteogenic differentiation of hUCMSCs in 
3D biomaterials, thus supporting the feasibility of utilizing these cells for bone tissue 
engineering.  
Chapter 12 is the conclusion, summarizing all the findings and serving as a 
reference for future studies using hUCMSCs. Moreover, the next steps en route to 
TMJ condyle tissue engineering are addressed in this chapter. 
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CHAPTER 2: Tissue Engineering the Mandibular Condyle* 
 
ABSTRACT 
 
Tissue engineering provides the revolutionary possibility for curing 
temporomandibular joint (TMJ) disorders. Although characterization of the 
mandibular condyle has been extensively studied, tissue engineering of the 
mandibular condyle is still in an inchoate stage. The purpose of this review is to 
provide a summary of advances relevant to tissue engineering of mandibular cartilage 
and bone, and to serve as a reference for future research in this field. A concise 
anatomical overview of the mandibular condyle is provided, and the structure and 
function of the mandibular condyle are reviewed, including the cell types, 
extracellular matrix composition, and biomechanical properties. Collagens and 
proteoglycans are distributed heterogeneously (topographically and zonally). The 
complexity of collagen types (including types I, II, III, and X) and cell types 
(including fibroblast-like cells, mesenchymal cells, and differentiated chondrocytes) 
indicates that mandibular cartilage is an intermediate between fibrocartilage and 
hyaline cartilage, with a fibrocartilaginous fibrous zone at the surface being separated 
from hyaline-like mature and hypertrophic zones below by a thin and highly cellular 
proliferative zone. Mechanically, the mandibular condylar cartilage is anisotropic 
under tension (stiffer anteroposteriorly) and heterogeneous under compression 
(anterior region stiffer than posterior). Tissue engineering of mandibular condylar 
cartilage and bone is reviewed, consisting of cell culture, growth factors, scaffolds, 
___________________________________________________________________________________ 
*Chapter published as Wang and Detamore. “Tissue engineering the mandibular condyle,” Tissue Eng 
13, 1955, 2007. (Special Issue on Emerging Technologies and New Basic Science Directions in Tissue 
Engineering.) 
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and bioreactors. Ideal engineered constructs for mandibular condyle regeneration 
must involve two distinct yet integrated stratified layers in a single osteochondral 
construct to meet the different demands for the regeneration of cartilage and bone 
tissues. We conclude this review with a brief discussion of tissue engineering 
strategies, along with future directions for tissue engineering the mandibular condyle. 
 
INTRODUCTION 
 
Temporomandibular joint disorders (TMDs) are a common subgroup of 
orofacial pain disorders, which cause trouble with chewing, swallowing, talking, pain 
and tenderness in the jaw, and even can be relevant to other afflictions, such as 
headaches and neck pain. All of these symptoms can be associated with mandibular 
condyle dysfunctions, including internal derangement, osteoarthrosis and traumas. 
Tissue engineering of the articular cartilage and bone, intending to create an 
osteochondral replacement, offers the opportunity to overcome current surgical 
limitations with both biologically and mechanically functional regeneration. Three 
elements are generally believed to be essential to engineered tissues: cells, signals, 
and scaffolds.1 Cells can be driven by specific bioactive molecules and other physical 
factors to proliferate, differentiate, migrate and secrete the extracellular matrix.2 The 
differentiation of mesenchymal stem cells into chondrocytes and osteoblasts makes it 
possible to culture an osteochondral graft from a single cell source.3-5 The scaffolds 
are central for tissue engineering constructs, which provide the necessary support for 
cells to proliferate and maintain their differentiated functions. In addition, the 
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architecture of scaffolds defines the ultimate shape of the new tissue engineered 
cartilage and bone. Recent emerging scaffold fabrication techniques, including 
electrospinning,6 rapid prototyping,7 fused deposition modeling (FDM),8 and other 
solid free-form (SFF) methods,9-11 have been applied to fabricate complex 
osteochondral scaffolds with controlled degradation rate and specific porosity.  
Tissue engineering the mandibular condyle is not the regeneration of a single 
tissue, but involves two integrated tissues (cartilage and bone) with dramatic 
distinctions in structure and function.12 Ideally, an osteochondral construct in the 
shape of the mandibular condyle would have heterogeneous physical and mechanical 
properties similar to native tissue. The scaffolds would be seeded with chondrocytes 
or chondrogenic cells, and osteoblasts or osteogenic cells to create a functional 
substitute of the mandibular condyle. This review begins with the anatomy of 
mandibular condyles, the characterization of cells and the extracellular matrix, and 
the mechanical properties of mandibular condylar cartilage and the underlying bone. 
The subsequent tissue engineering sections cover the discussion of cell culture 
conditions, growth factors, scaffolds, and bioreactors. 
 
ANATOMY 
 
Numerous studies have been done on the anatomy of human and various 
animal TMJs during the past four decades.13-19 This section provides a concise 
anatomical overview of the mature mandibular condyle. It should be noted that 
growth of the condyle during the postnatal period is accompanied by a significant 
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thickness increase in the fibrous zone and an obvious thickness decrease in the 
hypertrophic zone, with an overall decrease in the cartilage thickness.20 The condyle 
is longer mediolaterally than anteroposteriorly, forming an elliptical shape in the 
transverse plane.14 Anteriorly and posteriorly, the condyle is connected to the disc via 
collateral ligaments, which set a mechanical limitation on anteroposterior disc 
movement. Medially and laterally, the condyle is attached tightly to the capsule and 
disc through the poles of condyle. The mandibular condyle is covered by a zonal 
cartilage layer from the articular surface to the underlying bone, which serves to 
absorb shock and contribute to bone remodeling. There are several zonal 
categorizations of the mandibular cartilage,14, 21-25 which result from subtle 
differences in the cell types and extracellular matrix contents in the different layers. 
The classification scheme of four zones, consisting of the fibrous, proliferative, 
mature, and hypertrophic zones, will be used in this review. Essentially, the 
proliferative zone serves as a separating barrier between the fibrocartilaginous fibrous 
zone and the hyaline-like mature and hypertrophic zones. Below the cartilage is the 
mandibular bone, with cancellous bone covered by a layer of compact cortical 
plate.14, 17 Hansson et al.26, 27 divided the human condyle anteroposteriorly into three 
parts, anterior, superior, and posterior regions, and mediolaterally into four parts, 
lateral, lateralcentral, mediocentral, and medial regions. Anteroposteriorly, the 
thickest region of the mandibular cartilage is the superior area (0.4-0.5 mm). 
Mediolaterally, the cartilage of the healthy human condyle has greater thickness in 
the lateralcentral and mediocentral parts than in the medial and lateral parts. For the 
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underlying bone, the cortical bone is much denser in the lateral region than in the 
medial part of the condyle, which may suggest a greater stress on the lateral part.17 In 
the cancellous bone of the mandibular condyle, the compressive cancellous trabeculae 
are oriented vertically, extending into the cortical bone.17 The tensile cancellous 
trabeculae intersect perpendicularly with compressive trabeculae, forming an 
interconnected architecture that serves an important role in the biomechanical 
properties of the bone.17  
 
STRUCTURE AND FUNCTION OF 
MANDIBULAR CONDYLAR CARTILAGE 
 
Cell type and extracellular matrix  
The articular fibrous zone is comprised of fibroblast-like cells,13, 28 which 
have a flat shape and endoplasmic reticulum surrounded by dense cytoplasm.16 In 
addition to the mitotic activity of the fibroblast-like cells contributing to the growth of 
the fibrous zone,28 the underlying proliferative zone produces cells for the fibrous 
zone.29, 30 However, it remains a question whether the fibrous zone or the proliferative 
zone plays the predominant role in the growth of the cellularity of the fibrous zone.28 
The proliferative zone indeed plays an important role as a cell reservoir, which has 
mesenchymal cells distributed heterogeneously as chondrocyte precursors for the 
underlying zones.15, 31, 32 Thus, it is likely that these mesenchymal cells partly 
contribute to the changes in the thickness and shape of mandibular condylar cartilage 
in adaptation.31 Differentiated chondrocytes are found in the mature and hypertrophic 
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zones, where the degeneration of chondrocytes has been noted closer to the 
subchondral bone.16  
Collagen provides mandibular cartilage with tensile and shear resistance.33 In 
the fibrous zone, collagen fibers are oriented parallel to the cartilage surface but 
angled together to form a sheet-like structure.16, 34 The proliferative zone is composed 
primarily of cellular components and few collagen fibers are observed in this zone.34 
In the mature and hypertrophic zones, the collagen fibers demonstrate a random 
arrangement by crossing each other through a radial orientation.34 Regarding the 
collagen types, collagen type I is found throughout all of the mandibular condylar 
cartilage zones,35 which indicates a key difference between the mandibular articular 
cartilage and hyaline cartilage, the latter of which contains collagen type II 
predominantly. Collagen type II and collagen type X, while absent in the fibrous 
zone, are abundant in the mature and hypertrophic zones.36 
Proteoglycans are glycoproteins that consist of a protein core with covalently 
attached highly anionic glycosaminoglycan (GAG) chains. The primary proteoglycan 
in mandibular condylar cartilage is negatively charged aggrecan, capable of binding 
with a hyaluronan chain to form large aggregates.37 It has been immunologically 
verified that aggrecan is mainly located in the hypertrophic and mature zones.33, 38 
The major function of aggrecan is to provide osmotic swelling pressure to the 
cartilage and enable it to resist compressive forces, which results from the anionic 
character of the GAG chains.33, 38-40 In addition to aggrecan, other proteoglycans, such 
as versican and decorin, have been detected in the mandibular condylar cartilage as 
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well. Versican, consisting exclusively of chondroitin sulfate, was identified in the 
articular fibrous zone33, 38 and in the proliferative zone.38 Decorin, a regulator of 
collagen fibrillogenesis, has been reported in all zones of the rat mandibular condylar 
cartilage.41 
 
Biomechanic 
The mandibular condylar cartilage is a nonlinear viscoelastic material, with an 
initial toe region and a quasi-linear profile under tension.42 Anisotropy of the 
mechanical properties in mandibular condylar cartilage is confirmed by greater 
average tensile strength, tensile stiffness and energy absorption in the anteroposterior 
direction than in the mediolateral direction, but lower average failure strain in the 
anteroposterior direction than in the mediolateral direction.42 The reported Young’s 
moduli in the anteroposterior and mediolateral directions were respectively 9.0 ± 1.7 
MPa and 6.6 ± 1.2 MPa.42  
Kuboki et al.43 investigated the response of the mandibular condyle cartilage-
bone system under compression. Indentation testing demonstrated that the 
deformation pattern of mandibular condylar cartilage was similar to the hyaline 
articular cartilage from the knee or hip joint. The deformation of the cartilage was 
notably associated with magnitude of compression, and was greater in sustained 
compression than in the intermittent compression. Moreover, Hu et al.44 examined the 
compressive properties in different regions of the mature rabbit mandibular condylar 
cartilage using atomic force microscopy, which was divided into the anteromedial 
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(AM), anterolateral (AL), posteromedial (PM), and posterolateral (PL) regions. The 
Young’s moduli (AM>AL>PM>PL) and Poisson’s ratios (AM>AL>PM>PL) for the 
four regions indicated significantly different abilities to resist sustained compression 
among regions. A further study from the same group demonstrated rather uniform 
compressive properties on 7 day old rabbits, revealing the mechanical development of 
the mandibular condyle.45 In a macroscopic indentation study on porcine condylar 
cartilage, Tanaka and colleagues46 discovered that the moduli (dynamic complex, 
storage, and loss) were higher in the anterior region than in the posterior region, in 
agreement with the nanoindentation findings of Hu et al.44 
In summary, the condylar cartilage appears to be anisotropic and 
heterogeneous. It is stiffer anteriorly than anteriorly under compression, and stiffer in 
the anteroposterior direction than in the mediolateral direction under tension. 
 
STRUCTURE AND FUNCTION OF 
MANDIBULAR CONDYLAR BONE 
 
Bone is clearly a distinct connective tissue from the overlying cartilage in 
structure and function. The predominant collagen type in the subchondral bone is type 
I, which is distributed throughout the cancellous and cortical bones. Giesen et al.47 
investigated the mechanical anisotropy of the cancellous bone under compression in 
the human mandibular condyle. The results indicated that the cancellous bone was 3.4 
times stiffer and 2.8 times stronger in axial loading than in transverse loading, which 
was confirmed by micro-computed tomography techniques and finite element 
  
14
modeling.48 The Young’s moduli under the axial and transverse compressive loading 
were 431 ± 217 MPa and 127 ± 92 MPa, respectively.47 Further investigation 
demonstrated that decreased mechanical loading could reduce the density, stiffness, 
and strength of the cancellous bone in the mandibular condyle.49 Regarding the 
properties of the cortical bone, scanning acoustic microscopy revealed that the 
mechanical properties of the cortical bone were transversely isotropic with respect to 
the anteroposterior direction, and the cortical bone in the anteroposterior direction 
was stiffer than in the mediolateral and superiorinferior directions.50 Schwartz-
Dabney and Dechow,51 using ultrasonic techniques, investigated the mechanical 
variations of the cortical bone throughout the human dentate mandible. The elastic 
and shear moduli of the condylar part respectively ranged from 12.2 to 29.8 GPa and 
from 4.9 to 7.7 GPa. 
 
CELL SOURCES FOR MANDIBULAR 
CONDYLE TISSUE ENGINEERING 
 
Cell harvest from the condyle 
Many tissue engineering studies choose mature chondrocytes or osteoblasts 
for cartilage and bone regeneration. The traditional harvest method for articular 
cartilage is that the tissue slices are excised from the cartilage surface, minced with a 
scalpel, and then digested by successive enzymes.52 Takigawa et al.53 developed a 
method for harvesting mandibular condylar cartilage cells, whereby a rabbit 
mandibular condyle and disc were removed as a whole and stored in calcium-free and 
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magnesium-free balanced salt solution (pH 7.4). After the removal of the disc and 
ligament, the mandibular condylar cartilage was separated and minced, then digested 
in collagenase solution. The cells obtained through this method include various cell 
types from the different layers in the mandibular condyle. Another method for 
harvesting chondrocytes is to allow the cells from cultured explants to migrate out 
and grow onto a specific substrate. Subsequently, the cells are released from the 
substrate and suspended in medium. Tsubai et al.54 used this method to isolate the 
fibroblast-like cells from the fibrous zone of a fetal rabbit mandibular condyle. The 
mandibular condyle was collected and then washed in Hanks' Balanced Salt Solution 
(HBSS), and the tip of the condyle was allowed to contact with a gelfoam surgical 
sponge for 1 week. After this period, the gelfoam sponge was treated with 
collagenase to liberate the cells. The cell suspension was centrifuged, and then the 
cells were resuspended in minimum essential medium (MEM). To date, there have 
been no procedures described to isolate either the proliferative cells from the 
proliferative zone or the chondrocytes from the mature and hypertrophic zones for 
tissue engineering studies, although techniques developed for hyaline cartilage could 
perhaps be adapted to condylar cartilage to accomplish this.55, 56 
 
Cell sources 
Differentiated autologous cells for tissue engineering, such as chondrocytes 
and osteoblasts, could raise several problems. First, the patients suffer from donor site 
morbidity.5 Second, in large-scale tissue-engineered constructs, a high initial cell 
  
16
density is necessary to obtain sufficient cartilage and bone for clinical use, which is 
difficult to achieve with autologous articular chondrocytes and osteoblasts.57 
Furthermore, autologous mandibular condylar cartilage cells are not mandatory for 
tissue engineering the mandibular condyle, although the characterization of these 
cells will be valuable for validating engineered constructs. Recent efforts have been 
employed to explore stem cells in tissue engineering applications. Exposed to specific 
growth factors, stem cells, including adult marrow-derived mesenchymal stem cells 
(MSCs), embryonic stem cells (ESCs), and human umbilical cord matrix (HUCM) 
stem cells, have the pluripotent capability of differentiating into multiple cell lineages 
that can result in the formation of cartilage, bone, tendon and other connective 
tissues.58-66 In the United States in 2006, we would argue that MSCs are currently the 
best option because they are autologous, well characterized, and politically benign. It 
has been proven that marrow-derived MSCs have the ability to differentiate into 
chondrocytes and osteoblasts for tissue engineering the mandibular condyle.5, 57, 67, 68 
However, MSCs have their own limitations, such as the limited self-renewal and 
proliferative ability, the decrease in available cell numbers with age, and donor-site 
morbidity.69 It should be noted that an individual would be expected to have an 
adequate number of MSCs to regenerate their own mandibular condyles. ESCs 
demonstrate considerable promise for chondrogenic and osteogenic differentiation 
with self-renewal capacity.61, 62, 69-74 However, tissue engineered constructs from 
donor ESCs could involve immune rejection. HUCM stem cells, which develop from 
extraembryonic mesoderm that forms the umbilical cord matrix, may be a potential 
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alternative to ESCs.75 They have been shown to be multipotential stem cells with 
properties between ESCs and adult stem cells.75-78 There is a lower incidence of graft 
vs. host disease than with bone marrow transplants, and a significant absence of 
major histocompatibility complexes, suggesting that umbilical cord cells may have an 
innate mechanism to evade the immune system.77, 79, 80 Only recently have HUCM 
stem cells been considered for tissue engineering,64-66, 76, 81-83 and for the most part 
have been focused on vascular tissue engineering.65, 81-83 Bailey et al.66 investigated 
the potential of HUCM stem cells in mandibular condylar cartilage tissue 
engineering. The extracellular matrix formation, including collagens types I and II, 
and GAGs, revealed that HUCM stem cells may have the ability to differentiate into 
chondrocyte-like cells. Furthermore, a comparison of HUCM stem cells and 
mandibular condylar chondrocytes demonstrated that HUCM stem cells actually 
outperformed the mandibular condylar chondrocytes, producing higher cell numbers 
and higher collagen and GAG content. In a related study, a German group reported 
that they were able to differentiate HUCM stem cells into cells with osteoblastic 
properties.64 Therefore, HUCM stem cells may be an alternative cell source for 
mandibular condyle tissue engineering, and more broadly for orthopaedic 
osteochondral tissue engineering as well. In summary, although differentiated 
autologous cells and stem cells are acceptable for engineering an osteochondral 
mandibular condyle, stem cells in general may be better candidates, based on the 
inherent limitations of mature autologous cells. While marrow-derived MSCs are 
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currently the preferred type of stem cells for this application, HUCM stem cells and 
ESCs represent a promising alternative for the future. 
 
Cell expansion 
In order to get enough cells for tissue-engineered constructs, the harvested 
cells are usually multiplied and expanded in vitro in cell culture medium. Using 
mandibular condylar chondrocytes, Takigawa et al.53 investigated the effect of the 
initial cell seeding density on cell proliferation in monolayer culture and concluded 
that a high initial cell density benefited cell proliferation. When the initial cell density 
was 2.5x104 cells/cm2, the cells failed to proliferate after 11 days of culture. 
However, after the initial cell density was raised to 5x104 cells/cm2, the cell number 
appeared to increase logarithmically. 
Monolayer expansion is an effective way to obtain adequate cell numbers for 
tissue-engineered constructs. However, the expansion of chondrocytes results in cell 
dedifferentiation with the increase of culture time and passage number,84, 85 which 
will lead to the loss of chondrocyte phenotype and affect matrix synthesis.86, 87 The 
dedifferentiated cells have a fibroblast-like appearance, less production of 
proteoglycans, and a shift of the synthesized collagen types from type II to type I,87 
indicative of fibrous tissue formation. Several studies have shown that hydrogel 
encapsulation can be used successfully as a carrier to foster the phenotype retention 
of chondrocytes and the re-expression of the dedifferentiated chondrocytes harvested 
from the goat knee,84, 85 human femoral condyles,88 and rabbit and human auricular 
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cartilage.88, 89 In addition, a study by Darling and Athanasiou84 demonstrated that an 
aggrecan-coated surface had the ability to retain chondrocyte phenotype in monolayer 
culture, which may be an attractive alternative to hydrogel encapsulation as a means 
to retain phenotype. Recently, Chang et al.90 investigated human mandibular condylar 
chondrocytes in alginate gel beads suspended in culture medium. After 4 weeks of 
culture, most of the cells were round or elliptical, and immunological studies revealed 
the presence of type II collagen and aggrecan, indicating the sustainability of a 
chondrogenic phenotype in alginate with mandibular condylar cartilage cells.  
 
SCAFFOLDS FOR BONE AND CARTILAGE 
TISSUE ENGINEERING 
 
The function of scaffolds in tissue engineering is to provide a mechanical and 
structural support for tissue reconstruction and to serve as a carrier for the cells to 
attach, migrate, proliferate, and differentiate.91 The scaffolds in mandibular condyle 
tissue engineering must fulfill both the biological and mechanical requirements for 
cartilage and bone regeneration. These requirements include high porosity and 
surface area, mechanical stiffness and strength, controlled degradation, and 
biocompatibility for cell growth and extracellular matrix formation. Besides these 
criteria, a craniofacial scaffold must be designed with a complex shape, defined by 
clinical imaging data.10 Several new techniques, such as SFF and electrospinning, 
have been applied to accurately control scaffold dimensions. Using these approaches, 
scaffolds with specific shapes and porosities have been fabricated from a range of 
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biomaterials including hydroxyapatite (HA), tri-calcium phosphate (TCP), HA/TCP 
composites, polyglycolic acid (PGA), poly lactic-co-glycolic acid (PLGA), and 
polypropylene fumarate/tri-calcium phosphate (PPF/TCP) composites.9, 10, 92  
Due to the few scaffold studies on tissue engineering mandibular condylar 
cartilage and bone, a brief review related to general cartilage and bone tissue 
engineering studies will be imperative. Various scaffolds have been fabricated for 
articular cartilage tissue engineering. Synthetic scaffolds include PGA,93 polylactic 
acid (PLA),94, 95 and copolymers of PGA/PLA. The disadvantage of these synthetic 
scaffolds is relatively poor cell adhesion due to the hydrophobic surface. Natural 
scaffolds, such as collagen, fibrin, and chitosan, demonstrate the ability to improve 
cell attachment. Collagen is a natural component of cartilage and a collagen scaffold 
is known to play an important role during cell adhesion as well as chondrocyte and 
osteoblast differentiation.96-98 Surface modification of synthetic biomaterials, with the 
intent to improve adhesion and biocompatibility, has been extensively studied. 
Collagen-coating99 and RGD immobilization100 on the scaffold surface can be 
achieved by chemical techniques.100, 101 The immobilization of RGD peptides on PLA 
and PLGA scaffolds has been shown to promote cell attachment and mineralized 
matrix deposition.100, 102 Detailed reviews of scaffolds for cartilage tissue engineering, 
including relevant hydrogels, can be found in various reviews.103-106  
Scaffolds for bone tissue engineering, also reviewed elsewhere in detail,107-112 
require higher mechanical stiffness. Ceramics, such as hydroxyapatite 
[Ca10(PO4)6(OH)2] and β-tricalcium phosphate [Ca3(PO4)2, β-TCP], are widely used 
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in bone tissue engineering because of their biocompatible and osteoinductive 
properties.110 Synthetic polymers such as poly(ε-caprolactone) (PCL), PGA, 
polyethylene glycol (PEG), and polypropylene fumarate (PPF) could be modified and 
optimized to meet specific demands. The mechanical properties of polymers in 
general, however, must be improved for bone tissue engineering. Nanofiber scaffolds 
are emerging with the use of electrospinning techniques. To date, PCL, PLA, PGA, 
and PLGA have been fabricated via electrospinning methods.6, 113-116 These 
nanofibers form nonwoven meshes to provide enhanced mechanical properties such 
as tensile strength and elasticity as well as enhanced cell attachment due to 
similarities between the nanofiber and native ECM.101 Shin et al.117 examined 
nanofibrous PCL using MSCs in vivo and found that cells and ECM formation were 
observed throughout the constructs. In addition, mineralization and type I collagen 
were also detected.117 Referring back to cartilage tissue engineering, Li and 
coworkers118 found that nanofibrous PCL acted as a biologically preferred 
scaffold/substrate for proliferation and maintenance of the chondrocyte phenotype in 
comparison to monolayer culture. 
 
EFFECTS OF GROWTH FACTORS ON 
MANDIBULAR CONDYLAR CELLS 
 
Jiao et al.119 found that 10 ng/ml bFGF had the greatest stimulatory effect on 
the proliferation of mandibular condylar chondrocytes compared to 10 ng/ml TGF-β 
and 10 ng/ml insulin-like growth factor-I (IGF-I) in both low serum (0.4% newborn 
  
22
calf serum) and high serum conditions (10% serum) in monolayer culture. At the low 
serum concentration, the groups treated with bFGF had a moderate increase in cell 
numbers, while the effects of TGF-β and IGF-I demonstrated no statistically 
significant differences in comparison to the control group. At the high serum 
concentration, all three growth factors promoted cell proliferation, with an increase of 
65% with bFGF, 24% with IGF-I, and 13% with TGF-β compared to the control 
group. The synergetic effect of these three growth factors was also reported in this 
study. The combination of IGF-I, bFGF and TGF-β, the combination of IGF-I and 
bFGF, the combination of TGF-β and bFGF, and the combination of TGF-β and IGF-
I increased cell proliferation by 68%, 66%, 65%, and 57%, respectively, compared to 
the control group. The fact that the combinations that included bFGF had greater cell 
numbers indicated that bFGF seemed to be the leading effective factor in the 
synergetic promotion of proliferation. Besides the investigation of the isolated 
mandibular condylar cells, the effect of bFGF in the explant culture of mandibular 
condylar cartilage was studied. Fuentes et al.120 demonstrated that bFGF promoted 
cell proliferation with a 43% increase in cell number after 2 days of mandibular 
condylar explant culture in serum-free DMEM medium. Delatte et al.121 examined 
biosynthesis in addition to proliferation, reporting that bFGF stimulated cell 
proliferation while it inhibited GAG and collagen synthesis after 2 weeks of 
mandibular condylar explant culture, with Iscove's Modified Dulbecco's Medium 
(IMDM) supplemented with 0.1% bovine serum albumin (BSA). This study also 
revealed that bFGF inhibited the effect of IGF-I on GAG production. Recently, an 
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inhibitory effect of bFGF on chondrogenesis in the mandibular condyle was reported 
when fetal rat condylar explants were cultured in serum-free modified Fitton-Jackson 
BGJb medium.122 After 2 days of explant culture, the group treated with bFGF in the 
perichondrium had lower cell numbers than the untreated groups. After 5 days, the 
hypertrophic chondrocyte number in the bFGF-treated condyle was less than in the 
untreated groups as well. 
Regarding IGF-I, Yang et al.123 investigated its effect on the proliferation of 
cultured mandibular condylar chondrocytes at six concentrations (1, 5, 10, 50, 100, 
500 ng/ml). After a 24-hr period, the proliferation at all concentrations was enhanced 
in comparison to the control group, and the highest concentration led to the greatest 
cell proliferation. With rat condylar explant culture, Fuentes et al.120 demonstrated 
that an increased cell proliferation elicited by IGF-I was greater than with bFGF or 
TGF-β. Delatte et al.124 demonstrated that not only could cell proliferation be 
increased, but also the production of GAG and collagen could be up-regulated 
significantly by IGF-I in rat condylar explant culture. Delatte et al.121 also reported 
that the increases in cell proliferation and GAG synthesis stimulated by IGF-I were 
greater than TGF-β and bFGF in newborn rat condylar explant culture. Furthermore, 
local injection of IGF-I into rat mandibular condylar cartilage confirmed the positive 
effect of IGF-I on cell proliferation and matrix synthesis by increasing the thickness 
of the cartilaginous layer.125 
TGF-β has an inhibitory or stimulatory effect on cell growth and extracellular 
matrix formation, depending on the serum concentration in the culture medium. Song 
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et al.126 examined the effect of TGF-β on rat mandibular condylar cells in DMEM 
medium with 15% fetal bovine serum. The fourth passage chondrocytes were divided 
into 20 groups with four different TGF-β concentrations (0, 0.1, 1, and 10 ng/ml) for 
0, 6, 12, 18, and 24 hrs. Cell proliferation was evaluated by the proliferative index 
(PI). For each concentration group, the PI increased between 0 and 18 hrs and 
demonstrated a decreasing trend between 18 and 24 hrs. The PIs of all concentration 
groups were higher than the control group between 0 and 24 hrs. The PI increased 
with increasing concentration during all time periods. This study used fourth passage 
chondrocytes as a cell source in order to get enough cells; however, future phenotype 
research may be warranted to compare the result to lower passage cells since 
chondrocytes appear to lose their phenotype after several passages.85 In a related 
study, Jiao et al.119 found that TGF-β had an inhibitory effect on mandibular condylar 
chondrocyte proliferation with low bovine serum concentration (0.4%), and had a 
stimulatory influence with high bovine serum concentration (10%) after 3 days of 
culture. With respect to explant culture of mandibular condyles of newborn rats in 
IMDM medium supplemented with 0.1% BSA, TGF-β did not promote cell 
proliferation and collagen production, although 10 ng/ml TGF-β upregulated GAG 
content with a 23% increase relative to the control group.121  
Tsubai et al.54 investigated the effect of epidermal growth factor (EGF) on the 
mandibular condylar explants of fetal rabbits and on isolated fibroblast-like cells from 
the fibrous zone. For the isolated fibroblast-like cells, EGF accelerated the cell cycle 
in contrast with the control group. For explant culture, the cell numbers in all zones 
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were higher with the stimulation of EGF in comparison with the control group. 
However, the absolute cell numbers decreased with time with respect to initial cell 
numbers, which indicated that the mitosis of cells gradually decreased as the fetal 
period ended. Moreover, the thicknesses of the fibrous zone and hypertrophic zone 
with the EGF group were significantly greater than the initial thickness due to the 
increase of extracellular matrix. 
For bone tissue engineering, growth factors are not only needed to promote 
osteogenic regeneration, but also to support vascularization. Extensive reviews of the 
effects of growth factors on bone regeneration have been made by Zhang et al.,127 
Mistry and Mikos,110 and Gittens and Uludag.128 BMPs, the most common cytokines 
of the TGF superfamily, stimulate osteogenic differentiation of MSCs and 
proliferation of osteoblasts. BMP-2 and BMP-7, the most extensively studied BMPs, 
can induce endochondral bone formation in numerous primate models.128 TGF-β can 
promote the proliferation of osteoblasts, although it could also enhance bone 
resorption at certain concentrations.110 Platelet-derived growth factor (PDGF) has 
been shown to promote bone regeneration only when combined with IGF-I or 
dexamethasone.129-131 Other growth factors such as IGF-I and FGFs have multifaceted 
regulatory effects on bone formation, and further investigation is needed.132-134  
In summary, bFGF at high serum concentration is the best stimulator of 
proliferation in mandibular condylar chondrocytes, followed by IGF-I. IGF-I is a 
potent promoter of cell proliferation and biosynthesis, especially GAG production. 
TGF-β can induce biosynthesis significantly, including GAG and collagen formation. 
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However, further investigation of the mechanism of the effect of serum concentration 
in TGF-β treated medium on cell proliferation is needed to resolve inconsistencies 
between studies. EGF is a potent inducer of proliferation in fibroblast-like cells 
isolated from the fibrous zone. Therefore, a combination or sequence of bFGF and 
IGF-I may be an advisable choice for both cell proliferation and biosynthesis with 
mature condylar cartilage cells. A combination of different factors may be required 
with stem cells, promoting proliferation, then moving to differentiation and matrix 
synthesis. Finally, given that these growth factors each have different effects on bone 
and cartilage, perhaps a specific growth factor, such as IGF-I, could be delivered to 
an osteochondral construct, promoting the growth of bone and cartilage in their 
respective capacities. 
 
BIOREACTORS FOR CARTILAGE AND BONE 
TISSUE ENGINEERING 
 
The purpose of a bioreactor for tissue engineering is to enhance cell growth 
and the formation of extracellular matrix by creating a dynamic and controlled 
environment. The primary focus of this section in our review is on mass transfer 
bioreactors. The driving force for mass transfer in static culture is passive molecular 
diffusion, which can lead to undesirable nutrient and waste gradients and a resulting 
heterogeneity. The enhanced mass transfer within bioreactors strives to promote 
uniform distribution of cells in the scaffold, exchange of nutrients and wastes 
between cells and culture medium, and mechanical stimulation of cell growth. 
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According to the magnitude of the shear force that bioreactors create, a bioreactor can 
be classified as high-shear or low-shear.135 High shear force can be achieved by 
mixed flasks, orbital shakers and direct perfusion bioreactors. Low shear force can be 
obtained using rotating wall bioreactors. The following paragraphs will provide a 
recapitulative overview of current representative bioreactors for cartilage and bone 
tissue engineering, including stirred spinner flasks, direct perfusion bioreactors, and 
rotating wall bioreactors, which will be followed by a brief mention of mechanical 
stimulation bioreactors. 
In the stirred spinner flask, a magnetic stir bar at the flask bottom drives fluid 
flow, which can dramatically improve the exchange rate of oxygen and nutrients 
between the medium and the inner scaffold, and can thus result in more cells and 
extracellular matrix in the central section of scaffolds than with static culture.136  
Although the increase of mixing intensity may enhance cell proliferation and 
biosynthesis, it could increase the release of GAG from the tissue construct.137 For 
bone tissue engineering, Meinel et al.138 examined MSC-derived osteoblasts in 
spinner flasks and found that the scaffolds in the spinner flask contained more cells 
and mineralized matrix than those in static culture or in the perfusion system. The 
velocity field created by the vortex of the stir bar was non-uniform, as the cells and 
matrix on the surface were exposed to a greater shear force than internally.136 Due to 
greater mechanical stimulation on the surface, accumulation of mineralized matrix at 
the periphery was found in bone tissue engineering using the spinner flask.138 
Similarly, in cartilage tissue engineering, a thick fibrous capsule was seen 
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surrounding the scaffolds and native tissue explants in the stirred spinner flask after 6 
weeks of in vitro culture, despite the fact that continuous cartilaginous matrix was 
formed in the inner scaffold.139, 140 It should be noted that spinner flask seeding 
requires that the constructs are skewed on a wire, resulting in a hole in the constructs. 
Perhaps due in part to this inherent limitation, spinner flasks are primarily used for 
cell seeding.  
In rotating bioreactors, the medium consisting of cell-seeded scaffolds is filled 
either in a single cylinder or between two concentric cylinders, where the objective is 
to suspend constructs in perpetual free fall, such that they are relatively stationary 
with respect to an observer.135, 136, 141 The laminar flow in the rotating wall bioreactor 
generates a low shear force, which is much lower than other types of bioreactors, in 
an effort to stimulate cell proliferation and biosynthesis and to avoid the shear-related 
damage to cell growth. Increased GAG and collagen content has been reported for 
cartilage regeneration in rotating wall bioreactors.140, 142-144 With the culture time 
increasing up to 7 months, the GAG content has achieved the same wet weight 
fraction as explanted native cartilage.145 However, a study by Detamore and 
Athanasiou141 demonstrated the neutral performance of a rotating bioreactor in tissue 
engineering with the TMJ disc. They found that the rotating bioreactor did not induce 
uniform distribution of extracellular matrix or a significant increase in total matrix 
content and compressive stiffness in comparison to static culture, although a dense 
matrix and cellular composition was reported in the rotating bioreactor. It was 
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suggested that a static culture period of 3-4 weeks prior to bioreactor use may lead to 
improved results with the rotating bioreactor.  
In comparison with spinner flasks and rotating wall bioreactors, mass 
transport in perfusion bioreactors is especially enhanced in the interior scaffold with 
the forced flow penetrating the scaffold pores.135, 146, 147 Whereas spinner flasks and 
rotating bioreactors replenish the surrounding medium to maintain maximum 
concentration gradients and thus to facilitate passive diffusion, perfusion bioreactors 
impart a pressure gradient to drive nutrient and waste transport via convection. 
Perfusion of a scaffold seeded with chondrocytes has been shown to upregulate cell 
growth and extracellular matrix biosynthesis in a time-dependent and velocity-
dependent manner,148, 149 and to promote better distribution of cells throughout the 
constructs as well.147 For bone marrow stromal osteoblasts in the perfusion system, 
significantly more mineralized matrix deposition accumulated on titanium fiber 
meshes150 and PLLA scaffolds151 after 16 days in comparison to static culture, with 
the increased shear force from perfusion not only accelerating mineralized matrix 
deposition but also improving extracellular matrix distribution. In an experiment by 
Sikavitsas et al.,150 change of shear force was achieved by changing the viscosity of 
the fluid at a constant fluid superficial velocity. The double and triple of the viscosity 
resulted in a 4-fold and 7-fold increased mineralized matrix deposition, respectively. 
Although uniform distribution of mineralized matrix was reported by Meinel et al.,138 
they found that the perfusion bioreactor provided reduced proliferation and 
mineralized matrix deposition compared to the spinner flask configuration, where the 
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mineralized matrix mainly formed at the outer rim of the collagen scaffold. A couple 
of potential limitations with perfusion bioreactors are that unidirectional flow could 
result in the alignment of cells and extracellular matrix parallel with the flow 
direction,148 and that dense matrix formation can result on the surface facing the 
oncoming medium flow.135 A possible solution might be oscillating perfusion 
bioreactors, in which the medium flow direction would reverse at a specific 
frequency.152 In our group, we are exploring intermittent perfusion as another 
alternative, whereby uncoupling mass transport and shear stress may lead to the 
greatest overall benefit.  
Mechanical stimulation as a secondary phenomenon, such as shear stress in 
bioreactors, may regulate cell differentiation and extracellular matrix synthesis. 
Generally, chondrocytes and osteoblasts respond to specific magnitudes and 
frequencies of mechanical loading with increased cell proliferation and 
biosynthesis.147 Mechanical load may also modulate cell adhesion.153, 154 Mechanical 
stimulation bioreactors in cartilage regeneration rely on direct compression, shear 
stress, or hydrostatic pressure, which have been reviewed by Darling and Athanasiou 
in detail.155 With bone regeneration, a pair of reviews has been provided by Hughes-
Fulford156 and Anselme.153 Generally speaking, oscillatory stimulation has proven 
most effective for both cartilage and bone regeneration, with a notable exception 
being TMJ disc cells.157 Future work in this field may look to develop new 
bioreactors to combine these mechanical stimuli with current mass transfer 
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bioreactors, in an effort to provide multiple stimuli to maximize the stimulatory effect 
on cell growth and matrix synthesis.135  
Although bioreactors provide a stimulatory dynamic environment for tissue 
regeneration, parameters such as the mixing intensity, rotation rate and perfusion rate 
are still far from being optimized. The traditional trial-and-error approach is time 
consuming for multiple changes of operation conditions. Modeling of bioreactor 
environments, involving computational fluid dynamics, may improve bioreactor 
designs significantly.158 Venkat et al.159 investigated hydrodynamics in the impeller 
region of spinner-flask bioreactors using particle tracking velocimetry. Full 
experimental and computational fluid models for spinner flasks were established by 
Sucosky et al.160 and Bilgen et al.161 The velocity field was measured by particle-
image velocimetry followed by the calculations of shear-stress field, flow periodicity, 
Reynolds-stress field and turbulence-intensity field according to the distribution of 
velocity. For rotating-wall perfused-vessel bioreactors, Begley and Kleis162 developed 
a mathematical model originating from the momentum and continuity equations, 
which were solved by numerical methods. The fluid dynamics and shear stress were 
characterized in the bioreactor, and then validated by experimental data with less than 
5% difference. To enhance the understanding of tissue growth in the scaffold in 
response to mechanical shear stress in the rotating wall bioreactor, mathematical 
models of tissue growth were introduced by Lappa163 to explain the interplay between 
increasing tissue size and the structure of the flow field, and to predict tissue growth 
and progression of extracellular matrix deposition under the stimulation of fluid shear 
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stress. In a perfusion system, the dynamic environment was characterized to evaluate 
the effect of different parameters such as scaffold porosity and flow rate on the local 
shear stress distribution in the perfused scaffold.164 The simulation results 
demonstrated that the pore size influenced the predicted shear stress level, whereas 
the porosity was related to the statistical distribution of the shear stresses.164 
In summary, bioreactors can lead to significantly improved cell proliferation 
and biosynthesis. In comparison to spinner flasks, rotating and perfusion bioreactors 
generally appear to provide more uniform distribution of cells and extracellular 
matrix. However, the spinner flask is an effective cell seeding method for controlled 
cell density and uniform cell distribution.165 Although there are no direct comparisons 
between rotating and perfusion bioreactors, the forced flow in perfusion bioreactors 
leads to better mass transfer than with rotating bioreactors, which perhaps may be 
advantageous in producing osteochondral tissues in a full-scale. In addition, the 
development of modeling bioreactors will provide accurate parameters for building 
and operating bioreactors.  
 
TISSUE ENGINEERING THE MANDIBULAR 
CONDYLE 
 
Whereas characterization of the native condyle began more than four decades 
ago, tissue engineering of the mandibular condyle is in its infancy, with fewer than 20 
condylar tissue engineering studies published, all in this decade.5, 9-11, 57, 68, 91, 92, 166-172 
An early attempt conducted by Weng et al.91 produced a homogenous PGA/PLA 
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scaffold in the shape of the human mandibular condyle for mandibular condylar 
reconstruction. The scaffold was seeded with osteoblasts harvested from bovine 
periosteum-derived explant culture, and bovine chondrocytes from the forelimbs were 
painted onto the scaffold surface as a cartilage layer. 12 weeks of implantation 
demonstrated that the scaffold maintained the condylar shape, and an interface was 
formed between the bone and cartilage. The significance of this study was in 
demonstrating the feasibility of creating the tissue engineered mandibular condyle in 
the form of two stratified layers using differentiated autologous cells. Histology was 
used in this study in lieu of quantified biochemical assays, thus cell numbers, GAG 
content, and collagen content data were not available. 
Ueki et al.169 implanted a PLGA and gelatin sponge complex (PGS) following 
condylectomy in rabbits. Three groups were compared: PGS without BMP-2, PGS 
with BMP-2, and the control. After 24 weeks, the new tissue in the control group was 
composed of a mixture of fibrous tissue, fibro-cartilage and hypercellular cartilage, 
without new bone formation. In both PGS groups, the growth of bone and cartilage-
like tissue was observed with hematoxylin-eosin staining. Although BMP-2 was 
considered to be an osteoinductive signal, no significant differences were found 
between the PGS and BMP-treated PGS groups. Essentially, the cartilage-like and 
bone tissue were derived from MSCs in the underlying bone marrow. In order to 
enhance tissue regeneration, it was recommended that PGS be seeded with MSCs 
before implantation. This study also revealed that a PGS complex could be a good 
candidate for tissue engineering, because both PGS with or without BMP-2 could 
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induce the formation of cartilage-like and bone tissues. A concern here was that the 
new tissue regenerated in this way had a mixture of cartilage and bone together as 
opposed to cartilage and bone located in separate layers. 
Subsequent research was focused intensively on seeking new cell sources and 
on developing osteochondral scaffolds. Abukawa et al.168 seeded MSCs into PLGA 
scaffolds in the shape of the mandibular condyle, which were prepared by the 
particulate-leaching technique. 6 weeks of in vitro culture in a rotational bioreactor 
revealed the presence of osteocytes and bone matrix. Similar studies conducted by 
Chen et al.167, 170 demonstrated the feasibility of using porous natural coral seeded 
with MSCs for bone regeneration with the evidence of bone neogenesis in condylar-
shaped scaffolds. The significance of both studies was to reveal osteogenesis of 
MSCs in 3D scaffolds while the scaffolds maintained the original shape. However, 
both studies focused on only bone tissue engineering in a single scaffold. 
Furthermore, Mao and colleagues5, 57, 67, 68, 171 differentiated MSCs into chondrocytes 
and osteoblasts, which were seeded in different layers of a PEG-based hydrogel 
fabricated by photopolymerization. The osteogenic and chondrogenic cells were 
entrapped in the PEG-based hydrogel suspension, and then sequentially loaded into a 
hollow human mandibular condyle-shaped polyurethane mold and photopolymerized. 
After 4 weeks of in vivo implantation, histology showed that the chondrogenic layer 
had scattered chondrocyte-like cells and intercellular matrix, and the osteogenic layer 
contained osteoblast-like cells in island-like structures. The results of these studies 
showed the possibility of engineering the mandibular condyle in the shape of the 
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human mandibular condyle from a single population of bone marrow-derived 
chondrogenic and osteogenic cells.  
With respect to the development of new scaffolds, image-based design (IBD) 
and SFF were introduced by Hollister and colleagues9-11, 92, 166, 172 to design and 
fabricate craniofacial composites with specific physical and mechanical properties, 
which included not only the specific shape and porosity, but also the desired elasticity 
and permeability. PCL scaffolds have been fabricated successfully via selective laser 
sintering (SLS), an indirect SFF method, in the mandibular condyle shape with 
mechanical properties similar to trabecular bone.11 These scaffolds were seeded with 
bone morphogenetic protein (BMP) transduced fibroblasts, and after implantation into 
mice for 5-8 weeks, bone formation was verified by histological staining and CT 
scans. Furthermore, a PLA/HA composite was fabricated for tissue engineering the 
mandibular condyle.172 The PLA and HA scaffolds were designed and fabricated to 
meet the different requirements of the regeneration of cartilage and bone, and were 
joined tightly with PLA rods. This composite was seeded with chondrocytes in the 
polymeric PLA phase and transduced fibroblasts with BMP-7 in the ceramic HA 
phase. 4 weeks of in vivo culture in mice demonstrated GAG formation, indicated by 
Safranin O staining in the polymeric layer, and bone formation with marrow space in 
the ceramic layer, as indicated by hematoxylin and eosin (H&E). The advantage of 
IBD and SFF is that accurate control over biomaterials made the patient-specific 
scaffolds possible and allowed more detailed experiments to build optimized 
scaffolds. 
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To the best of our knowledge, to date, there is only one study using a 
bioreactor to tissue engineer the mandibular condyle. As we discussed earlier, 
Abukawa et al.168 cultured MSC-derived osteoblasts in a rotational bioreactor system. 
The PLGA scaffolds were seeded with osteoblasts and placed in gas-permeable 
centrifuge tubes, which rotated for 6 weeks at 6 rpm. A layer of new tissue-
engineered bone, consisting of cells and densely staining osteoid, was formed 
uniformly on the surfaces of the constructs. In the internal section, osteocytes and 
bone matrix were observed. This important study will lead the way for future 
bioreactor studies in mandibular condyle tissue engineering. 
 
DISCUSSION AND CONCLUSIONS 
 
A tissue-engineered osteochondral mandibular condyle construct would be a 
promising and improved treatment for severe TMJ disorders. A schematic of our 
approach to tissue engineer the mandibular condyle, which will eventually be 
combined with a tissue engineered disc,173 is provided in Fig. 2.1. Chondrocytes and 
osteoblasts can be either directly harvested, or indirectly derived from stem cells, 
such as ESCs, bone marrow-derived MSCs or HUCM stem cells. Passaging these 
cells is imperative for obtaining sufficient cell numbers for large scale cell seeding. 
Then these cells can be seeded statically or dynamically into 3D scaffolds as a 
stratified cartilage layer and bone layer. The shape of these scaffolds can be pre- 
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Figure 2.1: Schematic of our strategy to tissue engineer the mandibular condyle. 
First, the product must be developed in vitro (static or bioreactor) or in vivo, 
and compared to the native condyle. This developed technology in clinical 
application may then be combined with an engineered TMJ disc to treat 
patients with severe TMJ disorders. 
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defined according to clinical imaging data and fabricated with desired porosity to 
meet the mechanical strength and biological function requirements. Optimized 
selection of the types, concentrations and timing of growth factors can accelerate the 
proliferation of chondrocytes and osteoblasts and the formation of extracellular 
matrix. Further culture of cells in the scaffolds can be achieved in vitro (static or 
bioreactor) or in vivo. Bioreactors are recommended because they can not only 
enhance the mass transfer of nutrients and wastes, but also provide mechanical 
stimulation as a means to not only promote biosynthesis, but also to facilitate matrix 
organization and consequently improve mechanical function. Finally, the biologically 
and mechanically functional comparison between tissue engineered products and 
native tissue will be necessary as validation before clinical application, emphasizing 
the need for native characterization data.  
En route to tissue engineering a functional mandibular condyle, a number of 
challenges need to be considered. A native tissue characterization of the mandibular 
condyle, including both the surface cartilage and underlying bone, should be 
examined systematically for tissue engineering studies. Further investigation should 
focus on quantification of biochemical compositions in the cartilage. Age-related 
variations of these compositions should go to further the understanding of the 
adaptation to specific biomechanical loading.22 The molecular level mechanism of 
growth factors on chondrocytes and osteoblasts must be further investigated to 
conciliate conflicting results in previous studies. Understanding how cells respond to 
exogenous growth factors will be critical not only for the selection of growth factors, 
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but also for the usage of the optimized dosage for maximized benefit to cell 
proliferation and biosynthesis. Due to the insufficient mass transfer within large 
scaffolds, the scale-up of osteochondral constructs may be limited by the inability to 
achieve homogenous cell densities and maintain cell viability and differentiated 
function in the dimensions of the human condyle. 
Although tremendous strides have been made for both cartilage and bone 
regeneration, tissue engineering of osteochondral tissues is still in its infancy. Only 
recently has the musculoskeletal tissue engineering community begun to 
acknowledge the significance of osteochondral tissue engineering, which is not 
merely a simple combination of cartilage and bone tissue engineering. Osteochondral 
tissue engineering is an “autocatalytic” process in the sense that the mutually 
inductive nature of chondrocytes and osteoblasts push the other down their respective 
lineages, which may be a missing key ingredient in the isolated approaches of 
engineering cartilage or bone alone. Gerstenfeld et al. 174 strongly supported this 
point, demonstrating that only co-culture with chondrocytes (as opposed to 
osteoblasts and fibroblasts) was successful at promoting osteogenesis of 
mesenchymal stem cells. We are aware of only a select number of groups who have 
published osteochondral tissue engineering studies, and methodologies vary widely.3, 
5, 8, 68, 91, 171, 175-182 Some groups have used mesenchymal stem cells,3, 5, 68, 171, 176, 177, 181 
while others relied on differentiated cartilage and/or bone cells.8, 91, 178-180 From the 
viewpoint of translational research, a single stem cell source may offer advantages 
over obtaining both bone and cartilage biopsies from a patient. With respect to growth 
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factors, it is necessary to further examine the synergistic effect since the regeneration 
of the complex tissue may require the combination of several growth factors. With 
respect to scaffolds, it is essential to improve the design and fabrication techniques of 
osteochondral scaffolds to make a multilayered composite, with controlled spatial 
distribution of physical and mechanical properties in two layers for cartilage 
regeneration and bone formation. Moreover, there is no easy solution to integrating 
the two layers, and researchers should be commended for their creative approaches 
heretofore, which include layering of chondro- and osteo-induced regions,5, 8, 68, 171 
painting chondrocytes onto an osteoblast-containing construct,91 suturing179 or press-
fitting180, 181 the two layers together, use of a fibrin sealant3 to adhere the two, and 
simply relying on in vivo conditions.176, 177 In addition, the cartilage layer would 
ideally resemble zonal organization in native cartilage,183 and vascularization within 
the osseous portion of the construct is still a challenge, which depends on the 
regeneration of blood vessels.  
As TMJ tissue engineering progresses, we must be cognizant of practical 
issues with clinical application on the horizon. Attaching engineered tissues in this 
highly complex joint will not be an easy feat. For example, surgeons may prefer to 
attach an engineered TMJ disc to an engineered condyle rather than attempt to attach 
it to the existing condyle in certain cases, as making the challenging medial 
attachments to an existing degenerated condyle may not be an attractive option. 
Nevertheless, attaching the engineered disc and condyle will be a challenge, as will 
connecting surrounding soft tissues and anchoring the engineered condyle to the 
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ascending ramus. We urge the TMJ tissue engineering community to keep these 
factors in mind as the field matures, such that we can prepare for these clinical 
hurdles. 
In conclusion, the ultimate goal of tissue engineering the mandibular condyle 
is to reconstruct a functional replacement equivalent to the native tissues in cellular 
and biochemical composition and organization, and in biomechanical properties and 
behavior. The native tissue characterizations of mandibular condylar cartilage and 
bone must be investigated further to provide a basis for tissue engineering design and 
validation. The cell sources are not limited to autologous differentiated cells, as 
MSCs, ESCs and HUCM stem cells are promising choices. Despite the abundance of 
growth factor studies, inconsistencies must be resolved, and both synergistic and 
sequential effects need to be identified to engineer the mandibular condyle. We must 
emphasize the need to design and fabricate seamless stratified osteochondral 
constructs as a single unit. Furthermore, it may be advantageous for investigators to 
develop composite mechanical stimulation and mass transfer bioreactors for tissue 
engineering osteochondral tissues. The end goal is to create an engineered condyle 
that a surgeon could affix to the ascending ramus of the mandible, and perhaps attach 
to an engineered disc and to existing and/or engineered attachment tissues. This 
combination of engineered tissues would be a revolutionary treatment to a community 
of TMJ surgeons and patients desperate for answers. 
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CHAPTER 3: Tissue Engineering with Human Umbilical 
Cord Mesenchymal Stromal Cells* 
 
ABSTRACT 
 
Multipotent mesenchymal stromal cells (MSCs) hold tremendous promise for 
tissue engineering and regenerative medicine, yet with so many sources of MSCs, 
what are the primary criteria for selecting leading candidates? Certainly the cells of a 
given source must be multipotential, and ideally will be inexpensive, easy and 
painless to collect, readily available in large numbers, immunocompatible, free of 
ethical controversy (politically benign), developmentally primitive, expandable in 
vitro for several passages, and obtained without donor site morbidity. Bone marrow 
MSCs do not meet all of these criteria, neither do embryonic stem cells. However, a 
promising new cell source is emerging in tissue engineering that appears to meet all 
of these criteria: umbilical cord mesenchymal stromal cells (UCMSCs). UCMSCs are 
derived from the Wharton’s jelly of umbilical cords, the jelly-like connective tissue 
supporting the umbilical vessels. Exposed to appropriate culture conditions, UCMSCs 
differentiate along several cell lineages such as the chondrocyte, osteoblast, 
adipocyte, myocyte, neuronal, pancreatic, or hepatocyte lineages. In animal models, 
hUCMSCs demonstrate great immunocompatibility with host organs/tissues, even in 
xenotransplantation, although it is unlikely that immunocompatibility is retained after 
differentiation or activation. However, UCMSCs can be banked at birth, as is 
commonly done with cord blood today, and accessed either as an autologous cell 
source or as a tremendous resource of MHC-matched allogeneic cells. Cumulatively, 
_________________________________________________________________________________ 
*Chapter submitted to Tissue Eng Part B as Wang, Seshareddy, Weiss, and Detamore. “Tissue 
engineering with human umbilical cord mesenchymal stromal cells,” August 2008. 
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the advantages of UCMSCs render them an attractive source of multipotent cells for 
tissue engineering applications. In this review, we address their cellular 
characteristics, multipotent differentiation ability and potential for tissue engineering 
with an emphasis on musculoskeletal tissue engineering.  
 
INTRODUCTION 
 
Increased efforts have been employed in the identification of cell sources that 
can be utilized for tissue engineering and regenerative medicine.184-186 Multipotent 
mesenchymal stromal cells (MSCs) reside in a variety of tissues, such as bone 
marrow, adipose tissue, blood, synovial fluid, dermis, muscle, dental pulp, and can 
differentiate along several mesenchymal lineages such as cartilage, bone, and adipose 
tissue.187-193 However, there are significant differences in their proliferation and 
differentiation abilities, and harvesting procedure among these MSCs,194 which may 
limit their application in tissue engineering. In recent years, the Wharton’s jelly (WJ) 
of human umbilical cords has been discovered as a reservoir of MSCs.195 Cells 
isolated from WJ are referred to as umbilical cord mesenchymal stromal cells 
(UCMSCs) in the following sections. Recent evidence supports that human UCMSCs 
(hUCMSCs) are a multipotent stromal cell population that share MSC surface 
markers such as CD73, CD90, and CD105, and are non-hematopoietic cells.196  
Before the 21st century, umbilical cord research focused on the structure of 
umbilical cords and the characterization of extracellular matrix and stroma cells as 
early as the 1940s.197, 198 Following the recognition of their neural differentiation 
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ability demonstrated early in the current decade,75 hUCMSCs have evoked a rapidly 
growing interest with over 30 studies published during the last 5 years.64, 75-77, 80, 81, 186, 
195, 196, 199-220 It has been reported that hUCMSCs can differentiate along several cell 
lineages in all three germ layers including chondrogenic, osteogenic, adipogenic, 
myogenic, pancreatic, neurogenic, and hepatogenic.75, 81, 195, 199, 215 In vivo 
transplantation of these cells has been demonstrated to prevent progressive 
deterioration with brain injury and to rescue the eye from retinal disease in a rodent 
model.213, 214 Recent tissue engineering studies with hUCMSCs have focused on 
cardiovascular tissue engineering,65, 81, 82, 205, 221, 222 and on musculoskeletal tissue 
engineering.66, 207 In this review, we have emphasized the mesenchymal 
differentiation of hUCMSCs and their potential for musculoskeletal tissue 
engineering. Cell biology and transplantation reviews of hUCMSCs can be found in 
detail in the literature.196, 200, 223  
 
CELL CHARACTERIZATION 
 
The human umbilical cord includes one vein, two arteries, and a surrounding 
connective tissue known as Wharton’s jelly (Fig. 3.1). The connective tissue may be 
divided into three zones: subamniotic, intervascular, and perivascular stromata.195 
hUCMSC-like cells, called prechondrocytes, were isolated by McElreavey et al.224 in 
the early 90s using the explant method. Enzyme digestion of trypsin and/or 
collagenase has been recently utilized to extract hUCMSCs with fast isolation and 
high yield.76, 77, 80, 195 UCMSCs include cells from all three stromata, and the 
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umbilical cord perivascular cells, obtained via enzyme digestion of the area 
surrounding umbilical vessels, may isolate a subpopulation.77, 218, 225 hUCMSCs 
resemble fibroblasts in their morphology (Fig. 3.1) and have been defined as 
myofibroblasts based on their positive expression of vimentin, desmin, and/or α-
smooth muscle actin (ASMA) in native tissue or with in vitro cultured  
 
 
Figure 3.1: Structure of umbilical cords (UC) and differentiation schematic diagram 
of human mesenchymal stromal cells (hUCMSCs). 
 
cells.75, 226, 227 In a recent review,196 UCMSCs were proposed to be a primitive stromal 
population that possess characteristics of bone marrow MSCs (BMSCs) defined by 
the International Society for Cellular Therapy (ISCT).196 hUCMSCs express surface 
markers that have been identified in other MSCs, including CD10,80 CD13,80, 199, 204, 
208 CD29,76, 80, 204, 208 CD44,76, 77, 80, 195, 199, 204, 208 CD49e,80, 225 CD51,76 CD73/SH3,76, 
77, 195, 199, 204 CD90 (Thy-1),77, 80, 199, 208, 225 CD105/SH2,76, 77, 80, 195, 199, 204 CD106,204 
CD117,75, 77, 199 CD146,225 CD166,199, 204, 208 and HLA-1/HLA-ABC;77, 80, 204, 208 and 
are negative for hematopoietic markers (e.g., CD14, CD31, CD34, CD38, CD45, 
HLA-DR).64, 65, 75-77, 80, 81, 83, 195, 199, 201, 204, 208, 209, 225 On the other hand, hUCMSCs 
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express pluripotency markers such as Oct-4, Nanog, and Sox-2 at the transcription 
level in porcine umbilical cord cells, although at a lower level than embryonic 
tissues,201 indicating that hUCMSCs may have a subpopulation that share properties 
of both pluripotent and non-pluripotent stem cells.201 The perivascular cells express 
STRO-1 (~1%),225 an MSC surface marker that has been used to enrich fibroblast 
colony-forming units (CFU-F) cells from bone marrow.228 Therefore, hUCMSCs 
present adherent cells with a non-hematopoietic and non-endothelial (CD34 negative) 
phenotype and share a similar set of surface markers with other adult MSCs. 
hUCMSCs demonstrate the ability to differentiate along several cell lineages 
of mesodermal origin and along a neural lineage of ectodermal origin (Fig. 3.1).75, 81, 
195, 199 Furthermore, recent studies reported that hUCMSCs were able to differentiate 
both in vivo and in vitro into hepatocyte-like cells and pancreatic islet precursors of 
endodermal origin.199, 215 Exposed to a hepatogenic culture medium, hUCMSCs 
expressed hepatic markers including albumin, α-fetoprotein, cytokeratin-19, 
connexin-32, and dipeptidyl peptidase IV.199 This study provided the foundation for 
the application of hUCMSCs for liver regeneration. Work from Chao et al.215 
suggests that UCMSCs may be differentiated into pancreatic islet precursors, produce 
human insulin, and respond to a glucose challenge for up to 12 weeks in a 
xenotransplantation type I DM model. As a fetal-derived cell source, hUCMSCs have 
a rapid proliferation rate with shorter doubling time than other adult stem cells.196 
Following cell harvesting, hUCMSCs can be passaged for 7 times to achieve a 300-
fold increase in cell number while the differentiation potential is maintained.195 The 
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rapid proliferation rate, accompanied by the wide availability of umbilical cords, is 
highly desirable for tissue engineering as it is possible to obtain a large number of 
cells in a short time. 
 
DIFFERENTIATION AND TISSUE 
ENGINEERING 
 
Chondrogenic differentiation and cartilage tissue engineering 
Cartilage, which plays a critical role in load bearing and distribution, has 
limited self-regeneration capabilities after injury. Compared to the current clinical 
approaches such as microfracture, artificial prosthesis, and cell-based implantation, 
tissue engineering may be an ideal method to fully restore the cartilage function.229 
Cell dedifferentiation of mature chondrocytes during monolayer expansion makes it 
difficult to obtain enough cells for tissue engineering.85 Thus, the application of 
MSCs in tissue engineering is promising mainly due to their self-renewal and 
differentiation ability. Chondrogenic differentiation of MSCs can be triggered by the 
transforming growth factor-β isoforms (TGF-β1, β2, and β3) and be enhanced by the 
addition of dexamethasone.230-232 Insulin-like growth factor-I (IGF-I), an important 
anabolic agent, remains controversial with its role in chondrogenic differentiation.232-
234 However, a recent study reported that IGF-I and TGF-β had equal 
chondroinductive ability with MSCs after the removal of insulin from insulin-
transferrin-selenious acid Premix (ITS Premix), a substitute for FBS in serum-free 
chondrogenic medium.234  
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Like other MSCs, hUCMSCs are able to differentiate along a chondrogenic 
lineage under the stimulation of TGF-βs in 3D cell pellets and polyglycolic acid 
(PGA) scaffolds.66, 76, 195, 225, 235 In the late 1990s, Naughton et al.235 reported the 
chondrogenic differentiation of hUCMSCs on 3D PGA scaffolds in a conference 
abstract. Exposed to TGF-β for 6 weeks, constructs formed a dense fibrocartilage-like 
tissue with both types I and II collagen. The significance of the study is that it was not 
only the first to report the chondrogenic differentiation of hUCMSCs in biomaterials, 
but also to suggest their potential for cartilage tissue engineering. In the following cell 
pellet studies, the chondrogenic ability of hUCMSCs was also supported by Alcian 
blue staining for glycosaminoglycans (GAGs),76, 225 and immunohistochemical 
staining for type II collagen.76, 195 However, the chondrogenic studies of hUCMSCs 
have had inconsistent results in the literature.76, 195 In a study by Wang et al.,76 
untreated cells in the control group (no TGF-β1) also demonstrated positive staining 
for GAGs and collagen type II. In contrast, no type II collagen was observed with the 
control group in a study by Karahuseyinoglu et al.,195 although only a trace of type II 
collagen was detected with human BMSCs (hBMSCs), in contrast to the formation of 
abundant type II collagen in previous hBMSC studies.58, 236 Type I collagen was also 
identified in this study in both hBMSCs and hUCMSCs. Nevertheless, larger pellets 
were observed in the hUCMSC group with a better filamentous extracellular matrix 
than hBMSCs.195, 225 Moreover, the GAG quantification revealed that the perivascular 
cells, a subpopulation of hUCMSCs, produced a quantity of GAGs comparable to 
hBMSCs after 21 days, although the perivascular groups had fewer GAGs than 
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hBMSC groups during the first week. Therefore, the better differentiation ability 
compared to hBMSCs and the co-existence of types I and II collagen in both cell 
pellets and biomaterial-based culture indicate that hUCMSCs may be considered as a 
MSC source for fibrocartilage tissue engineering applications such as for the 
temporomandibular (TMJ) disc, intervertebral disc, and knee meniscus. In our group, 
following the initial effort in cartilage tissue engineering by Naughton et al.,235 we 
applied hUCMSCs for musculoskeletal tissue engineering.  
The first full-length study of hUCMSCs for musculoskeletal tissue 
engineering was a comparison of hUCMSCs to TMJ condylar cartilage cells in vitro 
for TMJ regeneration.66 Both types of cells were cultured in PGA scaffolds over a 4-
week period. The hUCMSC constructs formed a fibrocartilage-like tissue similar to 
the native TMJ cartilage and outperformed TMJ condylar cartilage cells with higher 
cellularity and biosynthesis of collagen and GAGs. Based on the limited availability 
of TMJ cells relative to umbilical cord cells and the superior biosynthesis of 
hUCMSCs, hUCMSCs were suggested as a promising alternative to mature condylar 
cartilage cells for TMJ tissue engineering. In a 3D comparison of hUCMSCs and 
hBMSCs for cartilage tissue engineering, hUCMSCs also demonstrated superior 
extracellular matrix synthesis with more GAGs and collagen than hBMSCs 
(unpublished data). We further explored cell seeding density for fibrocartilage tissue 
engineering using hUCMSCs.207 hUCMSCs were seeded in PGA scaffolds at 5 (low), 
25 (middle), or 50 (high) million cells/ml of scaffold. After a 4-week culture period, 
the high and medium density groups possessed significantly higher cell numbers and 
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extracellular matrix content per construct and per cell than the lower density group. 
More importantly, constructs in the high and medium density groups maintained their 
mechanical integrity, which was confirmed by unconfined compression testing. 
Therefore, a seeding density greater than 25 million cells/ml was recommended for 
related future fibrocartilage tissue engineering studies. In a parallel study 
(unpublished data), we revealed that a sequential signaling strategy, switching from a 
chondrogenic signal (TGF-β3) to an anabolic agent (IGF-I) in the middle of the 
culture period, promoted cartilage-like matrix synthesis and type II collagen gene 
expression better than continuing with TGF-β3 alone throughout the culture period.  
In summary, the formation of fibrocartilage-like tissue in cell pellet culture 
and biomaterial-based tissue engineering studies indicates that hUCMSCs may be an 
excellent cell source candidate for fibrocartilage regeneration. In addition, a further 
modified chondrogenic environment, perhaps including the investigation of factors 
such as bioactive chemical signals (e.g., growth factors, aggrecan), oxygen tension, 
co-culture, mechanical stimulation and/or in vivo regulation, will be needed to 
enhance chondrogenesis to apply hUCMSCs in hyaline cartilage tissue engineering. 
 
Osteogenic differentiation and bone tissue engineering 
Unlike cartilage, bone is a vascularized tissue with an innate self-healing and 
remodeling ability.237 Although bone defects can be treated by autologous bone 
grafts, the current gold standard, this method is limited by donor site morbidity, 
malformation and infection.238 Moreover, there is no satisfactory treatment for some 
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severe bone injuries.111 As a tissue engineering approach, BMSCs can be 
incorporated into biomaterials for direct implantation, with or without prior in vitro 
culture in osteogenic media. A typical osteogenic medium includes osteogenic signals 
of dexamethasone and/or BMP-2, in addition to β-glycerophosphate and ascorbic acid 
to aid in matrix synthesis. Exposure of BMSCs to this medium before implantation 
allows the delivery of more mature osteogenic cells to defects and thus accelerating 
the in vivo bone regeneration.111  
To date, there have been no 3D bone tissue engineering studies published with 
UCMSCs. However, osteogenic induction of hUCMSCs in 2D (monolayer) has been 
accomplished by treatment with dexamethasone and β-glycerophosphate.76, 77, 195, 204, 
208, 225 During the course of osteogenic differentiation in monolayer culture, positive 
alkaline phosphatase (ALP) activity was observed,76, 77, 225 osteopontin gene 
expression was confirmed,76, 204 the bone-specific immunostaining of osteonectin, 
osteocalcin and bone sialoprotein-2 was visualized,195 and mineralization was verified 
by von Kossa staining and Alizarin red staining.76, 77, 195, 204, 208 Like hBMSCs, 
mineralization was observed with hUCMSCs in 2-weeks76, 195, 204, 208 and similar side-
by-side gene expression was also observed during this period.204 It appears that 
hUCMSCs had less mineralization than hBMSCs as evidenced by Alizarin red 
staining.195 However, perivascular cells from the umbilical cord demonstrated better 
osteogenic potential with higher ALP activity and richer bone-specific extracellular 
matrix than both BMSCs and the whole population of hUCMSCs.77, 225 Exposed to 
osteogenic medium, the perivascular cells differentiated faster along the osteogenic 
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lineage with the formation of bone nodules after only 4-5 days.77 When hUCMSCs 
were cultured for 7 days in monolayer with a medium containing osteoinductive 
biomaterials such as demineralized bone matrix,239 their proliferation was inhibited, 
their morphology appeared shortened and flattened, and ALP activity increased 
significantly. These phenomena indicated that hUCMSCs may differentiate along the 
osteogenic lineage,239 while long-term culture will be needed to verify the presence of 
late stage osteogenic markers.  
Therefore, in monolayer culture, hUCMSCs demonstrate osteogenic 
differentiation ability after exposure to chemical signals and osteoinductive 
biomaterials, and perivascular cells appear to exhibit superior osteogenesis compared 
to hUCMSCs and hBMSCs. The osteogenic differentiation in 3D biomaterials is still 
unexplored in the literature and future tests are warranted to utilize hUCMSCs for 
bone tissue engineering. In fact, in our group (unpublished data), hUCMSCs did 
differentiate along the osteogenic lineage when placed in poly(L-lactic acid) (PLLA) 
and PGA scaffolds. Osteogenic differentiation was concluded based on ALP activity, 
collagen production, and calcium deposition, which were greater with higher cell 
seeding densities. In the future, it will be valuable to make a 3D osteogenic 
comparison among hUCMSCs, the perivascular cells, and hBMSCs. Moreover, in 
vivo studies and methods to improve osteogenic differentiation will be high priority 
areas of future investigation. 
 
Undifferentiated hUCMSCs and cardiovascular tissue engineering 
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Detailed reviews regarding the application of hUCMSCs in cardiovascular 
tissue engineering can be found in the literature,240, 241 so only a brief overview will 
be provided here. hUCMSCs were utilized for cardiovascular tissue engineering prior 
to the identification of multipotent differentiation,81 and in subsequent studies have 
been shown to be a suitable cell source for this application.65, 82, 205, 221, 222 In 
monolayer culture, undifferentiated hUCMSCs expressed a positive staining of 
ASMA and vimentin with the deposition of types I and III collagen in 2 weeks in a 
culture medium containing only Dulbecco’s Modified Eagle’s Medium and 10% fetal 
bovine serum, which was phenotypically similar to the native cells in heart valve 
leaflets.81 This similarity provided the rationale for using these cells for 
cardiovascular regeneration.81 The culture of hUCMSCs on 3D PGA/poly-4-
hydroxybutyrate (PGA/P4HB)65, 81, 82, 205, 222 or P4HB221 scaffolds produced a layered 
tissue with types I and III collagen, GAGs, elastin, and a mechanical stiffness 
comparable to native cardiovascular tissue. These tissue-engineered constructs can be 
endothelialized under cyclic strain with human umbilical cord blood endothelial 
progenitor cells (UC-EPCs) to provide a functional endothelial layer.205 Hence, the 
approach using hUCMSCs for cardiovascular tissue engineering is attractive, since 
UC-EPCs can also be obtained at birth along with the hUCMSCs. This alone, will not 
solve the problem of tissue rejection. However, if the umbilical cord is collected from 
children who have a congenital heart defect, then UC-EPCs and UCMSCs can be 
used to construct bilaminar constructs. 
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Adipose differentiation and tissue engineering 
Traditional autologous fat tissue transplantation suffers from the loss of graft 
volume with time.242 When tissue engineering is applied to adipose tissue 
regeneration, the usage of mature adipocytes is limited by the inferior in vitro 
proliferation and expansion ability of these cells, and stem cells thus have been 
proposed.243 Adipose differentiation of hUCMSCs has been induced in monolayer 
culture by dexamethasone, insulin, indomethacin, and isobutylmethylxanthine, and 
has been verified by lipoid deposits that were detected by Oil Red O staining.76, 195, 204, 
208, 225 Following adipogenic differentiation, adipose-related genes, such as 
peroxisome proliferator-activated receptor γ 2 (PPARγ2),76 lipoprotein lipase,204 and 
plasminogen activator inhibitor-1 (PAI-1),195 were detected in hUCMSCs by RT-
PCR. Compared to hBMSCs, hUCMSCs took a longer period to achieve adipose 
differentiation (40 days vs. 21 days, respectively).195 A similar observation has been 
made between fetal MSCs and adult MSCs. In addition, hBMSCs formed more 
homogeneous lipid droplets and had a more round morphology than the 
hUCMSCs.195 However, in a 2-week study by Lu et al.,204 no significant difference 
was found in the percentage of adipogenic positive cells between hUCMSCs and 
hBMSCs (69.4% vs. 57.3%, respectively). In another study,219 after long-term 
exposure to adipogenic medium, 90% of hUCMSCs differentiated toward the 
adipogenic lineage and formed mature adipocytes. Therefore, the adipose 
differentiation ability of hUCMSCs makes them a promising alternative to autologous 
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fat cells for adipose tissue engineering, despite the fact that hUCMSCs have not yet 
been used for adipose tissue engineering. 
 
ESCS AND BMSCS 
 
An ideal cell source for tissue engineering should satisfy requirements 
including ease of access, sufficient cell number and immunocompatibility. Mature 
autologous cells have commonly been used in previous studies, due to the advantages 
of already being differentiated and immunocompatibility. In contrast to mature 
autologous cells, ESCs are a major area of contemporary research interest, and offer 
significant potential to treat or even cure a plethora of diseases. They can differentiate 
into a wide range of cell lineages in all three germ layers, such as hematopoietic cells, 
insulin-secreting cells, and keratinocytes, which BMSCs may not be able to 
differentiate into or are inefficiently differentiated into. The self-renewal ability of 
ESCs also allows a large number of undifferentiated cells to be produced for tissue 
engineering applications. However, ESCs suffer from a series of constraints including 
in vitro culture, political concerns, availability, difficulty in obtaining a viable line, 
and potential immunorejection. Although induced pluripotent (iPS) cells have the 
potential to overcome the immunorejection obstacle,244, 245 a great deal of work 
remains before they can be developed into a safe therapy in humans. 
BMSCs are the most extensively investigated MSCs for tissue engineering 
applications and have been considered as the “gold standard” cell source in 
musculoskeletal tissue engineering. In bone marrow, MSCs create a 
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microenvironment for hematopoiesis and also provide a stem cell reservoir for bone 
repair and turnover. BMSCs have the ability to differentiate in vitro and in vivo into 
several connective tissues such as cartilage, bone, and adipose tissues. The main 
advantage of using BMSCs is to provide an autologous cell source for tissue 
engineers to avoid potential immunorejection. They are also easy to access, but have 
limited self-renewal ability. hBMSCs are the first stem cell source that were used via 
a tissue engineering approach to treat bone defects in clinical studies.246, 247 In a 7-
year clinical trial,246, 247 porous ceramic scaffolds seeded with undifferentiated, in 
vitro-expanded autologous hBMSCs were implanted to treat a large bone (4-8 cm) 
defect. After 5–7 months, the implants were completely integrated together with the 
host bone and no post-surgery complications were observed in all 3 patients. In the 7th 
year follow-up,247 this integration was maintained and no further fractures were 
observed. This pilot study demonstrated the feasibility of a tissue engineering 
approach in human bone regeneration with long-term durability, which provided a 
substitute method for autologous bone grafts. However, there are some known 
hurdles which limit the applications of BMSCs. The relative number of hBMSCs in 
the marrow, their proliferation ability, and their differentiation potential decrease 
significantly with age.248 Moreover, the invasive harvesting procedure may lead to 
complications and morbidity.249  
 
DISCUSSION, CONCLUSION AND FUTURE 
DIRECTIONS 
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In this review, hUCMSCs were introduced to the tissue engineering 
community as an alternative to mature cells, ESCs, and BMSCs, with clear 
advantages over each (Table I). Practically speaking, hUCMSCs are much easier and 
less expensive to harvest and culture. In addition, hUCMSCs are less controversial in 
the current political climate than ESCs. In terms of availability and harvesting 
efficiency, hUCMSCs offer a major advantage over ESCs, as there is an endless 
supply of umbilical cords and hUCMSCs can be prepared from close to 100% of cord 
samples. With regard to their self-renewal ability, hUCMSCs, as fetus-derived MSCs, 
have a better in vitro expansion capability than adult stem cells, perhaps due to their 
longer telomeres.250 The rapid proliferation rate compared to BMSCs and their 
extensive availability make it possible to obtain a tremendous number of hUCMSCs 
cells in a short time (orders of magnitude larger than BMSCs) to meet the need of 
tissue engineering applications. As for their differentiation ability, hUCMSCs have 
been shown to differentiate along mesenchymal lineages and cross germ layer 
boundaries. With regard to their immunocompatibility, hUCMSCs thus far appear to 
be more immunocompatible than ESCs.251, 252 hUCMSCs can be also used as an 
autologous MSC source, which can be cryogenically frozen, and thus it is possible to 
avoid immunorejection. Even if evidence of immunogenicity is discovered after 
differentiation,253 allogeneic hUCMSCs would be a viable option with the availability 
of cord cell banks, as routine tissue-typing (HLA/MHC matching) with a tremendous 
donor selection would be straightforward and would thus reduce any potential 
immunogenicity along with immunosuppressants, as is done for transplant patients 
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(but without waiting indefinitely for a donor). Nevertheless, as an allogeneic source, 
hUCMSCs have demonstrated their immunocompatibility and even 
immunosuppressive nature in animal models.77, 78, 80, 216, 217, 254 In xenotransplantation 
studies, UCMSCs survived without immune response and displayed a rescue 
phenomenon in retinal and Parkinson’s disease.78, 213 The immunogenicity of 
hUCMSCs was only observed in one study after repeated injection of hUCMSCs into 
in the same diseased region.254 With all of these characteristics, we believe that 
hUCMSCs will be a suitable, attractive, and potentially preferred cell source for 
tissue engineering.  
Table I: Criteria for cell source selection in tissue engineering 
Factor Mature BMSCs ESCs* UCMSCs 
Large supply (availability)    X 
Easy to obtain and to use X X  X 
Low immunogenicity X X  X 
Politically non-controversial X X  X 
Pluripotent  X X X 
No donor site morbidity   X X 
Developmentally primitive cells   X X 
Multiple passaging   X X 
BMSC = bone marrow mesenchymal stromal cell, ESC = embryonic stem cell, 
hUCMSCs = umbilical cord mesenchymal stromal cell 
* = includes embryonic germ cells 
 
Although it is still unclear whether hUCMSCs are a true stem cell population 
due to no available evaluation of their long-term engraftment or in vivo differentiation 
and self-renewal ability in the literature,196 hUCMSCs can differentiate into various 
cell lineages and have great in vitro expansion ability, which certainly support the 
contention that these cells may indeed act as true stem cells. En route to the 
application of hUCMSCs in tissue engineering, a number of concerns remain to be 
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addressed, including cell-biomaterial surface interaction, cell culture environment, 
and safety. Tissue engineering strategies require hUCMSC to adhere efficiently to 
biomaterials. Indeed, high seeding efficiency with hUCMSCs, coupled with fast 
proliferation, can reduce the quantity of cords and the cost of culture reagents 
significantly. Tissue engineering strategies also require an optimal culture 
environment that can maintain cell growth, differentiation potential, phenotype, and 
genomic stability.255 Currently, the most common medium for hUCMSCs involves 
the usage of bovine serum which may cause disease transmission and the immune 
reaction to foreign proteins. As tissue engineering using hUCMSCs is translated into 
clinical practice, a serum-free medium may be preferred to avoid these problems. In 
fact, a low-serum medium has been successfully used to culture hUCMSCs. It 
includes only 2% bovine serum, 1X serum substitute (ITS), and growth factors 
containing epidermal growth factor (EGF) and platelet-derived growth factor 
(PDGF).80 In this medium, cells grew robustly and most of the initial surface markers 
were maintained after 4 passages. In the future of clinical practice, human autologous 
serum may be an option to replace this 2% animal serum, although clearly a serum-
free medium would be ideal. Moreover, to engineer large-scale tissues, typical scale-
up problems need to be addressed as the diffusion of nutrients and wastes is hindered 
in large constructs.256  
In conclusion, UCMSCs represent an exciting MSC source for tissue 
engineering applications with clear advantages over other cell sources including but 
not limited to the ease to access, extensive availability (e.g., 4.1 million births in the 
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United States alone in 2005257), non-invasive harvesting, and in vitro expansion 
ability. Investigations of hUCMSCs in cartilage and cardiovascular tissue engineering 
have shown encouraging results based on the in vitro evaluation, and in vivo tissue 
engineering studies of hUCMSCs are warranted en route to clinical trials. Following 
the current successes in cartilage and cardiovascular tissue engineering, we believe 
that hUCMSCs have the potential to be successfully used in other tissue engineering 
areas such as adipose, bone, and neural tissue. Future work should include the 
optimization of cell culture environment, scaffold design, and bioreactor 
development, all of which can be integrated in stem cell-based tissue engineering 
strategies toward clinical application.  
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CHAPTER 4: Effects of Growth Factors and Glucosamine 
on Porcine Mandibular Condylar Cartilage Cells and 
Hyaline Cartilage Cells for Tissue Engineering 
Applications* 
 
ABSTRACT 
 
Temporomandibular joint (TMJ) condylar cartilage is a distinct cartilage that 
has both fibrocartilaginous and hyaline-like character, with a thin proliferative zone 
that separates the fibrocartilaginous fibrous zone at the surface from the hyaline-like 
mature and hypertrophic zones below. In this study, we compared the effects of 
insulin-like growth factor-I (IGF-I), basic fibroblast growth factor (bFGF), 
transforming growth factor beta1 (TGF-β1), and glucosamine sulfate on porcine TMJ 
condylar cartilage and ankle cartilage cells in monolayer culture. In general, TMJ 
condylar cartilage cells proliferated faster than ankle cartilage cells, while ankle cells 
produced significantly greater amounts of glycosaminoglycans (GAGs) and collagen 
than TMJ condylar cartilage cells. IGF-I and bFGF were potent stimulators of TMJ 
cell proliferation, while no signals statistically outperformed controls for ankle cell 
proliferation. IGF-I was the most effective signal for GAG production with ankle 
cells, and the most potent upregulator of collagen synthesis for both cell types. 
Glucosamine sulfate promoted cell proliferation and biosynthesis at specific 
concentrations and outperformed growth factors in certain instances. In conclusion, 
hyaline cartilage cells had lower cell numbers and superior biosynthesis compared to 
TMJ condylar cartilage cells, and we have found IGF-I at 100 ng/mL and 
____________________________________________________________________________________ 
*Chapter published as Wang and Detamore. “Effects of growth factors and glucosamine on porcine 
mandibular condylar cartilage cells and hyaline cartilage cells for tissue engineering applications,” Arch 
Oral Biol, Epub ahead of print, 2008. 
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glucosamine sulfate at 100 μg/mL to be the most effective signals for these cells 
under the prescribed conditions. 
 
INTRODUCTION 
 
Temporomandibular joint (TMJ) condylar cartilage is categorized as 
secondary cartilage formed by periosteum or endosteum. It has both 
fibrocartilaginous and hyaline-like character, with a thin proliferative zone that 
separates the fibrocartilaginous fibrous zone at the surface from the hyaline-like 
mature and hypertrophic zones below. The complexities of TMJ condylar cartilage 
distinguish it from both well-characterized hyaline cartilage and the TMJ disc, which 
we have investigated before.258, 259 There are only three studies from a single group 
about the differences between the cell types from hyaline cartilage and TMJ condylar 
cartilage, all of which investigated the effects of growth factors on cell behavior in rat 
explant culture.35, 121, 124 The first study found that the DNA content with TMJ 
condylar cartilage was significantly increased by 25 ng/mL IGF-I, while the femoral 
head cartilage was not affected. The second and third studies revealed that three 
growth factors, bFGF, IGF-I and TGF-β1, stimulated higher cell proliferation in the 
TMJ condylar explants than in the femoral head explants, while no significant 
difference in GAG content was discovered between these two types of cartilage.  
Glucosamine remains virtually untested in tissue engineering applications, 
with the exception of a few recent studies that presented conflicting results. Some 
studies revealed that glucosamine did enhance GAG260, 261 and collagen262, 263 
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synthesis, and upregulate the gene expression of aggrecan260, 262, 263 and type II 
collagen262, 263 in a concentration-dependent manner. However, other studies seem to 
suggest that its effects are mostly based on inhibiting catabolic activities rather than 
on anabolic ability to rebuild cartilage, indicated by the down-regulation of aggrecan 
and type II collagen.264, 265 To date, there have been no studies that have investigated 
the effects of glucosamine on TMJ condylar cartilage cells. The goal of the current 
study was to examine the in vitro effects of glucosamine sulfate and three growth 
factors, namely bFGF, IGF-I and TGF-β1, on proliferation and extracellular matrix 
synthesis of cells obtained from porcine TMJ condylar and ankle cartilage. 
 
MATERIALS AND METHODS 
 
Cell isolation 
One head and two ankles were obtained from the same hog (Chester white 
breed, female, age 8 months), acquired from Santa Fe Trail Meats (Overbrook, 
Kansas, USA). TMJ condylar cartilage cells and ankle hyaline cartilage cells were 
harvested by enzyme digestion.66 Briefly, for each cell type, two joints were sterilized 
using an iodine pad, the joint capsule was broken, and cartilage was obtained and 
minced. Following enzyme digestion overnight, the cells were resuspended, and 
cultured in the flasks containing cell culture medium consisting of Dulbecco’s 
modified Eagle medium (Invitrogen; Carlsbad, CA), 10% fetal bovine serum 
(Gemini; West Sacramento, CA), 25 μg/mL ascorbic acid (Sigma; St. Louis, MO), 
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1% non-essential amino acids (Invitrogen) and 1% penicillin-streptomycin-fungizone 
(Invitrogen). Cells were fed every other day until confluent and labelled as passage 1.  
 
Growth factor 
All growth factors were purchased from PeproTech, Inc. Cells were seeded in 
12-well plates at 150,000 cells/cm2 with 1 mL of medium per well. A total of 12 
groups (n = 4) were examined for each cell type, consisting of three growth factors 
tested at two concentrations each, glucosamine tested at five concentrations, and one 
control group (cell culture medium without growth factors or glucosamine). No 
synergistic effects were investigated. IGF-I and bFGF were each examined at 10 and 
100 ng/mL,259 TGF-β1 was examined at 5 and 30 ng/mL,259 and D-glucosamine 6-
sulfate was examined at 0.02, 0.1, 20, 100, and 700 μg/mL (corresponding to 0.08, 
0.39, 77.2, 385.8 and 2700.3 μM). Half of the media was changed every two days for 
3 weeks of culture.  
 
Measurement of cell number and biosynthesis 
After 3 weeks, medium was removed from each well and replaced with 1.5 
mL papain (120 μg/mL) for digestion. Plates were kept at 60 °C overnight and then 
stored at -20 °C. Cell number and biosynthesis were measured as described 
previously.266 Cell number was evaluated by measuring DNA content (PicoGreen Kit, 
Molecular Probes; Eugene, OR). A conversion factor of 7.7 pg DNA/cell was 
determined previously. Biosynthesis was evaluated by measuring total GAG and 
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collagen content. GAG content was measured using a dimethylmethylene blue 
(DMMB) dye binding assay kit (Biocolor; Newtownabbey, Northern Ireland). 
Collagen content was determined by using a modified hydroxyproline assay. A 
collagen standard (Accurate Chemical and Scientific Corporation; Westbury, NY) 
was used instead of hydroxyproline standards to alleviate the need for approximating 
a conversion from hydroxyproline to collagen and thus to directly provide collagen 
content values. All data were expressed as means ± standard deviations and analyzed 
by a single-factor analysis of variance (ANOVA) followed by a Fisher’s Protected 
Least Significant Difference post-hoc test. 
 
RESULTS 
 
Cell number 
With regard to cell morphology, there did not appear to be any significant 
morphological differences over the duration of the study between the two cell types in 
this high density culture environment. For TMJ condylar cartilage cells, all growth 
factor groups and glucosamine groups, except for TGF-β1 groups, had an increased 
cell number compared to the control group (Fig. 4.1). Both 100 ng/mL IGF-I and 
bFGF groups increased TMJ cell proliferation by 30% compared to the control group 
(p < 0.005). 10 ng/ml IGF-I resulted in 23% more cells than the control (p < 0.05). As 
an exception, TGF-β decreased cell proliferation with 16% and 35% fewer cells than 
the control at 5 ng/mL and 30 ng/mL (p < 0.005), respectively. Glucosamine 
promoted TMJ cell proliferation with 11%, 24%, 26%, 25%, and 17% increases at 
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0.02, 0.1 (p < 0.05), 20 (p < 0.05), 100 (p < 0.05), and 700 μg/mL, respectively, 
compared to the control.  
 
Figure: 4.1: Cell number per well via PicoGreen DNA assay (n = 4). TMJ cells 
outperformed ankle cells. I=IGF-I, b=bFGF, T=TGF-β, G=glucosamine 
sulfate, and number corresponds to concentration. Error bars represent 
standard deviations. * = significant difference compared to control. 
 
With regard to ankle cartilage cells, all growth factor groups, except for the 10 
ng/mL IGF-I group, had a moderate increase in cell proliferation, ranging from 7% to 
20% compared to the control, although none of these differences were statistically 
significant. All concentrations of glucosamine inhibited cell proliferation with an 
average of a 6% decrease compared to the control, without statistically significant 
differences. As for a comparison between TMJ cells and ankle cells, all growth 
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factors and glucosamine concentrations, with the exception of TGF-β, promoted 
higher cell proliferation with TMJ cells than with ankle cells (p < 0.001). 
 
GAG content 
For TMJ condylar cartilage cells, it must be noted that all three growth factor 
groups at low concentrations produced higher mean values for GAG content than the 
groups at high concentrations, and that GAG content in all growth factor groups had 
no significant differences compared to the control (Fig.4.2). Glucosamine groups 
produced a higher average amount of GAGs than growth factor groups. Specific 
concentrations of glucosamine enhanced GAG synthesis drastically compared to the 
control. The glucosamine groups at 0.02 μg/mL and 100 μg/mL produced 80% (p< 
0.05) and 82% (p < 0.05) more GAGs than the control, respectively. 
For ankle cartilage cells, all growth factor groups produced significantly more 
GAGs than the control, except for 5 ng/mL TGF-β (Fig. 4.2). The 100 ng/mL IGF-I 
group had the highest GAG production with 3.3 times more GAGs than the control (p 
< 0.00001), and the 10 ng/mL IGF-I and bFGF groups had 2.0 and 2.1 times more 
GAGs than the control (p < 0.00005). The other three growth factor groups led to 
increases in the range of 12-53%. High concentrations of growth factors, except for 
bFGF, stimulated more GAG formation than low concentrations (p < 10-6). The 
pattern of glucosamine acting on GAG production with ankle cartilage cells was 
similar to the pattern with TMJ condylar cartilage cells, with a 75% increase in GAG 
content for the 0.02 μg/mL concentration (p < 0.005) and a 120% increase for the 100 
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μg/mL concentration (p < 0.00001) compared to the control. The 0.1 μg/mL 
glucosamine group had 49% more GAG production than the control (p < 0.05). 
Additionally, the comparison between cell types indicated that ankle cartilage cells 
produced 86% more GAGs than TMJ condylar cartilage cells (p < 10-9). 
 
Figure 4.2: GAG content per well (n = 4). Ankle cells produced much more GAGs 
than TMJ cells. Error bars represent standard deviations. * = significant 
difference compared to control. 
 
Collagen content 
TMJ condylar cartilage cells produced more collagen at low concentrations of 
growth factors than at high concentrations without statistical significance (Fig. 4.3). 
For collagen production with TMJ cells, it must be noted that only the 10 ng/mL IGF-
I group statistically outperformed the control, with a 2.8-fold increase in collagen 
content (p < 0.05). Higher concentrations of glucosamine stimulated TMJ condylar 
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cartilage cells to produce more collagen without statistical significance. Glucosamine 
groups at 100 μg/mL and 700 μg/mL produced 2.2 and 2.0 times more collagen than 
the control, respectively.  
 
Figure 4.3: Collagen content per well (n = 4). Ankle cells outperformed TMJ cells in 
collagen production. Error bars represent standard deviations. * = significant 
difference compared to control. 
 
For ankle cartilage cells, high concentrations of growth factors promoted 
collagen biosynthesis better than low concentrations without statistical significance 
(Fig. 4.3). The groups treated with 100 ng/mL IGF-I and bFGF had the highest 
collagen production with 3.6 times (p < 0.00005) and 3.5 times (p < 0.0001) more 
collagen than the control, respectively. 10 ng/mL IGF-I and bFGF had 3.0 times (p < 
0.0005) and 2.4 times (p < 0.05) more collagen than the control, respectively. 0.02 
μg/mL and 100 μg/mL of glucosamine were the best stimulators for collagen 
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formation with 1.9 and 2.5 times more collagen than the control, respectively (p < 
0.05). Other concentrations of glucosamine groups had no statistically significant 
effects on ankle cartilage cells. With regard to the comparison between the two types 
of cartilage cells, ankle cartilage cells outperformed TMJ condylar cartilage cells, 
with 2 times more collagen than TMJ cells (p < 0.000005).  
 
 DISCUSSION  
 
This study revealed a distinct portrait of cell proliferation and biosynthesis 
between TMJ condylar cartilage cells and ankle cartilage cells and demonstrated that 
glucosamine sulfate at specific concentrations was comparable to growth factors. 
Passage 1 cells were used in the current study to prevent excessive chondrocyte 
dedifferentiation.84-87 The final cell density was less than the initial seeding density 
(150,000 cells/cm2), which revealed cell detachment during the culture period. The 
average number of TMJ condylar cartilage cells after 3 weeks was significantly 
higher than with the ankle cartilage cells, which could be explained by the 
heterogeneous cell populations in TMJ condylar cartilage. Fibroblasts in the fibrous 
zone of TMJ condylar cartilage have a faster proliferation rate than chondrocytes, 
resulting in higher cell numbers for TMJ condylar cartilage cells compared to the 
ankle cartilage groups. Another possible reason is that mesenchymal cells in the 
proliferative zone of TMJ condylar cartilage may proliferate faster than chondrocytes 
or may differentiate into fibroblasts. With regard to GAG and collagen content, ankle 
cells produced significantly more extracellular matrix than TMJ condylar cartilage 
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cells, which is similar to the native configurations in the two types of cartilages. We 
are aware that the comparison of the collagen type is critical for tissue engineering 
applications. In fact, TMJ condylar cells in polyglycolic acid (PGA) scaffolds 
expressed mainly type I collagen, while hyaline cartilage cells produced dominantly 
type II collagen (unpublished data). 
The current study demonstrated that glucosamine sulfate stimulated TMJ 
condylar cartilage cells to proliferate while inhibiting ankle cartilage cell 
proliferation. The same inhibition effect was observed with chondrocyte proliferation 
in 2D and 3D culture.262, 267 Glucosamine promoted GAG synthesis for both types of 
cells, and 0.02 and 100 μg/mL were optimal concentrations, a bimodal effect that was 
not expected. We can only speculate as to the biochemical pathways leading to the 
observed response, which may differ between these two ranges, although there are 
clearly two efficacious ranges that warrant further investigation. With regard to 
collagen synthesis, 0.02 and 100 μg/mL were again the best concentrations for ankle 
cells, while 100 and 700 μg/mL were superior for TMJ cells. It was interesting to note 
that, with ankle cells, 100 μg/mL glucosamine outperformed all growth factor groups 
for GAG synthesis except for 100 ng/mL IGF-I, and also surpassed 10 ng/mL IGF-I 
and bFGF and both concentrations of TGF-β (p < 0.05) for collagen synthesis. The 
TGF-β concentrations were relatively high, and perhaps lower concentrations (e.g., 
0.1 – 1 ng/mL) may prove more efficacious in the future. It must be noted that the 
total GAG content might include both endogenous GAG biosynthesis (with 
glucosamine acting as a bioactive signal) and exogenous glucosamine incorporation 
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(where glucosamine acts as a building block). Exogenous glucosamine, whether 
bound to cells or incorporated into the synthesized matrix, should be included in 
measuring the GAG content of an engineered construct because it is indeed part of the 
construct. Based on the results of both our and previous studies, we speculate that 
glucosamine may act primarily as a signal rather than as a building block alone. First, 
the GAG content did not increase with increasing concentrations of glucosamine to 
achieve a plateau effect, but rather acted in a concentration-dependent manner.262, 263, 
267 Second, a notable increase in collagen synthesis was also observed,6, 7 as was 
especially evident in this study with 100 μg/mL of glucosamine with ankle cells, a 
phenomenon independent of exogenous incorporation. Furthermore, Varghese et 
al.262 proposed that the up-regulation of TGF-β1 gene expression triggered by the 
exogenous glucosamine might be related to the increase of cartilage specific matrix 
production through the hexosamine pathway.268 To further isolate the effects of 
glucosamine, a TGF-ß1 blocking agent may be advantageous in future studies. 
In conclusion, TMJ condylar cartilage cells were more proliferative than ankle 
cartilage cells, whereas ankle cartilage cells prevailed over condylar cartilage cells in 
extracellular matrix production. 10 ng/mL and 100 ng/mL IGF-I were the best 
concentrations for TMJ condylar cartilage cells and ankle cartilage cells, respectively, 
due to an outstanding performance in promoting cell proliferation and GAG and 
collagen production. In addition, glucosamine demonstrated an ability to significantly 
promote biosynthesis and outperform growth factors in certain instances. In the 
future, experiments will include exploring synergistic effects of growth factors and 
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glucosamine sulfate and making comparisons in 3D culture to evaluate the 
differences between the 2D and 3D environments, for example to determine whether 
catabolic activity is observed with glucosamine in 3D.262 Moreover, it will be crucial 
to further investigate the mechanisms underlying the bimodal phenomenon observed 
with glucosamine signaling in 2D, and perhaps more importantly, to investigate 
whether this effect is also observed in 3D. Finally, it will be meaningful to investigate 
the cell behavior of subpopulations of TMJ condylar cartilage cells from the different 
zones.  
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CHAPTER 5: Hyaline cartilage cells outperform 
mandibular condylar cartilage cells in a TMJ fibrocartilage 
tissue engineering application* 
 
ABSTRACT 
 
Objective: To compare temporomandibular joint (TMJ) condylar cartilage 
cells in vitro to hyaline cartilage cells cultured in a three-dimensional environment for 
tissue engineering of mandibular condylar cartilage.  
Design: Mandibular condylar cartilage and hyaline cartilage cells were 
harvested from pigs and cultured for 6 weeks in polyglycolic acid (PGA) scaffolds. 
Both types of cells were treated with glucosamine sulfate (0.4 mM), insulin-like 
growth factor (IGF-I) (100 ng/ml) and their combination. At weeks 0 and 6, cell 
number, glycosaminoglycan (GAG) and collagen content were determined, types I 
and II collagen were visualized by immunohistochemistry and GAGs were visualized 
by histology.  
Results: Hyaline cartilage cells produced from half an order to a full order of 
magnitude more GAGs and collagen than mandibular condylar cartilage cells in 3D 
culture. IGF-I was a highly effective signal for biosynthesis with hyaline cartilage 
cells, while glucosamine sulfate decreased cell proliferation and biosynthesis with 
both types of cells. In vitro culture of TMJ condylar cartilage cells produced a fibrous 
tissue with predominantly type I collagen, while hyaline cartilage cells formed a 
fibrocartilage-like tissue with types I and II collagen. The combination of IGF and 
__________________________________________________________________________________ 
*Chapter published as Wang, Lazebnik, and Detamore. “Hyaline cartilage cells outperform mandibular 
condylar cartilage cells in a TMJ fibrocartilage tissue engineering application,” Osteoarthritis Cartilage, 
In Press, 2008 
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glucosamine had a synergistic effect on maintaining the phenotype of TMJ condylar 
cells to generate both types I and II collagen. 
Conclusion: Given the superior biosynthetic activity by hyaline cartilage cells 
and the practical surgical limitations of harvesting cells from the TMJ of a patient 
requiring TMJ reconstruction, cartilage cells from elsewhere in the body may be a 
potentially better alternative to cells harvested from the TMJ for TMJ tissue 
engineering. This finding may also apply to other fibrocartilages such as the 
intervertebral disc and knee meniscus in applications where a mature cartilage cell 
source is desired. 
 
INTRODUCTION 
 
Temporomandibular joint (TMJ) disorders resulting from arthritis, ankylosis, 
traumas, internal derangement and/or other afflictions can ravage TMJ structures that 
have limited capacity for regeneration. Tissue engineering may provide an ideal 
solution, especially when severe degeneration occurs.173, 269 Although our long-term 
goal is to regenerate the whole mandibular condyle of the TMJ, the specific focus of 
the current study was the condylar cartilage, where cell sources and signals were 
investigated. The purpose of this study was to compare the behavior of mandibular 
condylar cartilage cells and ankle (hyaline) cartilage cells under the regulation of 
insulin-like growth factor-I (IGF-I) and glucosamine sulfate. 
The composition and structure of mandibular condylar cartilage (henceforth 
referred to as TMJ condylar cartilage) differ from hyaline cartilage. Hyaline cartilage 
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cells are chondrocytes, and hyaline cartilage can be divided into four zones: 
superficial, middle, deep and calcified. In contrast, TMJ condylar cartilage has both 
fibrocartilaginous and hyaline-like character, with a thin proliferative zone that 
separates the fibrocartilaginous fibrous zone at the surface from the hyaline-like 
mature and hypertrophic zones below. Unlike hyaline cartilage, TMJ condylar 
cartilage contains predominantly fibroblasts and collagen I in the superficial fibrous 
zone.16, 22, 35 Undifferentiated mesenchymal cells are distributed in the proliferative 
zone, serving as a cell reservoir to provide cells for the fibrous zone and underlying 
zones.15, 29-32 The underlying mature and hypertrophic zones include differentiated 
chondrocytes and the collagen is both types I and II.16, 22, 35, 36 From the standpoint of 
embryonic origin, TMJ condylar cartilage is categorized as a secondary cartilage 
formed by periosteum or endosteum, while hyaline cartilage is a primary cartilage, 
which precedes bone formation. TMJ condylar cartilage falls under the classification 
of fibrocartilage, with a strong presence of both collagen types I and II.35, 36 However, 
hyaline cartilage contains predominately collagen type II in all zones.270 These 
contrasting structures make it imperative to investigate and compare the responses of 
TMJ condylar cartilage cells and hyaline cartilage cells to biological signals and 
biodegradable scaffolds. 
Previous tissue engineering studies of TMJ condylar cartilages utilized cells 
from the condyle itself,66 hyaline cartilage cells,91 fibroblasts10, 172 and stem cells5, 57, 
66-68, 167, 168, 170, 171 as cell sources. An early attempt conducted by Weng et al.91 seeded 
bovine hyaline chondrocytes from the forelimbs onto the surface of a polyglycolic 
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acid/polylactic acid (PGA/PLA) scaffold as a cartilage layer. Hollister and 
colleagues10, 172 also seeded bone morphogenetic protein (BMP)-transduced 
fibroblasts into scaffolds. In both studies, cartilage formation was observed after 
implantation by Safranin-O staining. Furthermore, bone marrow and umbilical cord 
matrix mesenchymal stromal cells5, 57, 66-68, 167, 168, 170, 171 were introduced to TMJ 
tissue engineering, demonstrating the feasibility of creating a tissue engineered 
mandibular condyle in the form of two stratified layers. In these studies, the positive 
immunohistochemical (IHC) staining for types I and II revealed the existence of a 
fibrocartilage. Although most previous studies used stem cells for TMJ tissue 
engineering,5, 57, 66-68, 167, 168, 170, 171 an advantage that mature cells possess over various 
types of stem cells is the absence of the variable of differentiation and reduced 
possibility of metaplasia. This study thus aimed to compare TMJ condylar cartilage 
cells to hyaline cartilage cells for tissue engineering applications.  
Although the cell behavior of TMJ condylar cartilage and hyaline cartilage 
has been extensively investigated, there are only three studies comparing the 
respective cell types, performed in newborn rat explant culture by a single group.35, 
121, 124 These studies revealed that basic fibroblast growth factor (bFGF), IGF-I and 
transforming growth factor beta (TGF-β) stimulated higher cell proliferation in the 
TMJ condylar explants than in the femoral head explants. IGF-I increased 
glycosaminoglycan (GAG) formation, while bFGF and TGF-β decreased GAG 
production in both types of cartilage. It must be noted that these studies used newborn 
rat condyles, which grew faster than mature condyles,20 whereas in the current study, 
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cells were isolated from mature porcine mandibular condylar and ankle cartilage. In a 
two-dimensional environment (2D) using mature cells,271 IGF-I promoted cell 
proliferation and biosynthesis for both types of cells. Therefore, based on both 
explant and monolayer cell culture, IGF-I was chosen in our three-dimensional (3D) 
study to regulate cell growth and biosynthesis. 
Glucosamine has been scarcely tested in tissue engineering applications, with 
a handful of recent studies. One recent investigation revealed that glucosamine 
hydrochloride up-regulated matrix production at concentrations between 0 and 2 
mM262. Glucosamine sulfate has been shown in vitro to promote aggrecan 
production,260, 261 and to inhibit matrix degrading protein production in 
chondrocytes.260 In our 2D monolayer culture,271 glucosamine sulfate also 
demonstrated an ability to significantly promote GAG and collagen production and to 
outperform growth factors in certain instances (between 0 and 0.4 mM) for both TMJ 
condylar cartilage cells and ankle cartilage. Consequently, besides IGF-I at 100 
ng/ml, glucosamine at 0.4 mM was adopted and the synergistic effects of IGF-I and 
glucosamine were also investigated in the current study. 
Non-woven polyglycolic acid (PGA) scaffolds have been broadly exploited in 
both hyaline165, 272, 273 and fibrocartilage cartilage141, 259, 274 tissue engineering, due to 
its good biocompatibility and biodegradability. Our previous study66 also 
demonstrated that non-woven PGA meshes did support proliferation and biosynthesis 
of TMJ condylar cartilage cells as evidenced by a significant increase in cell number 
and the presence of types I and II collagen and GAGs throughout the constructs. 
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Therefore, in this study, non-woven PGA scaffolds were seeded with porcine 
cartilage cells from mature TMJ condylar cartilage and hyaline cartilage from ankles. 
Exogenous signals including glucosamine sulfate (0.4 mM) and IGF-I (100 ng/ml) 
and their combination were employed to regulate cell proliferation and extracellular 
matrix production. The comparison between these two types of cells provide critical 
steps in demonstrating that hyaline cartilage cells may be a promising mature cell 
source for TMJ condylar cartilage tissue engineering. 
 
MATERIALS AND METHODS 
 
Cell harvesting 
Hog heads and ankles (Chester white breed, female, age 8 months) were 
acquired from Winchester Meat Processing (Winchester, KS, USA). The TMJ was 
first removed en bloc with capsule intact and placed into 100% ethanol for 20 min. 
The TMJ was scrubbed using a sterile iodine pad, then the joint capsule was broken 
and the disc was removed in a sterile manner with a scalpel in a tissue culture hood. 
TMJ condylar cartilage was removed by chopping cartilage from the surface of the 
TMJ condyle, washed with sterile phosphate buffered saline (PBS), minced, and 
digested for 24 hrs in 2 mg/ml type II collagenase (394U/mg; Worthington 
Biochemical; Lakewood, NJ, USA). The cell solution was centrifuged and cells were 
resuspended in a cell culture medium, consisting of Dulbecco’s Modified Eagle 
medium (Invitrogen; Carlsbad, CA, USA), 10% fetal bovine serum (FBS; Gemini; 
West Sacramento, CA, USA), 25 μg/ml ascorbic acid (Sigma; St. Louis, MO, USA), 
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1% non-essential amino acids (Invitrogen) and 1% penicillin-streptomycin-fungizone 
(Invitrogen). Cells were fed every other day until confluent. The confluent cell 
population was trypsinized and labeled as passage 1. The procedure to obtain 
cartilage cells from ankles was similar to harvesting TMJ condylar cartilage cells, 
although more straightforward. Briefly, skin was removed, the joint was sterilized 
using an iodine pad, the joint capsule was broken, and cartilage was obtained and 
minced. After digestion, the cells were resuspended, cultured in the flasks, and 
labeled as passage 1. 
 
Cell seeding and growth factor incorporation 
A non-woven PGA mesh (50 mg/cc; Synthecon; Houston, TX, USA) was 
punched into disc-shape scaffolds with a 5 mm diameter and 2 mm thickness, and 
then sterilized with ethylene oxide. After sterilization, the scaffolds were aired in 
sterilization pouches under a fume hood for one day, then wetted with sterile filtered 
ethanol for 5 min and two washes of sterile PBS. The scaffolds were then soaked in 
the cell culture medium for 1 day and then removed for cell seeding. P1 cells were 
seeded on the PGA scaffolds at 50 million cells per ml of scaffold. Highly 
concentrated cell solution (500 μl) was dispensed slowly onto scaffolds in 24-well 
plates, which were set on an orbital shaker at 150 rpm for 12 hrs. After 12 hrs, 500 μl 
of fresh medium was added. After 24 hrs, an additional 1 ml of medium was added 
and cells were allowed to attach statically in the medium for another day. After 
allowing 2 days for seeding and attachment (recorded as day 1), the medium was 
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replaced by 2 ml of either fresh medium or the medium supplemented with either 
growth factor or glucosamine. There were a total of eight groups in this study, 
including the TMJ condylar and hyaline cartilage cells treated by IGF (100 ng/ml; 
Pepro Tech; Rocky Hill, NJ, USA), D-glucosamine 6-sulfate (0.4 mM, corresponding 
to 100 mg/ml; Sigma) and their combination (100 ng/ml IGF and 0.4 mM 
glucosamine) and their respective controls (cultured in fresh medium without IGF and 
glucosamine treatment). Scaffolds were cultured in 2 ml of medium for 6 weeks and 
half of the medium was changed every other day. 
 
Biochemical analysis and immunohistochemical staining 
Scaffolds were examined at weeks 0 and 6 for cell number, GAG and 
hydroxyproline content. Cell number was measured using a Picogreen assay 
(Molecular Probes; Eugene, OR, USA) with a conversion factor of 7.7 pg 
DNA/cell.258 The GAG content was quantified by a dimethylmethylene blue 
(DMMB) dye assay (Biocolor; Newtownabbey, Northern Ireland).258 The 
hydroxyproline content was examined by a hydroxyproline assay (Accurate; 
Westbury, NY, USA).258 A conversion factor of 11.5 was determined in a preliminary 
study for converting hydroxyproline mass to collagen mass. Histological analysis was 
performed using a Safranin-O/fast green stain. Immunohistochemical (IHC) staining 
of types I and II collagen was performed in a Biogenex i6000 autostainer (San 
Ramon, CA, USA).66 The mouse monoclonal IgG anti-collagen I (1:1500 dilution) 
(Accurate Chemical, Westbury, NY, USA), mouse monoclonal IgG anti-collagen II 
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(1:1000 dilution) (Chondrex, Redmond, WA, USA) and mouse monoclonal IgG anti-
aggrecan (1:50 dilution) (Abcam, Cambridge, MA, USA) antibodies were chosen as 
primary antibodies. The streptavidin-linked horse anti-mouse IgG secondary 
antibody, ABC detection kit, and DAB (brown) and VIP (purple) substrate kits were 
obtained from Vector Laboratories (Burlingame, CA, USA). Double IHC staining of 
types I and II collagen was performed for sagittal sections of native ankle and TMJ 
tissues. Type I collagen staining was first conducted by following the above 
procedure with VIP as the substrate, avidin and biotin (Vector Laboratories) were 
then added in a blocking step to prevent the interaction between the first and second 
sets of labeling reagents, and type II collagen staining was finally performed with 
DAB as the substrate. Negative controls were prepared by omitting the primary 
antibodies, and the absence of non-specific staining was confirmed. 
 
Statistical analysis 
All data were expressed as means ± one standard deviation and analyzed by 
an analysis of variance (ANOVA) followed by a Fisher’s Protected Least 
Significance Difference post hoc test. Three-way ANOVAs with interaction were 
used to determine whether there were differences among time-points, different 
treatments, or cell types. A statistical threshold of p < 0.05 was used to indicate 
whether there were statistically significant differences among groups. 
 
RESULTS 
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Cell number 
Over 6 weeks of culture, the ankle groups had significantly more cells than the 
TMJ groups (p < 10-12) (Fig. 5.1). At week 0, there were 1.44 times more cells 
attached to scaffolds in ankle groups than in TMJ groups (p < 0.05), although two 
types of cells were seeded onto scaffolds at the same density (1.96 million cells per  
 
 
Figure 5.1: Cell number per construct at weeks 0 and 6 (n = 4). Gluco denotes 
glucosamine. Symbol * means statistically significant difference between 
ankle groups and TMJ groups. Error bars represent standard deviations. 
 
construct). At week 6, the average cell number of ankle groups was 1.63 million cells 
per construct, while the cell count of TMJ groups was 0.82 million cells per construct 
(p < 10-12). With regard to IGF and glucosamine, ankle cells were more sensitive than 
TMJ cells. In all ankle groups, except for the glucosamine group, cell numbers 
increased from week 0 to week 6 (p < 10-4), while cell numbers in TMJ groups did 
not exhibit any statistically significant differences from week 0 to week 6. In 
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comparison to their respective controls, significant differences in cell numbers were 
not observed for either cell type. However, IGF and the combination of IGF and 
glucosamine in ankle groups promoted cell number compared to the glucosamine 
group (p < 0.001). In fact, the glucosamine groups had 15% and 13% decreases in cell 
number compared to the control for both the ankle and TMJ groups (not statistically 
significant), respectively. 
 
 
Figure 5.2: GAG content per construct at weeks 0 and 6 (n = 4). Gluco denotes 
glucosamine. Symbol * means statistically significant difference between 
ankle groups and TMJ groups. Symbol # means statistically significant 
difference compared to the respective control group. Error bars represent 
standard deviations. 
 
GAG content 
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There was no significant difference in GAG content at week 0 between ankle 
and TMJ cells (Fig. 5.2). The average GAG production per construct of 107.4 μg in 
ankle groups was an order of magnitude higher than the average content of 11.3 μg 
per construct in TMJ groups after 6 weeks of culture (p < 10-11). Ankle groups at 
week 6, with the exception of the glucosamine group, had drastically increased GAG 
production over time, as the IGF, combination and the control groups had 8.3 (p < 10-
9), 7.0 (p < 10-8), and 4.1 (p < 10-4) times higher GAG contents than at week 0, 
respectively, while there was no significant difference among TMJ groups. Both IGF 
and the combination promoted GAG production, with 1.79 and 1.49 times more 
GAGs in ankle groups than in the control (p < 10-4 and 0.05, respectively), whereas 
glucosamine lessened the GAG production by 49% (p < 0.01). 
 
Hydroxyproline content 
As with cell number and GAG content, hydroxyproline content in ankle 
groups was significantly higher than in TMJ groups (p < 10-11) (Fig. 5.3). Despite the 
fact that the ankle group had 5.8 times more hydroxyproline than the TMJ group at 
week 0, there was no statistically significant difference between them. In comparison 
to week 0, hydroxyproline content in ankle groups at week 6 increased over time by 
8.9, 5.2, 8.0, and 6.0 times with the IGF group (p < 10-9), the glucosamine group (p < 
10-4), their combination (p < 10-8) and the control (p < 10-5) respectively, while no 
significant differences were detected among TMJ groups. IGF and the combination in 
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ankle groups had 26.0 and 24.0 μg of hydroxyproline per construct, which were 48% 
(p < 0.005) and 35% (p < 0.05) increases compared to the control, respectively. 
 
 
Figure 5.3: Hydroxyproline content per construct at weeks 0 and 6 (n = 4) (multiply 
by a factor of 11.5 for collagen content). Gluco denotes glucosamine. Symbol 
* means statistically significant difference between ankle groups and TMJ 
groups. Symbol # means statistically significant difference compared to the 
respective control group. Error bars represent standard deviations. 
 
IHC analyses 
At week 6, immunohistochemical analysis revealed a moderate staining of 
type I collagen and an intense staining of type II collagen in ankle groups (Fig. 5.4), 
with especially intense regions of collagen II staining in the IGF-glucosamine 
combination group. In the native ankle cartilage, type II collagen was dominant (Fig. 
5.5). The constructs in TMJ groups demonstrated a significant presence of type I 
collagen and a minute amount of type II collagen (Fig. 5.4). It must be noted that the 
group combining IGF and glucosamine in the TMJ group demonstrated much more 
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intense staining of type II collagen than all other TMJ groups. In native TMJ condylar 
cartilage, type I collagen was dominant in the superficial zone, abundant type I and 
moderate II collagen were observed in the proliferative zone, and type II collagen was 
dominant in the mature and hypertrophic zone (Fig. 5.5). In general, ankle cells had a 
weaker staining of type I collagen than TMJ cells and a stronger staining of type II 
collagen. IHC also revealed a more abundant presence of aggrecan in the IGF and the 
combination groups with ankle cells, compared to other ankle groups and all TMJ 
groups (Fig. 5.6), which was further confirmed by the GAG content from DMMB 
assays. 
 
 
Figure 5.4: Immunohistochemical test for types I and II collagen at week 6 (n =2). 
Positive staining is purple in color. The scale bar is 100 μm. CI = type I 
collagen, CII = type II collagen.  
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Figure 5.5: Double immunohistochemical staining for types I and II collagen in 
sagittal sections from native tissues. Positive staining of type I collagen is 
brown in color. Positive staining of type II collagen is purple in color. Note 
that the hyaline cartilage is stained almost exclusively for type II collagen, 
whereas in sharp contrast the mandibular condylar cartilage consists of 
distinct zones dominated either by collagen I (superficial zone) or collagen II 
(mature and hypertrophic zones) staining. The scale bar is 100 μm. 
 
DISCUSSION 
 
In this study, mature porcine cartilages were used since the pig has been 
identified as a suitable model for TMJ tissue engineering strategies,46, 173, 275-277 
although the different species and ages278 might lead to different results. The two 
types of cartilage cells were shown to differ in vitro in cell proliferation, GAG and 
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collagen production, and collagen type. In addition, the results revealed that the 
compositions of tissue engineered cartilages were different from their respective 
native tissues. Loading conditions may contribute to the different behaviors of the 
respective cell types, although it should be made clear that the TMJ is a load-bearing 
joint.275, 279 To the best of our knowledge, this was the first effort to compare cartilage 
cell sources for TMJ tissue engineering, as a first step in demonstrating that it may 
not be necessary to use cells from the same tissue when selecting a mature cell source 
for fibrocartilage regeneration. Moreover, this is the first example of collagen I and II 
double immunostaining of condylar cartilage, to the best of our knowledge.  
 
Figure 5.6: Immunohistochemical staining for aggrecan at week 6 (n =2). Arrows 
indicate examples of positive staining of aggrecan (light purple color). The 
black color indicates PGA debris. The scale bar is 400 μm. 
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Compared to hyaline cartilage cells, TMJ condylar cells were less 
proliferative in a 3D environment. The significant difference at week 0 in cell number 
between TMJ condylar cells and hyaline cartilage cells revealed that TMJ condylar 
cells had an inferior ability to attach onto PGA scaffolds compared to hyaline 
cartilage cells. This inferior attachment ability would likely explain the lower 
cellularity of TMJ groups at 6 weeks, given the superior proliferation rate of TMJ 
condylar cartilage cells in monolayer culture.280 The exploration of new biomaterials 
may enhance the adhering ability of TMJ cells, such as Arg-Gly-Asp (RGD)-
modified poly(lactic-co-glycolic acid) (PLGA)281 and poly-L-lactic acid (PLLA).282 
During the 6 weeks of culture, TMJ condylar cells maintained a relatively constant 
cell number, indicating that TMJ condylar cartilage cells exhibited a behavior more 
similar to fibrocartilage cells such as TMJ disc cells and knee meniscus cells, 
although they were more proliferative in monolayer culture than ankle hyaline 
cartilage.280 In fact, Almarza and Athanasiou274 reported that in vitro culture of 
fibrocartilage cells (TMJ disc cells) even demonstrated a decrease in cell number over 
a 4-week period. Mesenchymal stem cells (human umbilical cord mesenchymal 
stromal cells) in a chondrogenic medium also had a decreased or stable cell number in 
PGA scaffolds over 4 weeks of culture in a fibrocartilage tissue engineering 
application.207 The relatively invariable cellularity with TMJ condylar cells implied 
that a higher seeding density might be necessary. 
TMJ condylar cells were inferior in extracellular matrix synthesis to hyaline 
cartilage cells. The ratios of GAG to collagen content in the TMJ groups were 0.25 on 
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average, which is higher than the ratios in native tissues, while this ratio in the ankle 
groups was 0.47, which is comparable to native tissues.283-285 The dominance of type I 
relative to type II collagen in TMJ groups (except for the combination of IGF and 
glucosamine) might be unexpected since there is abundant type II collagen present in 
the mature and hypertrophic zones of native TMJ condylar cartilage, though type I 
collagen produced by fibroblasts in the fibrous zone likely contributed to collagen 
production. A strong IHC staining of type II collagen and a moderate staining of type 
I collagen were observed in hyaline cartilage groups, indicating the formation of a 
fibrocartilage-like tissue, which is the goal with TMJ condylar cartilage regeneration. 
The abundant type I collagen in TMJ groups and moderate type I collagen presence in 
ankle groups together suggest the inevitable shift of TMJ and ankle cell phenotypes 
during in vitro culture, due to the differences between the in vitro and in vivo 
microenvironments, such as mechanical conditions, bioactive signals, and the 
exchange of nutrients and wastes. The dedifferentiated hyaline chondrocytes may be 
redifferentiated in an agarose gel,86 alginate beads,286 by use of high density 
culture,287 by substituting serum with the combination of TGF-β2 and IGF-I,288 or by 
coating a surface with chondrogenic molecules such as aggrecan.84, 85 However, it is 
still questionable whether redifferentiated chondrocytes have the ability to generate a 
properly assembled matrix.289 
TMJ condylar cells were less responsive to the stimulation of exogenous 
signals than hyaline cartilage cells, in that the IGF and IGF/glucosamine combination 
both significantly upregulated collagen and GAG biosynthesis with hyaline cartilage 
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cells, whereas no signals produced statistically significant differences for the TMJ 
cells compared to the control. It was unanticipated that glucosamine at 0.4 mM 
exhibited a noticeable inhibition of biosynthesis with ankle cartilage cells, although 
this concentration was the best for the up-regulation of GAG and collagen in our 
preliminary monolayer studies,271 indicating that further optimization of glucosamine 
concentrations in a 3D environment is required. However, Mroz and Silbert290, 291 also 
revealed that glucosamine chloride did not stimulate the formation of chondroitin 
sulfate with rat chondrocytes and even inhibited it at specific concentrations. 
Glucosamine is an important building block of proteoglycans in cartilage. However, a 
previous study290 revealed that exogenous glucosamine did not participate in the 
pathway to produce GAGs, but rather played a role as a signal to regulate GAG and 
collagen production. Indeed, in the current study, the combination of IGF and 
glucosamine demonstrated a critical ability to retain type II collagen synthesis with 
TMJ condylar cells during in vitro culture, although the inherent mechanism needs to 
be further investigated in the future.  
Ideally, tissue-engineered TMJ condylar cartilage should mimic the native 
zonal structure to achieve a functional condylar replacement. One strategy to 
accomplish this could be to separately harvest cells from the different zones of the 
condylar cartilage. However, the separation of different cell populations from their 
respective layers is limited by the accurate dissection of different layers of TMJ 
condylar cartilage due to the irregular zonal distribution. Countercurrent 
centrifugation, a technique extensively used with hematopoietic progenitor cells, was 
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utilized in a previous study to elutriate five different fractions of cells from TMJ 
condylar cells based on the different sizes of cells.292 Characterization of these cells 
suggested that fibroblast-like cells, mesenchymal stem cells and hypertrophic cells 
might be identified from these five populations according to cell volume, alkaline 
phosphatase content, proteoglycan production, and collagen types. Seeding these cells 
into a stratified scaffold would be interesting but challenging work in the future. 
In vitro culture of both types of cartilage cells appeared to exhibit a 
phenotypic shift during the 6 weeks of culture in PGA scaffolds. In vitro tissue 
engineering of TMJ condylar cartilage using mature cells produced a fibrous tissue 
with dominant type I collagen. The combination of IGF and glucosamine 
demonstrated the ability to maintain the expression of both types I and II collagen 
with TMJ condylar cartilage cells. In vitro culture of hyaline cartilage cells resulted in 
the fibrocartilage-like tissue genesis with both types I and II collagen. Most 
importantly, cell number and extracellular matrix content in the hyaline cartilage cell 
groups were significantly higher than in the TMJ condylar cartilage cell groups. 
Furthermore, from a clinical perspective, it is more reasonable to obtain cells from 
hyaline cartilage (or perhaps costal cartilage) than from degenerated TMJ condylar 
cartilage, in which the healthy cells are very limited, or from a healthy contralateral 
TMJ, which may lead to bilateral dysfunction. Therefore, given the importance of the 
superior biosynthetic activity by hyaline cartilage cells, and the clinical difficulty in 
obtaining donor cartilage, hyaline cartilage cells may be a more promising mature cell 
source than the TMJ itself for TMJ condylar cartilage tissue engineering, a principle 
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which may also apply to other fibrocartilages such as the intervertebral disc and knee 
meniscus. In the future, experiments will include optimizing glucosamine 
concentrations in 3D culture, designing zonal scaffolds for seeding different 
populations of cells, and evaluating mechanical properties of tissue-engineered 
constructs for long-term culture (> 6 weeks). 
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CHAPTER 6: A Comparison of Human Umbilical Cord 
Matrix Stem Cells and TMJ Condylar Chondrocytes for 
Tissue Engineering TMJ Condylar Cartilage* 
 
ABSTRACT 
 
 The temporomandibular joint (TMJ) presents many problems in modern 
musculoskeletal medicine. Patients who suffer from TMJ disorders often experience a 
major loss in quality of life due to the debilitating effects that TMJ disorders can have 
on everyday activities. Cartilage tissue engineering can lead to replacement tissues 
that could be used to treat TMJ disorders. In this study, a spinner flask was used for a 
period of 6 days to seed polyglycolic acid (PGA) scaffolds with either TMJ condylar 
chondrocytes or mesenchymal-like stem cells derived from human umbilical cord 
matrix (HUCM). Samples were then statically cultured for 4 weeks either in growth 
medium containing chondrogenic factors or in control medium. 
Immunohistochemical staining of HUCM constructs after 4 weeks revealed a strong 
presence of collagen I and minute amounts of collagen II, whereas TMJ constructs 
revealed little collagen I and no collagen II. The HUCM constructs were shown to 
contain more GAGs than the TMJ constructs quantitatively at week 0 and 
histologically at week 4. Moreover, the cellularity of HUCM constructs was 55% 
higher at week 0 and nearly twice as high after 4 weeks, despite being seeded at the 
same density. The increased level of biosynthesis and higher cellularity of HUCM 
constructs clearly demonstrates that the HUCM stem cells outperformed the TMJ 
condylar cartilage cells under the prescribed conditions. HUCM stem cells may 
_______________________________________________________________________________ 
*Chapter published as Bailey, Wang, Bode, Mitchell, and Detamore. “A comparison of human 
umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue 
engineering temporomandibular joint condylar cartilage,” Tissue Eng 13, 2003, 2007. (Special Issue on 
Emerging Technologies and New Basic Science Directions in Tissue Engineering.) 
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therefore be an attractive alternative to condylar cartilage cells for TMJ tissue 
engineering applications. Furthermore, given the availability and ease of obtaining 
HUCM stem cells, these findings may have far-reaching implications, leading to 
novel developments in both craniofacial and orthopaedic tissue replacement therapies. 
 
INTRODUCTION 
 
The complexity of the temporomandibular joint (TMJ), or jaw joint, makes it 
difficult to treat its disorders such as arthritis, internal derangement, and ankylosis. 
TMJ disorders can restrict the range of mouth opening, and can make routine 
activities such as eating, talking, and yawning severely painful. Fortunately, tissue 
engineering may be able to address these problems. Our current efforts focus on the 
articular cartilage of the mandibular condyle. Native mandibular condylar cartilage is 
composed of four distinct layers, namely the fibrous zone with fibroblast-like cells, 
proliferative zone with mesenchymal cells, mature zone with differentiated 
chondrocytes, and hypertrophic zone with differentiated chondrocytes. Collagen type 
I is distributed throughout all of the zones,35 and collagen type II is abundant in the 
mature and hypertrophic zones.36 The major proteoglycan in the mandibular condyle 
is negatively charged aggrecan, in which GAG chains consist predominately of 
chondroitin sulfate and keratan sulfate.37 Ideally, tissue engineering aims to create the 
mandibular condylar cartilage with the same biochemical composition as the native 
cartilage. Much of the work in TMJ tissue engineering to date has focused on the 
TMJ disc, and has demonstrated the usefulness of poly(glycolic acid) (PGA) as a 
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scaffolding material.293, 294 Only a handful of condylar tissue engineering studies have 
been done, all published in this decade.5, 10, 11, 68, 91, 92, 166-172 These studies have 
utilized a variety of different cell sources, scaffold materials and chemical signals. 
Thus, tissue engineering for the TMJ condyle is a field in its infancy, and in the 
current study we investigate the crucial factor of cell source. 
Mature chondrocytes are a common choice for cartilage regeneration. 
However, autologous chondrocytes are faced with several potential limitations. First, 
in large-scale tissue-engineered constructs, a high initial cell density is necessary to 
obtain sufficient cartilage for clinical applications. The availability of sufficient cell 
numbers from autologous chondrocytes is limited due to their limited ability to 
expand in culture.57  Second, articular chondrocytes tend to lose their phenotype after 
passaging in monolayer culture.295 Adult mesenchymal stem cells (MSCs) derived 
from bone marrow have the capability to differentiate into multiple cell lineages in 
vitro including bone, cartilage, tendon, and other connective tissues.58-60 Exposed to 
specific growth factors, MSCs can differentiate into osteoblasts, chondrocytes, and 
periodontal ligament cells that could be used for replacement or regeneration of oral 
tissue in dental and craniofacial tissue engineering.57, 296  
Recent developments in the field of tissue engineering have shown that 
porcine TMJ disc cells seeded on bioresorbable polymer scaffolds showed promising 
proliferative and biosynthetic activity, which could ultimately lead to a viable 
material for TMJ disc replacement.259  Studies have shown that polyglycolic acid 
(PGA), as well as poly(lactic-co-glycolic acid) (PLGA)294, 297 can be used as a 
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suitable three dimensional scaffold for cell seeding. It has also been demonstrated by 
Almarza and Athanasiou294 that a spinner flask bioreactor can provide the necessary 
dynamic culture environment to seed PGA scaffolds with TMJ disc cells. 
In order to overcome the various limitations related to currently available cell 
sources, we propose the use of a promising new cell source for musculoskeletal tissue 
engineering. It has been shown that cells isolated from Wharton’s jelly, or the human 
umbilical cord matrix (HUCM), are multipotent stems cells that express 
mesenchymal stem cell (MSC) markers76, 298 Studies have analyzed the differentiation 
capacity of umbilical cord matrix cells and have shown that these cells are capable of 
differentiating into cells with osteogenic phenotypes.64, 76 
There are several options for cell sources, including mature cartilage and bone 
cells (or even skin or fat cells),299 mesenchymal stem cells (MSCs) from bone 
marrow, and embryonic stem cells. HUCM stem cells, which are multipotential stem 
cells with properties between embryonic stem cells and adult stem cells,75-78 offer 
several advantages for cell-based therapies. Umbilical cord stem cells are believed to 
be a type of mesenchymal stem cell because in addition to expressing a significant 
number of mesenchymal stem cell markers (e.g., CD10, CD13, CD29, CD44, CD90, 
SH2, SH3) and negative expression of hematopoietic markers (e.g., CD14, CD34, 
CD45, HLA-DR), they have demonstrated mesenchymal cell-lineage capacities for 
osteogenic, chondrogenic, myogenic and adipogenic differentiation in several 
instances.64, 76, 77, 80, 300-308 Although they have much in common with bone marrow 
derived MSCs, HUCM stem cells have distinct advantages in that they are easily 
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obtained and are in abundant supply, have no donor site morbidity, are 
developmentally more primitive cells, and can be expanded for several passages. 
Furthermore, HUCM stem cells can be expanded and cryogenically stored for years 
without losing viability or their stem cell properties. There is a lower incidence of 
graft vs. host disease than with bone marrow transplants, and a significant absence of 
major histocompatibility complexes, suggesting that umbilical cord cells may have an 
innate mechanism to evade the immune system.77, 79, 80 As human cells with low 
immunogenicity, HUCM stem cells are natural candidates for translational research. 
Use of HUCM stem cells is a new technology, and this is their first application in 
musculoskeletal tissue engineering, to the best of our knowledge. All indicators point 
to HUCM stem cells as having the potential to be a highly desirable cell source for 
musculoskeletal tissue engineering in the future. 
The current study examined the biosynthetic and proliferative activity of 
HUCM stem cells cultured in three-dimensional PGA scaffolds in the presence of 
factors that promote chondrogenic differentiation. These cells were compared to TMJ 
condyle cartilage cells, with the hypothesis being that HUCM stem cells would 
produce comparable or superior engineered constructs under the given conditions. 
 
MATERIALS AND METHODS 
 
 HUCM stem cells were harvested as described by Mitchell et al.75 with minor 
modifications. Human umbilical cords were obtained from a local obstetrician, 
washed in betadine, rinsed in sterile phosphate buffered saline (PBS), incubated in 
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hyaluronidase (40 U/mL) (MP Biomedical, Aurora, OH) and collagenase type I (0.4 
mg/mL) (Sigma) for 30 min at 37°C, and rinsed with sterile PBS. After removal of 
vascular tissue, the cords were finely minced, plated in six-well plates, and 
maintained in defined media (DM), which is composed of DMEM (Invitrogen) and 
MCDB-201 medium (Sigma) supplemented with 1× insulin-transferrin-selenium 
(Invitrogen), 0.15% lipid-rich bovine serum albumin (Albumax, Invitrogen), 0.1 nM 
dexamethasone (Sigma), 10 µM ascorbic acid-2-phosphate (Sigma), 1× 
penicillin/streptomycin (Fisher), 2% fetal bovine serum (FBS, HyClone; Logan, UT), 
10 ng/mL recombinant human epidermal growth factor, and 10 ng/mL human 
platelet-derived growth factor BB (R&D Systems, Inc.). After one week in culture, 
cord remnants were removed and the attached cells were maintained in DM. Cells 
were passaged by lifting with 0.05% trypsin EDTA and replated to maintain a density 
between 30 to 80%. 
 Cartilage tissue was harvested in a manner similar to that described by 
Detamore and Athanasiou.141, 258, 259 Briefly, the head of a Yorkshire male hog, age 6-
7 months, was obtained from a local butcher. TMJs were removed en bloc, and then 
both mandibular condyles were aseptically disengaged from the TMJ. The cartilage 
was removed from the condyle with a scalpel and placed in a Petri dish. The resected 
tissue was digested for 24 hrs in a 30 mL solution of 2 mg/mL collagenase (Type 2, 
394U/mg; Worthington Biochemical, Lakewood, NJ). The resulting cell solution was 
centrifuged and the cells resuspended in DMEM-high glucose, 10% FBS (Gemini 
BioProducts, Woodland, CA), 25 μg/mL ascorbic acid (Sigma-Aldrich; St. Louis, 
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MO), 1% non-essential amino acids (NEAA) (Invitrogen Corporation; Grand Island, 
NY), and 1% penicillin-streptomycin-fungizone (Invitrogen Corporation; Grand 
Island, NY). Approximately 21 million cells were obtained per condyle. Cells were 
plated and fed every other day until confluent, after which the cells were lifted and 
labeled as passage 1. 
 
Figure 6.1: Diagram of experimental design. HUCM stem cells were seeded onto 
PGA scaffolds in chondrogenic medium, and TMJ condylar chondrocytes 
were seeded in control medium. Constructs from both flasks were then split 
and cultured in either chondrogenic or control medium. 
 
Control medium was prepared by supplementing DMEM-high glucose with 
10% FBS, 50 μg/mL ascorbic acid, 1% NEAA, and 1% penicillin/streptomycin. 
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Chondrogenic medium was prepared by supplementing the above control medium 
with 10 ng/mL of recombinant human transforming growth factor-β1 (TGF-β1) 
(PeproTech, Inc.; Rocky Hill, NJ), and 50 mg/mL insulin transferrin-selenium plus 1 
premix (ITS+1) (Sigma-Aldrich; St. Louis, MO). 
 The experiment was set up using two spinner flasks, one containing 
chondrogenic medium and one containing control medium (Fig. 6.1). The HUCM 
stem cells were cultured in chondrogenic medium to produce an initial differentiation, 
and the condylar cartilage cells were cultured in control medium in order to produce 
two populations of cell-seeded scaffolds for comparison. After seeding, scaffolds 
were removed from the spinner flasks and cultured in either control or chondrogenic 
medium for an additional 4 weeks. Spinner flasks were prepared as described by 
Detamore and Athanasiou.141, 259 A polyglycolic acid (PGA) non-woven mesh 
(Concordia Manufacturing, Coventry, RI) with a thickness of 1.5 mm was used as the 
scaffold. A circular brass tube fitting and a surgical scalpel were used to cut 5 mm 
diameter scaffolds. The scaffolds were then skewered onto a steel wire, alternating 
with two glass beads, until a total of 16 scaffolds were placed on the wire in each 
flask. The spinner flasks, along with the scaffolds, were sterilized with ethylene oxide 
and then aired under a fume hood for 2 days. The scaffolds were then wetted with 
sterile filtered ethanol, and two washes of sterile PBS.  
This was followed by adding 200 mL of medium to each flask, and the flasks 
were then incubated at 37°C in 5% CO2 overnight. 3.4 x 106 HUCM stem cells were 
then added to the flask containing chondrogenic medium, and an equivalent number 
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of porcine mandibular condyle cartilage cells were added to the flask containing 
control medium. The flasks were incubated at 37°C in 5% CO2 and stirred 
continuously at 90 RPM. Stirring was stopped after 3 days, and an additional 1% pen-
strep was added to each flask. The cells were given an additional 3 days to adhere to 
the scaffolds. Scaffolds were then carefully transferred to two 24-well plates with 
each well coated with 600 μL of 2% agarose. Scaffolds from each group were 
cultured for 4 weeks in 1 mL of either chondrogenic medium or control medium. Half 
of the medium was changed every 2 days. 
 Scaffolds were analyzed biochemically, histologically and 
immunohistochemically for biosynthesis and proliferation at week 0 and week 4. 
Week 0 refers to the time immediately after the 6 day seeding period. Proliferation 
was measured using a Picogreen assay (Molecular Probes; Eugene, OR).258 A 
conversion factor of 7.7 pg DNA/cell was used for both condyle and HUCM stem 
cells.258 A dimethylmethylene blue (DMMB) dye assay was used to determine the 
amount of glycosaminoglycan (GAG) produced using a chondroitin sulfate standard 
(Biocolor; Newtownabbey, Northern Ireland).258 A hydroxyproline assay using a 
collagen standard (Accurate Chemical and Scientific Corporation; Westbury, NY) 
was used to quantify the amount of collagen produced.258 
 Immunohistochemical analysis of collagen I and II was performed as 
described by Detamore et al.141, 309 Staining was performed using a Biogenex i6000 
autostainer (San Ramon, CA). Slides were placed in the autostainer and rehydrated 
with PBS for 5 min. Endogenous peroxidase activity was quenched with 1% 
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hydrogen peroxide in methanol for 30 min, followed by blocking in 3% horse serum 
for 20 min. Samples were then stained with a primary antibody for 60 min. The 
mouse monoclonal IgG anti-collagen I (1:1500 dilution) and mouse monoclonal IgG 
anti-collagen II (1:1000 dilution) antibodies were obtained from Accurate Chemical 
and Scientific (Westbury, NY) and Chondrex, LLC (Redmond, WA), respectively. 
The primary antibody was followed by incubation with a streptavidin-linked horse 
anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA) for 30 
min. This was followed by incubation with avidin-biotinylated enzyme complex 
(Vector Laboratories) for 30 min and then 3,3’-diaminobenzadine for 4 min. The 
slides were counterstained with Harris hematoxylin, dehydrated with graded ethanol, 
and then mounted. Immunohistochemistry of chondroitin-4-sulfate (C4S) and 
chondroitin-6-sulfate (C6S) was conducted in the same manner, except a digestion for 
2 hr using 0.2 U/mL chondroitinase ABC (Seikagaku America) was added before 
serum blocking, as required by the first antibody manufacturer.141 The C4S (1:100) 
and C6S (1:100) antibodies were obtained from Chemicon. Histological analysis was 
performed using a Safranin O/fast green stain with Harris hematoxylin. 
 An analysis of variance (ANOVA) was used to determine statistical 
significance (p < 0.05). Comparisons among groups were done using a Fisher’s 
Protected Least Significant Difference post-hoc test. Sample sizes were n = 4 for all 
biochemical tests. 
 
RESULTS 
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 We hypothesized that due to the high proliferative capacity of HUCM stem 
cells in monolayer cell culture compared to condylar cartilage cells, that they may 
have a similar advantage when grown on PGA scaffolds. Indeed, despite beginning 
with equivalent cell numbers, there were approximately 140 ± 22 x 103 cells per 
HUCM construct compared to 90 ± 9 x 103 cells per TMJ construct at week 0 (p < 
0.01) (Fig. 6.2), corresponding to 4.75 x 106 and 3.06 x 106 cells/mL, respectively. 
 
 
Figure 6.2: Mean cell number per construct ± standard deviation (n = 4). HUCM 
refers to the human umbilical cord cell-seeded constructs and TMJ refers to 
condylar cartilage cell-seeded constructs. Values are given in thousands of 
cells per construct. * indicates a significant difference from week 0 for the 
same cell type and # indicates a significant difference between HUCM and 
condylar cartilage at a given time point. 
 
At week 4, the cell content increased to 638 ± 121 and 674 ± 173 x 103 cells 
per HUCM construct cultured in chondrogenic and control medium, respectively (Fig. 
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6.2). There was a significant increase in cell number between the HUCM week 0 
group and both of the HUCM week 4 groups (p < 0.00002). Condylar cartilage cells 
cultured in chondrogenic and control media also increased significantly from week 0 
to 327 ± 19 x 103 and 339 ± 38 x 103 cells per TMJ construct, respectively (p < 
0.002). There was also a significant difference in cell number between HUCM and 
TMJ constructs at week 4 in both chondrogenic and control media (p < 0.0001). 
We next wanted to evaluate the potential of HUCM cells to produce 
extracellular matrix molecules required for cartilage formation compared to the native 
cartilage-forming cells. To achieve this, we measured the GAG and collagen content 
and examined the distribution of GAGs and collagen types I and II at week 0 and 
week 4 post-seeding for all groups. 
At week 0, the GAG content was 8.6 ± 1.1 μg and 11.3 ± 2.3 μg per construct 
(93 ± 17 and 80 ± 21 pg per cell) for the TMJ and HUCM groups, respectively (Fig. 
6.3). There was a significant decrease in GAG content from week 0 to week 4 for 
both the HUCM and TMJ constructs cultured in either medium (p < 0.00004). 
However, there was no significant difference in GAG synthesis between 
chondrogenic and control media at 4 weeks within the HUCM group or within the 
TMJ group. The production of GAGs was supported by Safranin-O staining, which 
revealed a larger concentration of GAGs in HUCM constructs in both control and 
chondrogenic medium compared to the concentration in TMJ constructs cultured in 
either control or chondrogenic media (Fig. 6.4). At week 4, immunohistochemistry 
presented positive staining of chondroitin-4-sulfate and chondroitin-6-sulfate more 
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intensely in the HUCM group than in the TMJ group, which was consistent with the 
Safranin-O staining (C4S shown in Fig. 6.4).  
 
 
Figure 6.3: Mean GAG biosynthesis per construct ± standard deviation (n = 4). 
HUCM refers to the human umbilical cord cell-seeded construct. 
Chondrogenic and control refer to the culture medium.  
 
While immunohistochemical staining attempts on TMJ condyle constructs 
were unsuccessful at week 0 (constructs washed off slides during processing), 
immunohistochemical analysis of the HUCM constructs at week 0 revealed the 
presence of type I collagen, and minute amounts of type II collagen (data not shown). 
The detection of collagen with immunohistochemical analysis was supported by the 
results of the hydroxyproline assay at week 0, which reported 4.6 ± 1.0 μg of collagen 
per HUCM construct, compared to 6.0 ± 1.1 μg of collagen per TMJ construct, which 
was not a significant difference. 
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Figure 6.4: The left column is Safranin-O/fast green staining after 4 weeks. The right 
column is immunohistochemical staining of chondroitin-4-sulfate (C4S) after 
4 weeks.  From the top row to the bottom is HUCM stem cells in control (left) 
or chondrogenic (right) medium, TMJ cartilage cells in chondrogenic 
medium, and TMJ cartilage cells in control medium. This evidence suggests 
the ability of HUCM stem cells to progress down a chondrogenic lineage in 
3D after initial exposure to chondrogenic signals. Moreover, the significantly 
higher intensity of staining for both Safranin-O and C4S 
immunohistochemistry (IHC) in the HUCM constructs demonstrates that the 
HUCM stem cells significantly outperform TMJ cartilage cells in GAG 
synthesis. The scale bars are 25 μm. 
 
  
109
 
 
Figure 6.5: HUCM and TMJ construct sections from constructs cultured in 
chondrogenic and control media after 4 weeks. Photos are taken after 
immunohistochemical staining for collagen types I and II, plus background 
staining. H, T, +, -, CI, CII, and Neg refer to HUCM stem cells, TMJ condylar 
cartilage cells, chondrogenic medium, control medium, collagen type I, 
collagen type II, and negative control groups, respectively. The brown areas 
indicate a positive stain, and dark purple stains are cell nuclei. The last two 
pictures provide high magnification examples of HUCM constructs. The scale 
bars are 25 μm. 
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At week 4, immunohistochemical analysis of HUCM constructs cultured in 
control medium revealed the presence of type I collagen, and minute amounts of type 
II collagen (Fig. 6.5). Immunohistochemical analysis of the HUCM constructs 
cultured in chondrogenic medium revealed a significant presence of type I collagen 
and minute amounts of type II collagen (Fig. 6.5). The results of the hydroxyproline 
assay at week 4, however, were inconclusive for both HUCM groups because the 
collagen content was below the detection limit of the assay, as was also the case for 
the TMJ constructs at week 4. 
Immunohistochemical staining of TMJ constructs cultured in control medium 
did not conclusively reveal the presence of type I collagen or type II collagen (Fig. 
6.5). However, immunohistochemical staining of the TMJ constructs cultured in 
chondrogenic medium revealed a weak presence of type I and type II collagen (Fig. 
6.5). 
 
DISCUSSION 
 
 To the best of our knowledge, this is the first attempt to evaluate the potential 
value of HUCM stem cells for musculoskeletal tissue engineering, and to culture 
condylar cartilage cells in 3D for tissue engineering. Comparing these two cell types 
is an important early step in our effort to engineer condylar cartilage. 
 In general, the presence of the chondrogenic medium after seeding did not 
seem to have a large effect on the biosynthetic and proliferative activity of the HUCM 
stem cells, although there were slight differences in collagen I and II biosynthesis 
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suggested by immunohistochemistry. HUCM stem cells have been shown to express 
bmi-1 and p21, genes which are both involved in anti-apoptotic pathways 
(unpublished data). This could possibly explain in part the greater cell numbers in the 
HUCM constructs than in the TMJ cell constructs at week 0 and week 4. Another 
explanation could be that the HUCM stem cells are better able to adhere to the 
construct than cartilage cells, which tend to interact less with their tissue environment 
than other cells. The increase in cell number in both groups at week 4 is likely due to 
continued cell proliferation, or a shorter doubling time of cells in 3D culture. 
Comparisons of doubling times of these cell types in both media types in monolayer 
vs. 3D-culture needs to be done to support this contention. Most importantly, it was 
demonstrated that HUCM cells remained highly proliferative in this environment and 
supported our hypothesis that they would be more proliferative than condylar 
cartilage cells. 
 HUCM constructs cultured in chondrogenic medium contained approximately 
the same number of cells as HUCM constructs cultured in control medium. The same 
trend was also observed with the TMJ constructs. Based on this observation, it 
appears that the TGF-β1 and the ITS+1 at the concentrations used did not 
significantly affect cell proliferation for either group during the 4-week culture 
period. 
 The sharp decrease in collagen synthesis reported by the hydroxyproline assay 
in both the HUCM and the TMJ groups at week 4 was unexpected. The 
immunohistochemical staining indicated the presence of collagen I and II in the 
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HUCM groups. Contraction of the constructs was also observed, which would 
produce a denser collagen matrix. The contraction of the construct would increase the 
visual density of the collagen (immunohistochemical results), despite the fact that the 
total quantity may be less than before (hydroxyproline assay results). 
 The large concentration of GAG produced by the HUCM constructs at week 0 
could be due in part to the presence of heparin or heparan sulfate, both of which are 
sulfated glycosaminoglycans. According to the manufacturer of the DMMB dye assay 
(Accurate Chemical), the assay will detect the presence of both heparin and heparan 
sulfate. Heparin is commonly found in connective tissue and residual amounts might 
have been present in the HUCM cell culture or more likely produced by the HUCM 
stem cells themselves. However, this higher metabolic activity could also mean that 
functional proteoglycans such as aggrecan and decorin are being synthesized. Indeed, 
the intense immunohistochemical staining for chondroitin sulfates in the HUCM 
constructs confirms that the primary GAG component of aggrecan has a strong 
presence, and is thus largely responsible for the high sulfated GAG concentration 
revealed by Safranin-O staining. 
 The decrease in the observed GAG content at week 4, as indicated by the 
DMMB assay, could be due to the degradation of the polymer construct, as discussed 
previously by Detamore and Athanasiou.259 In this case, some polymer fibers 
dislodge as the scaffold degrades, falling from the construct along with the GAGs 
attached to those fibers. This occurs when the rate of polymer degradation exceeds 
the rate of tissue formation, which might be most appropriately addressed by higher 
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cell seeding densities in the future. This observation could also be due in part to the 
contraction of the constructs at week 4. The decrease in GAG at week 4 was not, 
however, supported by the Safranin-O staining, which showed a dramatic increase in 
GAG concentration for the HUCM constructs.  
The higher amount of collagen and GAGs present in the HUCM constructs 
after static culture, as indicated by the immunohistochemical staining for collagen I, 
collagen II, and chondroitin sulfates, and by the Safranin-O histology, in addition to 
the higher cell numbers in the HUCM constructs, indicate that the HUCM stem cells 
may be a better candidate for cartilage tissue engineering applications than the TMJ 
condylar chondrocytes. 
The logical next steps will be to optimize the chondrogenic medium 
components and to compare HUCM stem cells to mesenchymal stem cells (MSCs) 
derived from bone marrow. It must be noted that though HUCM stem cells are 
themselves considered to be MSCs, they provide clear advantages over MSCs in that 
HUCM stem cells are easily obtained from a normally discarded tissue, are in 
abundant supply, have no donor site morbidity, are developmentally more primitive 
cells, and can be expanded for several passages (>p10) prior to senescence or 
differentiation.  
The results of the present study have demonstrated that constructs seeded with 
HUCM stem cells can be induced to proliferate and biosynthesize collagen I and 
glycosaminoglycans. While synthesis of collagen I is a successful outcome for 
engineering fibrocartilages like the TMJ condylar cartilage, extensions of this work 
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into engineering hyaline cartilages as in the knee and hip will require a much higher 
production of collagen II. Based on the difficulty in obtaining donor cartilage for 
tissue engineering applications, and the superior biosynthetic activity by HUCM stem 
cells, we conclude that HUCM stem cells may have a significant potential therapeutic 
value for tissue engineering applications in the future. 
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CHAPTER 7: A Comparison of Human Bone Marrow-
Derived Mesenchymal Stem Cells and Human Umbilical 
Cord-Derived Mesenchymal Stromal Cells for Cartilage 
Tissue Engineering* 
 
ABSTRACT 
 
Bone marrow-derived mesenchymal stem cells (BMSCs) have long been 
considered the gold standard for stem cell sources in musculoskeletal tissue 
engineering. The true test of stem cell source is a side-by-side comparison with 
BMSCs. Human umbilical cord-derived mesenchymal stromal cells (hUCMSCs), one 
such candidate with high potential, are a fetus-derived stem cell source collected from 
a discarded tissue (Wharton’s jelly) after birth. Compared to human BMSCs 
(hBMSCs), hUCMSCs have the advantages of abundant supply, painless collection, 
no donor site morbidity, and faster and longer self-renewal in vitro. In this 6-week 
study, a chondrogenic comparison was conducted between hBMSCs and hUCMSCs 
in a 3D scaffold for the first time. Cells were seeded on polyglycolic acid (PGA) 
scaffolds at 25M cells/ml and then cultured in identical conditions. Cell proliferation, 
biosynthesis, and chondrogenic differentiation were assessed at weeks 0, 3, and 6 
after seeding. At weeks 3 and 6, hUCMSCs produced more glycosaminoglycans 
(GAGs) than hBMSCs. At week 6, the hUCMSC group had 3 times more collagen 
than the hBMSC group. Immunohistochemistry revealed the presence of collagen 
types I and II and aggrecan with both groups. However, type II collagen staining was 
more intense for hBMSCs than hUCMSCs. Quantitative RT-PCR revealed a decrease 
_________________________________________________________________________________ 
*Chapter submitted to Tissue Eng Part A as Wang, Ivy, Seshareddy, Weiss, and Detamore. “A 
comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-
derived mesenchymal stromal cells for cartilage tissue engineering,” July 2008. 
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of type I collagen mRNA and an increase of type II collagen mRNA with both cell 
types. Therefore, it was concluded that hUCMSCs may be a better option for use as a 
MSC cell source for cartilage tissue engineering than hBMSCs, given the numerous 
advantages and superior biosynthesis of hUCMSCs in a 3D matrix. However, further 
investigation into signals that best promote chondrogenesis specifically for 
hUCMSCs is warranted. 
 
INTRODUCTION 
 
Mesenchymal stem cells (MSCs) can differentiate along a variety of cell 
lineages that can be used for tissue engineering and regenerative medicine. MSCs 
reside in many tissues including bone marrow,187 adipose tissue,188 blood,189 synovial 
fluid,190 dermis,191 muscle,192 and dental pulp.193 Among them, human bone marrow 
stem cells (hBMSCs) are the most commonly used MSCs for scientific and clinical 
purposes. They are isolated via plastic adhesion or negative selection from bone 
marrow aspirate that includes a highly heterogeneous cell population such as 
hematopoietic cells, endothelial cells, and adipocytes.310 However, there are some 
limitations of hBMSCs. The relative number of hBMSCs in the marrow and their 
differentiation potential decrease significantly with age increase.248 Moreover, the 
harvesting procedure is painful and invasive and may lead to complications and 
morbidity.249 Due to all the disadvantages associated with hBMSCs, efforts have been 
employed to find alternative sources of mesenchymal stem cells that function as well 
as hBMSCs but overcome these key limitations.  
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In recent years, umbilical cord-derived mesenchymal stromal cells (UCMSCs) 
have been explored as a MSC source with clear advantages over hBMSCs. UCMSCs 
are extracted through enzyme digestion or explant culture method from Wharton’s 
jelly of umbilical cords,200 a discarded tissue in abundant supply. The harvesting 
procedure is not invasive or painful and there is no donor site morbidity. The enzyme 
extraction yields 10-50×103 cells per cm of cord,80, 195 corresponding to 
approximately 2-10×105 primary cells per cord, and can be expanded 300-fold for 
over seven passages without the loss of differentiation potential.195 hUCMSCs 
strongly express surface markers that have been identified with other MSCs, 
including CD10,80 CD13,80, 199, 204, 208 CD29,76, 80, 204, 208 CD44,76, 77, 80, 195, 199, 204, 208 
CD49e,80, 225 CD51,76 CD73/SH3,76, 77, 195, 199, 204 CD90 (Thy-1),77, 80, 199, 208, 225 
CD105/SH2,76, 77, 80, 195, 199, 204 CD106,204 CD117,75, 77, 199 CD146,225 CD166,199, 204, 208 
and HLA-1/HLA-ABC,77, 80, 204, 208 and are negative for hematopoietic markers (e.g., 
CD14, CD31, CD34, CD38, CD45, HLA-DR).64, 65, 75-77, 80, 81, 195, 199, 201, 204, 208, 209, 225 
Moreover, the presence of Oct-4, Nanog, and Sox-2 transcription factors indicated 
that a subpopulation of UCMSCs might share some properties of both embryonic and 
non-embryonic stem cells.201 hUCMSCs have the ability to differentiate into 
mesenchymal cell-lineages such as osteogenic, chondrogenic, myogenic, and 
adipogenic.64, 76, 77, 195, 225 Moreover, the number of fibroblast colony-forming units 
(CFU-F) is significantly higher in hUCMSCs than hBMSCs.204  
In the past four years, only five previous studies demonstrated the 
chondrogenic differentiation of hUCMSCs in cell pellet culture76, 195, 225 or 
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poly(glycolic acid) (PGA) scaffolds.66, 207 Wang et al.76 first revealed evidence of 
chondrogenesis by a positive immunohistochemical (IHC) staining of type II 
collagen, which was also observed with non-differentiated cells. Other than a 
conference abstract,235 the first application of hUCMSCs in 3D musculoskeletal tissue 
engineering were performed by our group.66, 207 In these studies, we demonstrated that 
3D culture of hUCMSCs in PGA scaffolds led to a fibrocartilage with intense type I 
collagen, and moderate collagen type II and aggrecan immunostaining.66, 207 Here, our 
objective is to compare hUCMSCs and hBMSCs in vitro in a cartilage tissue 
engineering application. Both types of cells were cultured in PGA scaffolds, and we 
evaluated their proliferation, biosynthesis, and chondrogenic differentiation over a 
period of 6 weeks. 
 
MATERIALS AND METHODS 
 
Cell harvest 
hUCMSCs were harvested following our previous methods, with IRB 
approval and informed consent.80 The cells were plated and recorded as P0 in six well 
plates containing a low-serum medium at a density of 10,000 cells/cm2. The medium 
was composed of low-glucose Dulbecco's modified Eagle's medium (DMEM-LG; 
Invitrogen, Carlsbad, CA) and MCDB-201 medium (Sigma, St. Louis, MO) 
supplemented with 1× insulin-transferrin-selenium (Invitrogen), 0.15% lipid-rich 
bovine serum albumin (Albumax; Invitrogen), 0.1 nM dexamethasone (Sigma), 10 
µM ascorbic acid-2-phosphate (Sigma), 1× penicillin/streptomycin (Fisher Scientific, 
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Pittsburgh, PA), 2% fetal bovine serum (FBS; Invitrogen), 10 ng/mL recombinant 
human epidermal growth factor (Invitrogen), and 10 ng/mL human platelet-derived 
growth factor BB (R&D Systems, Minneapolis, MN). Cells in the well plates were 
fed every two to three days and maintained in a cell culture incubator (NuAire, 
Autoflow, 5% CO2, 37◦C and 90% humidity). Cells were then detached at 80-90% 
confluence and plated into 25 cm2 flasks. At P1, cells were resuspended at the density 
of 1 million cells per ml of freezing medium composed of 90% FBS and 10% 
dimethyl sulfoxide (DMSO; Fishersci). The cell suspension was transferred into 
cryotubes, which were stored in Mr. Frosty freezing containers (Nalgene, Rochester, 
NY) at -80°C overnight, and then transferred to a liquid nitrogen cryogenic storage 
system at -196°C for future use. P0 frozen hBMSCs were obtained from StemCell 
Technologies, with IRB approval. The bone marrow was extracted from the posterior 
iliac crest from a maximum of 4 sites/donor (25 ml/site). The phenotype of P0 
hBMSC was evaluated by flow cytometry and cells included CD29 (>90%), CD44 
(>90%), CD105 (>90%), CD166 (>90%), CD14 (<1%), CD34 (<1%) and CD45 
(<1%).  
 
Cell seeding 
Both types of cells were thawed and expanded with a plating density of 5000-
6000 cells/cm2 in 300 cm2 flasks to P4 in a medium containing DMEM-LG, 10% fetal 
bovine serum (StemCell Technologies), 1% penicillin/streptomycin (Invitrogen), and 
1% non-essential amino acids (NEAA; Invitrogen). Non-woven PGA meshes (50 
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mg/cc; Synthecon, Houston, TX) were punched to cylindrical scaffolds with a 5 mm 
diameter and 2 mm thickness, and then sterilized with ethylene oxide. After 
sterilization, the scaffolds were aired under a fume hood for one day, then wetted with 
sterile filtered ethanol and two washes of sterile PBS. The scaffolds were then soaked 
in the medium for one day and the medium was removed for cell seeding. Both cell 
types, at P4, were seeded at 20 million cells per ml of scaffold via orbital shakers onto 
PGA scaffolds at 150 rpm for 24 hrs. Finally, the medium was replaced by 2 ml of 
chondrogenic-differentiation medium consisting of high-glucose DMEM (DMEM-
HG; Invitrogen), 1% NEAA, 1× insulin-transferrin-selenium premix (ITS premix; BD 
Biosciences, San Jose, CA), 10 ng/ml transforming growth factor beta-1 (TGF-β1; 
PeproTech, Rocky Hill, NJ), 100 nM dexamethasone (Sigma), 50 μg/ml ascorbic acid 
2-phosphate (Sigma), 100 mM sodium pyruvate (Fishersci), and 40 μg/ml L-proline 
(Sigma). This time point was recorded as week 0. Medium was changed every other 
day over a period of 6 weeks. 
 
Biochemical analysis 
At weeks 0, 3 and 6, constructs were digested by adding 1.1 ml papain 
solution (120 μg/ml) at 60 C overnight, and then constructs were stored at 　　 -20 °C 
for future assays. Cell number was determined by measuring DNA content via a 
PicoGreen kit (Invitrogen). A conversion factor of 8.5 pg DNA/cell was determined 
in preliminary studies. Biosynthesis was evaluated by measuring total GAG and 
hydroxyproline (HYP) contents. GAG content was measured using a 
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dimethylmethylene blue (DMMB) dye binding assay kit (Biocolor, Belfast, UK). 
From each sample, 100 μL was added to 1 ml of DMMB and allowed 30 min to bind. 
Solutions were then centrifuged, supernatant was discarded, and the pellet was 
resuspended and read at 656nm. HYP content was determined by using a modified 
HYP assay.311 Briefly, 400μL of each sample was hydrolyzed with an equal volume 
of 4N sodium hydroxide at 121oC for 30 min, neutralized with an equal volume of 4N 
hydrochloric acid, and then titrated to an approximate pH range between 6.5 and 7.0. 
One ml of this solution was combined with 0.5 ml Chloramine-T (14.1 g/L) in the 
buffer (50 g/l citric acid, 120 g/l sodium acetate trihydrate, 34 g/l sodium hydroxide 
and 12.5 g/l acetic acid), and the resulting solution was then combined with 0.5 ml of 
1.17 mM p-dimethylaminobenzaldehyde in perchloric acid and read at 550 nm. A 
conversion factor of 11.5 can be used to convert HYX mass to collagen mass based 
on our preliminary studies. 
 
Immunohistochemistry for types I and II collagen and aggrecan 
Immunohistochemical analysis was performed in a BioGenex i6000 
autostainer (BioGenex, San Ramon, CA). Scaffolds were frozen and sliced into thin 
sections (10 μm) that were fixed in chilled acetone (4 oC) for 10 min before staining. 
Slides were (n = 2) rehydrated with PBS for 5 min. Endogenous peroxidase activity 
was inhibited using 1% hydrogen peroxide in methanol for 30 min. Each section was 
blocked in 3% horse serum for 20 min and incubated with a primary antibody for an 
hour. Primary antibodies used in this study included the mouse monoclonal IgG anti-
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collagen I (1:1500 dilution; Accurate Chemical and Scientific, Westbury, NY), mouse 
monoclonal IgG anti-collagen II (1:1000 dilution; Chondrex, Redmond, WA), and 
mouse monoclonal IgG anti-aggrecan (1:50 dilution; Abcam, Cambridge, MA). 
Following primary antibody incubation, the sections were incubated with a 
streptavidin-linked horse anti-mouse IgG secondary antibody (Vector Laboratories, 
Burlingame, CA) for 30 min. After secondary antibody incubation, the sections were 
incubated with an avidin-biotinylated enzyme complex (ABC complex; Vector 
Laboratories) for 30 min, and then VIP substrate (purple color) (Vector Laboratories) 
was applied on sections for 6 min. Protocols run with the primary antibody omitted 
served as negative controls. 
 
RNA isolation and gene expression analysis 
Real-time reverse transcriptase polymerase chain reaction (real time RT-PCR) 
was used to quantify the relative gene expression level of types I and II collagen, and 
aggrecan. The constructs were collected at weeks 3 and 6 and homogenized with an 
electrical homogenizer in 1 ml of Trizol reagent (Invitrogen) to extract mRNA 
according to the manufacturer’s protocol. Total mRNA was reverse transcribed to 
cDNA using a High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, 
CA). Real-time RT-PCR reactions were run in an Applied Biosystems 7500 Fast 
Sequence Detection System. TaqMan gene expression assay kits (Applied 
Biosystems), including two pre-designed primers and one probe, were used for 
transcript levels of the proposed genes. 2 μl of cDNA from each sample was mixed 
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with 7 μl of RNase/DNase free water, 1 μl of 20 × TaqMan gene expression assay 
reagent, and 10 μl of 2 × TaqMan universal PCR master mix. Assay IDs of TaqMan 
gene expression assays were Hs00164004_m1 for type I collagen, Hs00156568_m1 
for type II collagen, Hs00153936_m1 for aggrecan, and Hs99999905_m1 for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Relative mRNA expression 
level for each target gene was evaluated using a 2−ΔΔCt method.312 The Ct values of 
target genes were first normalized by subtracting the Ct values of the TaqMan human 
housekeeping gene GAPDH to obtain ΔCt values. They were then normalized by 
subtracting the Ct value of the calibrator sample, the hBMSC group at week 3, to get 
ΔΔCt values, which were finally calculated to acquire the fold changes. Each sample 
was analyzed in triplicate.  
 
Statistical analysis  
All data were expressed as means ± one standard deviation and analyzed by 
analysis of variance (ANOVA) followed by Tukey’s Honestly Significant Difference 
(HSD) post hoc tests. Two-way ANOVAs with interaction were performed with time-
points and cell sources as statistical factors. A statistical threshold of p < 0.05 was 
used to indicate whether there were statistically significant differences among 
different groups. 
 
RESULTS 
 
Cell number 
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Figure 7.1: Seeding efficiency at week 0 (A) and cell number at weeks 0, 3, and 6 
(B). * = statistically significant difference between hUCMSC and hBMSC 
groups. # = statistically significant difference between weeks 0 and 3. Error 
bars represent standard deviations. 
 
During the monolayer expansion prior to 3D seeding stage, hUCMSCs had a 
higher proliferation rate than hBMSCs. At the same plating density of 5000-6000 
cells/cm2, hUCMSCs reached 80-90% confluence within 3-4 days, while hBMSCs 
took 4-6 days to reach the same confluence. At week 0, a seeding efficiency (defined 
as the percentage ratio of the number of attached cells to the number of seeded cells) 
of 75% was achieved with hUCMSCs, while a seeding efficiency of only 62% was 
observed with hBMSCs (p < 0.05) (Fig. 7.1A). After the initial seeding period, both 
hUCMSC and hBMSC groups maintained cell numbers over 6 weeks, except for a 
drop (p < 0.05) at week 3 in hBMSC groups. However, following the drop, a recovery 
increase in cell number occurred without significant difference. In comparison, the 
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cell number in the hUCMSC group was significantly higher than in the hBMSC 
group throughout the culture period (p < 0.05) (Fig. 7.1B). 
 
GAG and HYP content 
There was a continuing increase in GAG content per construct in the 
hUCMSC group over 6 weeks (p < 0.05), whereas the GAG content decreased in the 
hBMSC group from weeks 0 to 3 (p < 0.05) and then increased from weeks 3 to 6 (p 
< 0.05) (Fig. 7.2A). However, the increases did not lead to a significant difference 
between weeks 0 and 6 for either group. In comparison to the hBMSC group, the 
hUCMSC group had a 51% and 28% higher GAG content per construct at weeks 3 
and 6, respectively (p < 0.05). With regard to GAG content per cell, both the 
hUCMSC and hBMSC groups had a significant increase between weeks 0 and 6 (Fig. 
7.2B) (p < 0.05). There was also a significant increase in GAG content for the 
hBMSC group from weeks 3 to 6 (p < 0.05). In comparison to the hBMSC group, the 
hUCMSC group at week 3 had a higher GAG content per cell (p < 0.05), although 
there was no statistically significant difference between them at week 6. 
HYP content both per construct and per cell increased markedly from weeks 0 
to 3 in both the hUCMSC and hBMSC groups (Fig. 7.2C-D), while there was no 
increase in HYP content between weeks 3 and 6 for either group. Comparatively, the 
hUCMSC group had 2.5 and 2.9 times more HYP content per construct than the 
hBMSC group at weeks 3 and 6 (p < 0.05), respectively. Similar to HYP content per 
construct, the HYP content per cell increased from weeks 0 to 3 (p < 0.05) and then 
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maintained with no significant changes until week 6 for both groups. In comparison 
to each other, the hUCMSC group processed 1.7 and 2.1 times more HYP content per 
cell than the hBMSC group (p < 0.05).  
 
Figure 7.2: GAG and HYP contents per construct and per cell at weeks 0, 3, and 6. * 
= statistically significant difference between hUCMSC and hBMSC groups at 
a specific time point. # = statistically significant difference between weeks 0 
and 3 in either hUCMSC or hBMSC group. @ = statistically significant 
difference between weeks 3 and 6 in either hUCMSC or hBMSC group. Error 
bars represent standard deviations. 
 
Immunohistochemistry  
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Immunohistochemistry revealed positive staining for types I and II collagen 
and aggrecan with both the hUCMSC and hBMSC groups through the 6-week period 
(Fig. 7.3). At week 3, both the hBMSC and hUCMSC groups showed an abundant 
amount of type I collagen, a small amount of type II collagen, and a moderate amount 
of aggrecan. Relatively stronger staining of type I collagen and aggrecan was present 
in the hUCMSC group than in the hBMSC group. At week 6, both the hUCMSC and 
hBMSC groups presented a concentrated staining for type I collagen and a more 
intense staining for aggrecan than at week 3. There was a vast increase in type II 
collagen staining in the hBMSC group from weeks 3 to 6, while only a trace presence 
of type II collagen was detected in the hUCMSC group at week 6. 
 
 
Figure 7.3: Immunohistochemical staining for types I and II collagen, and aggrecan. 
The scale bar is 500 μm. CI = type I collagen, CII = type II collagen, @3WK 
= at week 3, and @6WK = at week 6. 
  
128
 
RT-PCR analysis 
Compared to hBMSCs, hUCMSCs had a lower mRNA level of type I 
collagen at weeks 3 and 6 (p < 0.05), a lower mRNA level of type II collagen at week 
6, and the same level of aggrecan at weeks 3 and 6 (Fig.7.4). From weeks 3 and 6, in 
both the hUCMSC and hBMSC groups, type I collagen mRNA level decreased (p < 
0.05) and aggrecan mRNA level remained at the same level. Type II collagen mRNA 
level had a 3.8-fold increase in the hBMSC group from weeks 3 to week6 (p < 0.05), 
while no change was observed in the hUCMSC group.  
 
Figure 7.4: Gene expression for types I and II collagen, and aggrecan. CI = type I 
collagen, CII = type II collagen. * = statistically significant difference 
between hUCMSC and hBMSC groups at a specific time point. # = 
statistically significant difference between weeks 3 and 6 in either hUCMSC 
or hBMSC group. 
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DISCUSSION 
 
It has been previously shown that hUCMSCs can differentiate toward a 
chondrogenic lineage.66, 76, 195, 225 However, the application of these cells in 
musculoskeletal tissue engineering has been scarcely investigated.66, 207, 235 This study, 
for the first time, specifically focused on the comparison between hUCMSCs and 
hBMSCs in a biomaterial-based 3D environment. This comparison is vital to the 
validation of hUCMSCs as a formidable cell source for cartilage—and more broadly, 
musculoskeletal—tissue engineering. 
The faster proliferation rate of the hUCMSCs on monolayer culture provides 
for a larger number of cells in a shorter time period to better meet the needs of tissue 
engineering and clinical practice. The higher seeding efficiency with the hUCMSCs 
at week 0 indicated that hUCMSCs were more adherent to PGA scaffolds than 
hBMSCs. This higher seeding efficiency resulted in a higher cell number for the 
hUCMSC group, which was maintained over 6 weeks and likely contributed in part to 
the higher matrix production in the hUCMSC group. The decrease in cell number 
with hBMSCs from weeks 0 to 3 may be due to the degradation of the PGA scaffold, 
as we have noted in the past.207, 259 In fact, the hUCMSC group also experienced a 
slight loss of cells (not statistically significant). The maintenance of cell numbers 
with hUCMSCs can be explained by the ability of hUCMSCs to proliferate at a 
higher rate as well as the higher matrix content that helps to retain cells in scaffolds. 
To overcome cell loss caused by PGA degradation, slowly degraded scaffolds such 
PLLA and PLGA will be investigated in the future. 
  
130
In this study, the hUCMSC group produced more GAGs than the hBMSC 
group. The higher GAG content per construct with hUCMSCs was due to the larger 
number of cells, as the GAG content per cell at week 6 was similar for the two 
groups. With regard to collagen production, both the hBMSC and hUCMSC groups 
showed an increase in collagen content throughout the 6-week culture, with the 
largest increase occurring between weeks 0 to 3. The higher porosity of cell-scaffold 
constructs in the first 3 weeks might contribute to higher collagen production, as it 
provided large space for matrix synthesis and nutrient diffusion. When compared 
directly to each other, the hUCMSC group produced 2.5 and 3.5 times more collagen 
per construct than the hBMSC group at weeks 3 and week6, respectively. More 
importantly, the hUCMSC group had more collagen per cell than the hBMSC group, 
indicating that hUCMSCs are better able to produce collagen than hBMSCs under the 
prescribed conditions. Thus, the high collagen content produced by hUCMSCs is 
attractive for cartilage tissue engineering. 
Exposed to chondrogenic media, both types of cells produced a cartilage-like 
tissue with both types I and II collagen, and aggrecan. The chondrogenic 
differentiation of both cell types was accompanied by a down-regulation of type I 
collagen gene expression during this period. A higher type II collagen expression in 
the hBMSC group at both the mRNA and protein levels suggested that chondrogenic 
differentiation was more extensive with hBMSCs under the prescribed conditions. 
However, mRNA and protein expression of aggrecan was comparable between the 
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two groups, which suggests that hUCMSCs were at least in one capacity matching the 
apparent chondrogenesis of hBMSCs. 
In previous hUCMSC pellet culture,76, 195 plentiful type II collagen76, 195 was 
observed with a little type I collagen19 around the periphery. Limited oxygen 
(hypoxia) exists in the center of cell pellets due to low diffusion coefficient,313 which 
may have contributed to the production of type II collagen.314 It was unexpected that 
only a trace amount of type II collagen19 was observed in hBMSC pellets because 
hBMSCs generally produced dominant type II collagen in pellets.315 Compared to cell 
pellets, the constructs based on highly porous PGA scaffolds (> 95% porosity) in the 
current study had better diffusion, especially at the early stages. Moreover, the 
differences of chondrogenic media (TGF-β1 vs. β3) and harvesting methods might 
explain these conflicting results between the pellet culture in the literature and the 
biomaterial-based culture in this study.  
In conclusion, hUCMSCs proliferated faster, were seeded more efficiently, 
and demonstrated superior biosynthesis with nearly three times more collagen 
production. Although hBMSCs appeared to have progressed further down a 
chondrogenic lineage based on superior collagen II production, one may expect that 
the hUCMSCs will require a slightly modified set of signals to provide for optimal 
chondrogenesis. With the identification of this set of signals, it would be expected 
that hUCMSCs will be capable of producing a similar tissue in a drastically reduced 
time, which will translate to better patient care. hUCMSCs provide clear advantages 
over hBMSCs in that hUCMSCs are easily obtained from a discarded tissue, are in 
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abundant supply, have no donor site morbidity, and are highly expendable prior to 
senescence or differentiation. Moreover, in the future, if parents cryogenically save 
part of their child’s umbilical cord, these hUCMSCs would also be available as an 
autologous cell source later in life with all of the aforementioned advantages. Based 
on these known advantages, and the results of this study, we therefore conclude that 
hUCMSCs are indeed a highly desirable cell source for cartilage tissue engineering, 
with significant and distinct advantages over the “gold standard” of hBMSCs. 
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CHAPTER 8: The Effect of Initial Seeding Density on 
Human Umbilical Cord Mesenchymal Stromal Cells for 
Fibrocartilage Tissue Engineering* 
 
ABSTRACT 
 
Cells derived from Wharton’s jelly from human umbilical cords (called 
umbilical cord matrix mesenchymal stromal cells, here) are a novel cell source for 
musculoskeletal tissue engineering. In this study, we examined the effects of different 
seeding densities on seeding efficiency, cell proliferation, biosynthesis, mechanical 
integrity and chondrogenic differentiation. Cells were seeded on non-woven 
polyglycolic acid (PGA) meshes via orbital shaker, at densities of 5, 25 or 50 million 
cells/ml, then statically cultured for 4 weeks in chondrogenic medium. At week 0, 
initial seeding density did not affect seeding efficiency. Throughout the 4 week 
culture period, absolute cell numbers of the 25 and 50 million cells/ml (higher 
density) groups were significantly larger than the 5 million cells/ml (lower density) 
group. The presence of collagen types I and II and aggrecan was confirmed by 
immunohistochemical staining. GAG and collagen contents per construct in the 
higher density groups were significantly higher than in the lower density group. 
Constructs in the high density groups maintained their mechanical integrity, which 
was confirmed by unconfined compression testing. In conclusion, human umbilical 
cord matrix cells demonstrated the potential for chondrogenic differentiation in 3D 
tissue engineering, and higher seeding densities better promoted biosynthesis and 
mechanical integrity and thus a seeding density of at least 25 million cells per ml is 
__________________________________________________________________________________ 
*Chapter published as Wang, Seshareddy, Weiss, and Detamore. “The effect of initial seeding density 
on human umbilical cord matrix mesenchymal stromal cells for fibrocartilage tissue engineering,” 
Tissue Eng Part A, In Press, 2008. 
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recommended for fibrocartilage tissue engineering with umbilical cord matrix 
mesenchymal stromal cells. 
 
INTRODUCTION 
 
Fibrocartilage, is a primarily avascular tissue that is distinctly different from 
either fibrous tissues or hyaline cartilage.316, 317 For example, fibrocartilage contains 
more type I collagen and less type II collagen and proteoglycans than hyaline 
cartilage.316 Tissue engineering of fibrocartilage, aiming to create a functional 
replacement, offers promise for regenerative medicine with fibrocartilage defects. 
The approach of using differentiated adult cells is limited by insufficient cell 
availability and the loss of cell phenotype during in vitro expansion.84-87 Tissue 
engineering with mesenchymal stem cells (MSCs) is attractive because of their 
expansion ability (self-renewal ability) and their ability to differentiate into cartilage, 
bone or other tissues in vitro. 
Bone marrow-derived mesenchymal stem cells (BMSCs) are extensively used 
in musculoskeletal tissue engineering. They differentiate into multiple cell lineages 
including bone, cartilage, and other mesenchymal tissues when exposed to specific 
growth factors.58, 231, 318-320 However, BMSCs have limited self-renewal ability and an 
age-dependent decrease in cell availability and proliferation. Furthermore, isolation of 
BMSCs requires an invasive and painful surgical procedure. Recently, umbilical cord 
matrix mesenchymal stromal cells (UCMSCs) have been shown to have extensive in 
vitro expansion capability, and ability to differentiate into mesenchymal cell-lineages 
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such as osteogenic, chondrogenic, myogenic, and adipogenic.64, 76, 77, 195, 225 These 
cells are extracted through enzyme digestion or explant culture method from 
Wharton’s jelly of umbilical cords.200 The extraction yields 10-50×103 cells per cm of 
cord,80, 195 which can be expanded 300-fold for over seven passages without the loss 
of differentiation potential.195 UCMSCs have the appearance of myofibroblasts, in 
terms of positive staining for the expression of vimentin, desmin, and/or α-smooth 
muscle actin in native tissue or in vitro cultured cells.75, 226, 227 UCMSCs process 
markers found in BMSCs including CD29, CD44, CD90, CD105, and CD166.80, 195 
Moreover, the presence of Oct-4, Nanog, and Sox-2 transcription factors indicated 
that a subpopulation of UCMSCs might share some properties of both embryonic and 
non-embryonic stem cells.201 Therefore, with the advantages of being easily obtained 
from a normally discarded tissue, abundant supply, no donor site morbidity, and 
expansion ability prior to senescence, UCMSCs are an attractive alternative for tissue 
engineering and regenerative medicine. 
Recently, human UCMSCs (hUCMSCs) have been proposed for use in 
musculoskeletal tissue engineering.66 The chondrogenic ability of hUCMSCs has 
been indicated by Alcian blue staining76, 225 and toluidine blue staining for 
glycosaminoglycans (GAGs),195 picrosirius red staining and Heidenhain's azan 
staining for collagen,195, 225 and immunohistochemical staining for type I and II 
collagen.76, 195 Our previous study compared hUCMSCs and mandibular condylar 
cartilage cells for tissue engineering mandibular condylar cartilage, the first full study 
with hUCMSCs in 3D musculoskeletal tissue engineering.66 Both types of cells were 
  
136
seeded on non-woven polyglycolic acid (PGA) meshes using spinner flasks and then 
statically cultured for 4 weeks in well plates containing either chondrogenic or control 
medium. The results demonstrated that hUCMSCs can be induced to produce type I 
collagen, chondroitin sulfates, and other GAGs. When compared to the tissue-
engineered constructs using condylar cartilage cells, hUCMSC constructs had more 
cells and higher GAG production.  
Toward tissue engineering using hUCMSCs, the initial cell density is critical 
for cell growth and extracellular matrix synthesis.274, 321, 322 A previous study with 
fibrocartilage cells demonstrated that a lower cell density led to a loss of mechanical 
integrity, while a higher density benefited collagen production.274 The goal of the 
current study was to demonstrate the fibrochondrogenic differentiation of hUCMSCs 
on non-woven PGA scaffolds and evaluate the effects of initial cell seeding density 
on cell number, biosynthesis and biomechanical properties. We hypothesized that 
hUCMSCs would form a fibrocartilage-like tissue with both types I and II collagen 
and aggrecan, and that a higher seeding density would maintain scaffold integrity and 
increase matrix synthesis per construct and per cell. 
 
MATERIALS AND METHODS 
 
Cell harvest 
Human umbilical cord collection and cell harvests were approved by the 
Kansas State University human subject board (IRB approval no. 3966). Cells were 
isolated via enzyme digestions as described by Weiss et al.80 with minor 
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modifications. In brief, human umbilical cords were collected and cut into 3-5 cm 
pieces, and then vessels were removed from cord segments. Cord segments were 
incubated in hyaluronidase (1 mg/ml; Catalog# H2126; Sigma, St. Louis, MO) and 
collagenase type I (300 units/ml; Catalog# 17100-017; Invitrogen, Carlsbad, CA) for 
1 hr at 37°C. After 1-hr incubation, the tissue pieces were crushed with tweezers to 
release cells from Wharton’s jelly. The remaining segments were moved to new 
centrifuge tubes containing 0.1% trypsin/EDTA for another 30 min of incubation at 
37°C and were then squeezed again to release additional cells from Wharton’s jelly. 
Both vials containing cells from Wharton’s jelly were combined and centrifuged at 
250 x g for 5 min immediately after the second digestion. The cells were resuspended 
and plated in six well plates containing a low-serum medium at a density of 10,000 
cells/cm2. The medium is composed of low-glucose Dulbecco's modified Eagle's 
medium (DMEM-LG; Catalog# 11885-092; Invitrogen) and MCDB-201 medium 
(Catalog# 045k8310; Sigma) supplemented with 1× insulin-transferrin-selenium 
(Catalog# 51300-044; Invitrogen), 0.15% lipid-rich bovine serum albumin (Catalog# 
11020-021; Albumax, Invitrogen), 0.1 nM dexamethasone (Catalog# D2915; Sigma), 
10 µM ascorbic acid-2-phosphate (Catalog# A-8960; Sigma), 1× 
penicillin/streptomycin (Catalog# 30-001-CI; Fisher Scientific, Pittsburgh, PA), 2% 
fetal bovine serum (FBS; Catalog# 16141079; Invitrogen), 10 ng/mL recombinant 
human epidermal growth factor (Catalog# 13247-051; Invitrogen), and 10 ng/mL 
human platelet-derived growth factor BB (Catalog# 220-BB-050; R&D Systems, 
Inc.). Cells in the well plates were recorded as P0 and were fed every two to three 
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days and maintained in a cell culture incubator (NuAire, Autoflow, 5% CO2, 37◦C 
and 90% humidity). When cells had reached 80-90% confluence, they were detached 
and plated into 25 cm2 flasks. At P1, cells were resuspended at a density of 1 million 
cells per ml freezing medium, composed of 90% FBS and 10% dimethyl sulfoxide 
(DMSO; Catalog# 61097-1000; Fisher Scientific). The cell suspension was 
transferred into cryotubes (Catalog# 5000-1020; Nalgene Labware, Rochester, NY), 
which were stored in Mr. Frosty freezing containers (Catalog# 5000-0001; Nalgene) 
at -80°C overnight, and transferred to a liquid nitrogen cryogenic storage system at -
196°C for future use. 
 
Cell seeding 
Cells were thawed and expanded to P5 in the complete medium containing 
DMEM-LG, 10% fetal bovine serum (Catalog# 6472; StemCell Technologies), 1% 
penicillin/streptomycin (Catalog# 15140-122; Invitrogen), and 1% non-essential 
amino acids (NEAA; Catalog# 11140-050; Invitrogen). Non-woven PGA meshes 
(Concordia Manufacturing, Coventry, RI) were punched to round-shape scaffolds 
with a 5 mm diameter and 1.5 mm thickness, and then sterilized with ethylene oxide. 
After sterilization, the scaffolds were aired under a fume hood for one day, then 
wetted with sterile filtered ethanol and two washes of sterile phosphate buffered 
saline (PBS). The scaffolds were then soaked in complete medium for one day and 
then removed for cell seeding. P5 hUCMSCs were seeded at 5, 25 and 50 million 
cells per ml of scaffold via orbital shakers onto PGA scaffolds at 150 rpm for 24 hrs, 
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and were allowed to attach in the culture medium for another day. Finally, the 
complete medium was replaced by 2 ml chondrogenic medium including high-
glucose DMEM (DMEM-HG; Catalog# 10566-016; Invitrogen), 1% NEAA, 1× 
Insulin-Transferrin-Selenium premix (Catalog# 354350; ITS premix; BD 
Biosciences, San Jose, CA), 10 ng/ml transforming growth factor beta-1 (TGF-β1; 
Catalog# 100-21C; PeproTech, Rocky Hill, NJ), 100 nM dexamethasone (Catalog# 
D4902; Sigma), 50 μg/ml ascorbic acid 2-phosphate (Catalog# A-8960; Sigma), 100 
mM sodium pyruvate (Catalog# SH3023901; Fisher Scientific), and 40 μg/ml L-
proline (Catalog# P5607-25G; Sigma). This time point was recorded as week 0. 
Medium was changed every other day for 4 weeks. 
 
Biochemical analysis 
At week 0, week 2, and week 4, constructs (n = 4) were digested by adding 
1.1 ml papain solution (120 μg/ml) at 60 °C overnight, and then constructs were 
stored at -20 °C for biochemical assays. Cell number was determined by measuring 
DNA content, which was accomplished via a reaction between PicoGreen and DNA 
using a kit with provided DNA standards (Kit# P7589; Invitrogen). A conversion 
factor of 8.5 pg DNA/cell was determined in preliminary studies. Biosynthesis was 
evaluated by measuring total GAG and collagen content. GAG content was measured 
using a dimethylmethylene blue (DMMB) dye binding assay kit (Kit# B1500; 
Biocolor; Northern Ireland). Chondroitin sulfate provided with the kit was used as the 
GAG standard. From each sample, 100 μL was added to 1 ml of DMMB and allowed 
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30 min to bind. Solutions were then centrifuged, supernatant was discarded, and the 
pellet was resuspended and read at 656 nm. Hydroxyproline content was determined 
by using a modified hydroxyproline assay.311 Briefly, 400 μL of each sample was 
hydrolyzed with an equal volume of 4N sodium hydroxide at 121oC for 30 min, 
neutralized with an equal volume of 4N hydrochloric acid, and then titrated to an 
approximate pH range between 6.5 and 7.0. One ml of this solution was combined 
with 0.5 ml Chloramine-T (14.1 g/L) in the buffer (50 g/l citric acid, 120 g/l sodium 
acetate trihydrate, 34 g/l sodium hydroxide and 12.5 g/l acetic acid). The resulting 
solution was then combined with 0.5 ml of 1.17 mM p-dimethylaminobenzaldehyde 
in perchloric acid and read at 550 nm.  
 
Immunohistochemistry for types I and II collagen, and aggrecan 
Immunohistochemical analysis was performed in a BioGenex i6000 
autostainer (BioGenex, San Ramon, CA). Frozen sections of the 3D constructs (10 
μm) (n = 2) were rehydrated with PBS for 5 min and endogenous peroxidase activity 
was inhibited using 1% hydrogen peroxide in methanol for 30 min. The sections were 
then blocked in 3% horse serum for 20 min and incubated with a primary antibody for 
1 hr. Primary antibodies used in this study included the mouse monoclonal IgG anti-
collagen I (1:1500 dilution; Catalog# BYA6520-1; Accurate Chemical and Scientific, 
Westbury, NY), mouse monoclonal IgG anti-collagen II (1:1000 dilution; Catalog# 
7005; Chondrex, Redmond, WA), and mouse monoclonal IgG anti-aggrecan (1:50 
dilution; Catalog# ab3778-1; Abcam, Cambridge, MA). Following primary antibody 
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incubation, the sections were incubated with a streptavidin-linked horse anti-mouse 
IgG secondary antibody (Kit# PK-6102; Vector Laboratories, Burlingame, CA) for 30 
min. After secondary antibody incubation, the sections were incubated with avidin-
biotinylated enzyme complex (Kit# PK-6102; ABC complex; Vector Laboratories) for 
30 min, and then VIP substrate (purple color) (Catalog# SK-4600; Vector 
Laboratories) was applied on sections for 4 min. Protocols run with the primary 
antibody omitted served as negative controls. 
 
Mechanical integrity 
At week 4, unconfined compression tests were performed using a uniaxial 
testing apparatus (Instron 5848). Hydrated samples (n = 4) were placed on the testing 
platen in a custom-made bath, and a tare load of 0.01 N was applied. The bath was 
then filled with 0.1 M PBS at 37 ºC to equilibrate under the tare load for 5 min. A 
20% ramp strain was then applied at 1 mm/min, followed by stress relaxation for 1.5 
hrs. Compressive elastic moduli were determined from the strain-stress curve. The 
stress relaxation following the ramp strain was fitted by the second order generalized 
Kelvin model as described by Fung:323 
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where ER is the equilibrium modulus, σ(t) is the stress profile, εo is the ramp strain, 
and τσ and τε are the creep and stress relaxation time constants, respectively. 
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Statistical analysis 
All data were expressed as means ± one standard deviation, and analyzed by 
analysis of variance (ANOVA) followed by Tukey’s Honestly Significant Difference 
(T-HSD) post hoc tests. Two-way ANOVAs with interaction were used to determine 
whether there were differences among either time-points or seeding densities. In 
addition, one-way ANOVAs were performed to specifically compare the differences 
among groups at specific time points or at specific densities. A statistical threshold of 
p < 0.05 was used to indicate whether there were statistical significances among 
different groups. 
 
RESULTS 
 
Scaffold morphology 
After 4 weeks of culture, the dimensions of the scaffolds decreased to 20.8 ± 
7.1% of the original volume at the medium density and 57.2 ± 9.2% at the high 
density (Fig. 8.1A). It was not possible to record accurate dimensions for the low 
density group due to the formation of tiny cell pellets with irregular shapes and poor 
mechanical integrity. The volume loss corresponded to an increase in the cell density 
of the scaffolds (Fig. 8.1B). Cell densities in the medium and high density groups 
each significantly increased from week 0 to week 4 (p < 0.05). 
 
Cell number 
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Figure 8.1: Scaffold size and cell density (cells per scaffold volume) (n = 4). * = 
statistically significant difference between the medium and high density 
groups. # = statistically significant difference between weeks 0 and 4. Error 
bars represent standard deviations. 
 
There were no significant differences among the seeding efficiencies, with 
56.6 ± 0.9% at the low density, 57.3 ± 5.0% at the medium density, and 54.7 ± 2.8% 
at the high density. The cell numbers in all groups had moderate or significant 
decreases through the 4-week culture time (Fig. 8.2), despite the increase in cell 
density. All groups had a significant decrease in cell number between week 0 and 
week 2. Although the low seeding density group had a significant decrease from week 
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2 to week 4, there was no significant decrease in either the medium seeding density or 
high seeding density group between weeks 2 and 4. As expected, the high density 
group maintained higher cellularity than the medium group over the culture period (p 
< 0.05) (Fig. 8.2). At week 2, the high density group had 2.4 and 14.1 times more 
cells than the medium group (p < 0.05) and the low density group (p < 0.05), 
respectively. At week 4, the high density group had 1.9 and 25.1 times more cells 
than the medium group (p < 0.05) and the low density group (p < 0.05), respectively. 
 
 
Figure 8.2: Cell number per construct with low, medium and high cell seeding 
density derived from DNA content (n = 4). * = statistically significant 
difference. Error bars represent standard deviations.   
 
GAG and hydroxyproline content 
There was a significant decrease in the GAG content per construct with all 
density groups from week 0 to week 4 (Fig. 8.3A). The low density group at week 4 
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Figure 8.3: GAG content per construct (A) and per cell (B) with low, medium and 
high cell seeding density (n = 4). * = statistically significant difference. Error 
bars represent standard deviations.    
 
almost lost all GAG content (less than 1 μg), and the GAG content per cell in the low 
density group exhibited a decrease as well (Fig. 8.3B). The GAG content per cell in 
the low density group at week 0 was significantly higher than the medium and high 
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Figure 8.4: Hydroxyproline content per construct (A) and per cell (B) with low, 
medium and high cell seeding density (n = 4). * = statistically significant 
difference. Note that the high density group had significantly higher 
hydroxyproline content per construct than the medium density group. Error 
bars represent standard deviations. For collagen content, multiply values by a 
conversion factor of 11.5.  
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density groups. However, the GAG contents per construct of the medium and high 
density groups at week 4 were 62.7% and 72.9% of their values at week 0, 
respectively, while the GAG content per cell between these two groups had no 
significant differences at any time point. The high density group possessed a higher 
GAG content per construct than the low and medium density groups at every time 
point (p < 0.05). At week 2, the constructs in the high density group had 2.9 and 15.4 
times more GAGs than the medium group (p < 0.05) and the low density group (p < 
0.05), respectively. At week 4, the high density group had 2.3 and 59.6 times more 
GAGs than the medium (p < 0.05) and the low density groups (p < 0.05), 
respectively.  
Both the hydroxyproline content per construct and per cell in the medium and 
high density groups increased significantly after 4 weeks of culture, although there 
was no detectable hydroxyproline in the low density group (Figs. 8.4). The 
hydroxyproline contents of the medium and high density groups increased from week 
0 to week 2 (p < 0.05). There was no difference in hydroxyproline content for the 
medium density group between weeks 2 to 4. It was interesting that the 
hydroxyproline content in the high density group decreased by 37.4% from week 2 to 
week 4 (p < 0.05), and hydroxyproline content per cell also had significant decrease. 
The high density group maintained a higher hydroxyproline content than the medium 
group at every culture time point (p < 0.05). At week 0, the high density group had 
5.2 times more hydroxyproline per construct than the medium density group. At week 
4, the high density group had 2.9 times more hydroxyproline per construct than the 
  
148
medium density group (p < 0.05). However, there was no significant difference in 
collagen density (content per ml of scaffold) between the low and high density groups 
at week 4. A conversion factor of 11.5 can be used to convert hydroxyproline mass to 
collagen mass, based on our preliminary studies (unpublished data). 
 
Figure 8.5: Immunohistochemical staining for types I and II collagen, and aggrecan. 
The scale bar is 100 μm. Moderate type II collagen and aggrecan staining 
indicates the chondrogenic differentiation of hUCMSCs. CI = type I collagen, 
CII = type II collagen.  
 
Immunohistochemical results 
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Figure 8.6: Mechanical testing of unseeded PGA at week 0 and seeded constructs at 
week 4. Compressive elastic modulus and relaxation modulus (n = 4). * = 
statistically significant difference. Error bars represent standard deviations.  
 
Immunohistochemistry revealed positive staining for types I and II collagen, 
and aggrecan through the 4-week culture (Fig. 8.5). At week 2, immunohistochemical 
analysis demonstrated intense staining of type I collagen in the medium and high 
density groups. The high density group had moderate amounts of type II collagen and 
aggrecan, while the medium density group had no type II collagen and a minute 
amount of aggrecan. At week 4, both the medium and high density groups had strong 
staining of type I collagen and moderate staining of type II collagen and aggrecan. In 
comparison, there was more intense type I collagen staining in medium and high 
density groups at week 2 than at week 4, and more intense type II collagen and 
aggrecan staining at week 4 than at week 2. Moreover, the high density group 
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appeared to have stronger staining of types I and II collagen and aggrecan than the 
medium density group. 
 
Mechanical properties 
There were no significant differences in both compressive elastic moduli and 
relaxation moduli among unseeded PGA scaffolds at week 0 and the medium and 
high density groups at week 4 (Fig. 8.6). Mechanical tests could not be performed on 
the low density group due to the lack of mechanical integrity.  
 
DISCUSSION 
 
 
hUCMSCs are fetus-derived cells and more primitive cells compared to adult-
derived stem cells based upon their expansion ability in vitro and their tissue 
origin.200 hUCMSCs have the ability to differentiate toward mesenchymal lineage 
cells such as cartilage, bone, adipose, and possibly neural cells of the ectodermal 
lineage.64, 66, 75-77, 80, 195, 202-204, 208, 210, 225 Moreover, there have been studies in the past 
3 yrs that have focused on cardiovascular tissue engineering using hUCMSCs and 
umbilical cord vein cells.65, 205, 222, 240, 241, 324 Here, we explored chondrogenic 
differentiation in 3D PGA scaffolds, and the effects of initial cell seeding density of 
hUCMSCs for fibrocartilage engineering.  
Seeding with orbital shakers demonstrated consistent efficiency (57% at the 
low density, 57% at the medium density, and 55% at the high density). In a parallel 
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study, we found higher rotation speeds improved efficiency (data not shown here). 
All groups decreased cell numbers between week 0 and week 2. At the low density, 
cell numbers were also significantly decreased from week 2 and week 4. These cell 
number decreases might be explained by degradation of the PGA scaffolds. In a 
previous study, quenched PGA demonstrated rapid mass decrease and water content 
increase after 10 days in PBS at 37 ºC.325 In a previous comparison to poly(lactic-co-
glycolic acid) (PLGA; 82:18) and poly-L-lactic acid (PLLA), PGA fibers degraded 
faster, losing their integrity and becoming fiber fragments in the cell culture medium 
within 2 weeks.326 Ideally, extracellular matrix created by hUCMSCs will fill the 
space created by scaffold degradation. In the low density group, insufficient 
extracellular matrix was produced due to the low cell number; leading to 
“contraction” (inward collapse) of the scaffolds. As observed under the microscope 
during culture, many cells and PGA debris fell into the cell culture medium, and 
scaffolds lost their mechanical integrity in the low seeding density cultures. In a 
future experiment, the measurement of cell number and matrix content in the medium 
can be done to correlate the relationship between scaffold degradation and the loss of 
cells and matrix. The medium and high seeding densities better maintained 
mechanical properties due to greater matrix production. Therefore, the medium and 
high cell seeding densities are recommended for future work with rapidly degrading 
scaffolds based on cell number and matrix production demands. 
In this study, the high density group maintained a higher GAG content 
throughout the 4 week culture period, although all groups had lower GAG contents at 
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week 4 than at week 0. Some tissue engineering studies using mature chondrocytes 
reported the same phenomena of a GAG decrease in hyaluronic acid scaffolds with 
swine chondrocytes,327 in poly(ethylene glycol)-co-PLLA hydrogels with calf 
chondrocytes,328 and in PGA scaffolds with calf chondrocytes in a perfusion 
chamber.329 In cartilage explant culture, medium molecular weight GAGs such as 
chondroitin and keratan sulfates have been shown to leach out.330, 331 Thus, it is 
possible that the drop in GAG content in the current study could in part be attributed 
to some leaching out of GAGs. Scaffold degradation also may contribute to the 
decrease of GAG content as discussed in the above section. Extensive PGA scaffold 
degradation in the low density group not only influenced the direct GAG loss into the 
culture medium, but also decreased GAG content indirectly by the loss of cells (Fig. 
8.3). In the medium and high density groups, the GAG decrease was most likely due 
to cell loss since the GAG content per cell remained constant. After the 2-day seeding 
period, the GAG content per cell in the medium and high density groups achieved an 
equilibrium over 4 weeks of culture. The dynamic environment in the orbital shaker 
might promote GAG synthesis during the seeding periods.332-334 It must be noted that 
the highest GAG content at week 0 does not necessarily indicate the presence of 
GAGs specific to cartilage proteoglycans. 
This study also demonstrated a significant increase in collagen content with 
the medium and high density groups during the 4-week culture period. At the low 
density, there was no detectable collagen by hydroxyproline assays due to the 
dissociation of PGA scaffolds. The rapid increases of hydroxyproline content 
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occurred between weeks 0 and 2, which helped to maintain the mechanical integrity. 
There was the same and even decreased hydroxyproline content with the medium 
density and high density from week 2 to week 4, respectively. During the first two 
weeks, there was enough space in the scaffolds for collagen synthesis; however, the 
scaffold shrinkage141 led to a more dense packing of cells (Fig 8.1). The highly-
packed cell and extracellular matrix (especially evident with the high density group at 
week 2) may limit the nutrient diffusion and also provide limited room for 
extracellular matrix synthesis, perhaps affecting the balance of the collagen metabolic 
activity in which collagen catabolism led to the loss of collagen. In native cartilage 
tissues, collagen contributes primarily to the tensile properties, while GAGs (when 
associated with aggrecan) contribute to compressive integrity. No such positive 
correlation was found between matrix content (GAG and collagen) and compressive 
stiffness, although high collagen content helped retain overall construct integrity. A 
weak correlation between GAG and collagen contents and mechanical integrity was 
previously observed in tissue engineering constructs using mature hyaline cartilage 
cells and fibrocartilage cells.274, 335 It was not surprising that statistically significant 
differences in moduli were not observed between groups, as differences would only 
be expected with much larger increases in matrix content and organization over a 
longer period of time. Moreover, the larger matrix content in the higher density group 
was distributed over a larger volume, so it was also not surprising that the modulus 
variations between the medium and high density groups were minimal. 
  
154
Compared to mature TMJ condylar cells in a prior study, hUCMSCs did 
demonstrate a superior performance with 2 times more cells and 4 times more 
GAGs.66 However, the contraction was still observed with the highest density of 50 
million cells/ml in the current study, along with a commensurate loss of cells and 
matrix as discussed earlier. More slowly degrading scaffolds such as PLGA or PLLA 
should be investigated in the future. In fact, PLLA has demonstrated its potential to 
maintain scaffold integrity with ample matrix production in fibrocartilage tissue 
engineering with TMJ disc cells.336 On the other hand, the improvement of seeding 
technique and culture conditions can aid the tissue-genesis in PGA scaffolds. Highly-
packed cells and matrix might block the pathway of nutrition and waste exchange, 
delaying the tissue-genesis inside of the scaffolds and contributing to the contraction 
of PGA scaffolds. Perfusion bioreactors might be used to provide a more 
homogenous cell distribution throughout scaffolds, assist in mass transport, and 
stimulate cell growth mechanically.149, 164, 329 Moreover, bioactive signals such as 
IGF-I and TGF-β1 can enhance biosynthesis to help maintain the original shape of 
scaffolds.336 
In the past four years, only four previous studies demonstrated the 
chondrogenic differentiation of hUCMSCs in cell pellet culture76, 195, 225 or PGA 
scaffolds.66 In comparison to BMSCs, larger pellets were observed in hUCMSC 
groups with a better filamentous extracellular matrix.195, 225 hUCMSC pellets had 
more intense collagen staining than BMSC groups. In a parallel tissue engineering 
study (unpublished data), hUCMSCs also had a higher cell number, GAG content, 
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and collagen content than hBMSCs after 6 weeks of culture on PGA scaffolds. Slight 
type I collagen and plentiful type II collagen were observed with 
immunohistochemical staining in hUCMSC pellets, while only a trace amount of type 
II collagen was observed in BMSC pellets.195 Here, intense type I collagen staining, 
and moderate collagen type II and aggrecan staining was shown; this is similar to 
native fibrocartilage. The decrease of type I collagen staining and increase in type II 
collagen and aggrecan staining from week 2 to week 4 suggests that further 
chondrogenic differentiation occurred during this period. Despite the lower amount of 
type II collagen produced in this study in comparison to hBMSCs in the literature,315 
hUCMSCs may progress further down a chondrogenic lineage with more collagen II 
production with the investigation of a slightly modified set of signals to provide for 
optimal chondrogenesis. The identification of these signals, with further validation 
via analysis of gene expression, will be an important area of future investigation.  
In conclusion, human umbilical cord matrix mesenchymal stromal cells 
exhibited characteristics of differentiation along a fibrocartilaginous lineage. The 
production of an abundance of type I collagen, and a moderate amount of type II 
collagen and aggrecan suggest that hUCMSCs may be a suitable cell source for 
fibrocartilage-tissue engineering. A concentrated effort to drive hUCMSCs down an 
exclusively chondrogenic lineage (collagen II expression and production in lieu of 
collagen I) will be an exciting area of future investigation. As hypothesized, the 
constructs in the medium and high density groups had more cells and extracellular 
matrix (per construct and per cell) than the low density group over 4 weeks of culture, 
  
156
and more importantly, retained their mechanical integrity, unlike the low density 
group. Thus, it is recommended that the cell seeding density in related future studies 
be not less than 25 million hUCMSCs per ml. 
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CHAPTER 9: Insulin-like Growth Factor-I Improves 
Chondrogenesis of Pre-differentiated Human Umbilical 
Cord Mesenchymal Stromal Cells* 
 
ABSTRACT 
 
Human umbilical cord mesenchymal stromal cells (hUCMSCs) are an 
attractive cell source for tissue engineering with numerous advantages over other 
adult stem cell sources such as great expansion ability in vitro and extensive 
availability. The objective of this 6-week study was to test the hypothesis that 
switching from chondrogenic transforming growth factor-beta3 (TGF-β3) to anabolic 
insulin-like growth factor-I (IGF-I) at the 3-week time point would produce more 
cartilage-like matrix than TGF-β3 alone. hUCMSCs were seeded into polyglycolic 
acid (PGA) scaffolds and then cultured in chondrogenic medium containing TGF-β3 
for 3 weeks. The TGF-β3-treated hUCMSCs were then exposed for 3 more weeks to 
one of four different conditions: 1) continued in chondrogenic medium, 2) control 
medium (no TGF-β3), 3) control medium with 10 ng/ml IGF-I, or 4) control medium 
with 100 ng/ml IGF-I. Compared to continuing with TGF-β3, switching to IGF-I 
increased collagen production, and furthermore increased both collagen type II gene 
expression and immunostaining. In conclusion, the shift from TGF-β3 to IGF-I at 
week 3 resulted in a significant increase of cartilage-like extracellular matrix, 
confirming our hypothesis.  
 
__________________________________________________________________________________ 
*Chapter submitted to J Orthop Res as Wang and Detamore. “Insulin-like growth factor-I improves 
chondrogenesis of pre-differentiated human umbilical cord mesenchymal stromal cells,” August 2008.
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INTRODUCTION 
 
Umbilical cord mesenchymal stromal cells (UCMSCs), extracted from 
Wharton’s jelly of umbilical cords,200 are a primitive stromal population that possess 
the characteristics of mesenchymal stromal cells (MSCs) defined by the International 
Society for Cellular Therapy (ISCT).196 Human UCMSCs (hUCMSCs) express 
surface markers that were identified with other mesenchymal stromal cells (MSCs) 
such as CD73, CD90, CD105, and are negative for hematopoietic markers such as 
CD34 and CD45.76, 195, 202, 204, 225 hUCMSCs can differentiate along a variety of cell 
lineages that can be utilized for tissue engineering and regenerative medicine such as 
osteogenic, chondrogenic, myogenic, and adipogenic.64, 76, 77, 195, 225  
In chondrogenic differentiation, transforming growth factor-beta isoforms 
(TGF-β1, β2 and β3) are known to play an important role.236 In cell pellets, TGF-β176 
or β3195, 225 have been incorporated into serum-free media to induce chondrogenic 
differentiation that were revealed by a positive immunostaining for type II collagen. 
In our group, we demonstrated that 3D culture of hUCMSCs in polyglycolic acid 
(PGA) scaffolds with chondrogenic medium containing TGF-β1 led to a 
fibrocartilage with intense type I collagen, and moderate type II collagen and 
aggrecan immunostaining.66, 207 With hBMSCs, although both TGF-β1 and β3 were 
chondro-inductive signals, TGF-β3 appeared to be more effective, leading to higher 
GAG production and earlier and more extensive type II collagen expression.236 For 
this reason, TGF-β3 was chosen as the chondrogenic signal in the current study. 
Insulin-like growth factor-I (IGF-I), an important anabolic agent for several different 
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tissues in the body,337-339 has been demonstrated by most studies to have little or no 
effect on chondrogenic differentiation,232, 234 but promoted proliferation and 
biosynthesis in vitro of both mature hyaline cartilage and fibrocartilage cells.271, 340 
On the other hand, how IGF-I sequentially affect the TGF-β-treated hUCMSCs and 
other MSCs is seldom reported in the literature.341 
In the current study, we cultured hUCMSCs in chondrogenic medium 
containing TGF-β3 for 3 weeks to induce differentiation in PGA scaffolds, and then 
switched to IGF-I for another 3-week period. As controls, another group continued in 
TGF-β3, and another group continued without either TGF-β3 or IGF-I. The rationale 
for this approach was to determine whether it was possible to first steer the 
hUCMSCs along the desired path with a chondrogenic signal (TGF-β3), and then to 
provide a boost in matrix synthesis with an anabolic signal (IGF-I) to provide the best 
overall results. Therefore, we hypothesized that switching from TGF-β3 to IGF-I at 
the 3-week time point would produce more cartilage-like matrix than continuing with 
TGF-β3 for the entire 6-week duration.  
 
MATERIALS AND METHODS 
 
Cord collection and cell isolation 
One human umbilical cord (female, C-section, and 18 cm long) was obtained 
from the University of Kansas Medical Center (KU Medical Center IRB approval no. 
10951, KU-Lawrence IRB approval no. 15402). Cords were first washed in sterile 
phosphate buffered saline (PBS) three times and then cut into 3-5 cm segments. 
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Vessels were pulled out from these segments, and the remaining segments were 
minced and digested in 0.75 mg/ml type II collagenase (298 U/mg; Worthington 
Biochemical; Lakewood, NJ) at 37°C in an incubator for 4 hrs. This cell solution was 
centrifuged, and the supernatant was discarded. Finally, cells in the bottom were 
resuspended in a complete culture medium consisting of low-glucose Dulbecco's 
modified Eagle's medium (DMEM-LG; Invitrogen, Carlsbad, CA), 10% MSC-
qualified fetal bovine serum (FBS; StemCell Technologies, Canada), and 1% 
penicillin/streptomycin (PS; Invitrogen). Cells were seeded at 8000 cells/cm2 (P0 
cells) in cell culture flasks and the medium was replaced every 2-3 days. At 80-90% 
confluence, P0 cells were frozen for future use following a previously described 
procedure.207  
 
Cell seeding and culture 
Non-woven PGA meshes (50 mg/cc, >95% porosity) were purchased from 
Synthecon, Inc. (Houston, TX). The PGA sheets were punched into cylinder-shaped 
scaffolds that were 5 mm in diameter and 2 mm in thickness, to create a total of 54 
scaffolds used in the study. The scaffolds were then processed and seeded into 
scaffolds at 50 million cells per ml of scaffold according to our previous procedure.207 
Scaffolds were then cultured in 2 ml of chondrogenic medium containing high-
glucose DMEM (DMEM-HG; Invitrogen), 1% NEAA, 1× insulin-transferrin-
selenium premix (ITS premix; BD Biosciences, San Jose, CA), 20 ng/ml TGF-β3 
(RDI, Flanders, NJ, USA), 100 nM dexamethasone (Sigma), 100 mM sodium 
  
161
pyruvate (Fisher Scientific), 40 μg/ml L-proline (Sigma) and 50 μg/ml ascorbic acid 
2-phosphate (Sigma). This time point was recorded as week 0. After 3 weeks of 
culture, 2 ml of chondrogenic medium was removed and hUCMSCs were exposed for 
3 more weeks to one of four different conditions: 1) continue in chondrogenic 
medium, 2) control medium (no TGF-β3), 3) control medium with 10 ng/ml IGF-I, or 
4) control medium with 100 ng/ml IGF-I. Half of the medium was changed every 
other day over the 6-week period, except for the complete replacement at week 3.  
 
Assessment of biosynthesis and cell proliferation 
At weeks 0, 3 and 6, constructs (n = 4 per group) were homogenized in 1.2 ml 
papain solution (120 μg/ml) and digested at 60　°C overnight for the following 
biochemical assays. Biosynthesis was evaluated by measuring total GAG and 
hydroxyproline (HYP) contents. GAG content was measured using a 
dimethylmethylene blue (DMMB) dye binding assay kit (Biocolor, Belfast, UK) 
according to the manufacturer’s procedure. A modified HYP assay was used to test 
HYP content as described previously.207 HYP mass can be converted to collagen 
mass by using a conversion factor of 11.5, based on our preliminary studies. A 
PicoGreen kit (Invitrogen) was used to measure DNA content. DNA content was 
converted to cell number by a conversion factor of 8.5 pg DNA/cell determined in 
preliminary studies. 
 
Immunohistochemistry for types I and II collagen and aggrecan 
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The primary antibodies were mouse monoclonal IgG anti-collagen I (1:1500 
dilution; Accurate Chemical and Scientific, Westbury, NY), mouse monoclonal IgG 
anti-collagen II (1:1000 dilution; Chondrex, Redmond, WA), and mouse monoclonal 
IgG anti-aggrecan (1:50 dilution; Abcam, Cambridge, MA). A horse anti-mouse IgG 
secondary antibody was obtained from Vector Laboratories (Burlingame, CA). The 
frozen scaffolds were sliced into 10 μm sections, which were then fixed in chilled 
acetone (4 oC) for 10 min before staining. Specimens were hydrated and then treated 
with 1% hydrogen peroxide in methanol to quench endogenous peroxidase. The 
sections were then blocked in 3% horse serum and then incubated with the primary 
antibodies for 1 hr. After primary antibody incubation, the sections were incubated 
with the secondary antibody followed by an avidin-biotinylated enzyme complex 
(ABC complex; Vector Laboratories). Finally, the sections were visualized with VIP 
substrate (purple color) (Vector Laboratories). A negative control was designed with 
the primary antibodies omitted. 
 
RNA isolation and real-time RT-PCR 
The relative mRNA expression level of types I and II collagen, and aggrecan 
were quantified by using a real-time reverse transcriptase polymerase chain reaction 
(real time RT-PCR) in an Applied Biosystems (Foster City, CA) 7500 System (n = 4 
per group). At weeks 3 and 6, the constructs were homogenized in 1 ml of Trizol 
reagent (Invitrogen) to isolate total mRNA according to the manufacturer’s 
instruction. The mRNA samples were then converted to cDNA using a High-Capacity 
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cDNA Archive kit (Applied Biosystems). TaqMan gene expression assay kits 
(Applied Biosystems) were Hs00164004_m1 for type I collagen, Hs00156568_m1 for 
type II collagen, Hs00153936_m1 for aggrecan, and Hs99999905_m1 for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). A 2−ΔΔCt method was used to 
evaluate relative the mRNA expression level for each target gene.312 Briefly, ΔCt 
values were obtained by the difference between the Ct values of target genes and the 
GAPDH gene. They were then normalized by subtracting the ΔCt value of the 
calibrator sample, their respective groups at week 3, to obtain ΔΔCt values. 
 
Statistics and data analysis 
Statistical analysis was performed with one-way analysis of variance 
(ANOVA) followed by Tukey’s Honestly Significant Difference (HSD) post hoc 
tests. The statistically significant differences were determined by a statistical 
threshold of p < 0.05.  
 
RESULTS 
 
Cell number 
After the initial seeding period, all groups at weeks 3 and 6 had fewer cells 
than at week 0 (p < 0.05) (Fig. 9.1). However, the cell number was maintained 
between weeks 3 and 6 in all groups. At week 6, TGF-β3 stimulated cell proliferation 
with 22% more cells than the control group (p < 0.05), whereas IGF-I at both 
concentrations had no effect on cell proliferation during the last 3 weeks. With regard 
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to the comparison between TGF-β3 and IGF-I, the TGF-β3 group had 20% more cells 
than the 10 ng/ml IGF-I group (p < 0.05), and no statistically significant difference 
from the 100 ng/ml IGF-I group. 
 
 
Figure 9.1: Cell number at weeks 0, 3, and 6 (n = 4). W0 = week 0, W3 = week 3, 
W6 = week6, I10 = IGF at 10 ng/ml, I100 = IGF at 100 ng/ml, and TGF = 
TGF-β3 at 20 ng/ml. # = statistically significant difference (p < 0.05). @ = 
statistically significant difference from the TGF-β3 group (p < 0.05). * = 
statistically significant difference between growth factor groups and the 
control group at week 6 (p < 0.05). Error bars represent standard deviations. 
 
GAG content 
Similar to the cell number result, there was a 37% drop in the GAG content 
per construct from weeks 0 to 3 (p < 0.05), and thus the GAG content per cell 
maintained the same level in this period (Fig. 9.2). Following this initial decrease of 
GAG content per construct, there was a recovery with an increase from weeks 3 to 6 
(p < 0.05) in all groups. The GAG content per construct at week 6 in the IGF-I groups 
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at 10 and 100 ng/ml, the TGF-β3 group, and the control group increased by 37%, 
51%, 44%, and 19%, respectively, compared to at week 3. Among all growth factor 
groups, only the 100 ng/ml IGF-I group promoted the GAG content per construct 
with 28% more than the control (p < 0.05). Despite a higher GAG content per 
construct in the TGF group than the control, there was no statistically significant 
difference between them. Like the GAG content per construct, the GAG content per 
cell in all groups increased from weeks 3 to 6 (p < 0.05). However, there were no 
significant differences in GAG content per cell among all groups at week 6. 
 
 
Figure 9.2: GAG content per construct and per cell at weeks 0, 3, and 6 (n = 4). W0 
= week 0, W3 = week 3, W6 = week6, I10 = IGF at 10 ng/ml, I100 = IGF at 
100 ng/ml, and TGF = TGF-β3 at 20 ng/ml. # = statistically significant 
difference (p < 0.05). * = statistically significant difference between growth 
factor groups and the control group at week 6 (p < 0.05). Error bars represent 
standard deviations. 
 
HYP content 
The HYP content both per construct and per cell increased continuously and 
markedly throughout the 6-week period (p < 0.05) (Fig. 9.3). From weeks 0 to 3, the 
  
166
HYP content per construct and per cell increased by 4.3 and 6.3 times, respectively (p 
< 0.05). From weeks 3 to 6, the HYP content per construct and per cell increased by 
1.5 and 1.6 times, respectively (p < 0.05). In comparison to the control group, IGF at 
both 10 and 100 ng/ml stimulated collagen production with 1.3 and 1.6 times more 
HYP content per construct, respectively. Moreover, IGF at 100 ng/ml had 1.5 times 
more HYP content per cell than the control groups, while the TGF-β3 group did not 
affect the HYP synthesis. Compared to the TGF-β3 group, the 10 and 100 ng/ml IGF-
I groups had 1.3 and 1.6 times more HYP content per cell, respectively, and the 100 
ng/ml IGF-I group had 1.4 times more HYP content per construct (p < 0.05). 
 
 
Figure 9.3: HYP content per construct and per cell at weeks 0, 3, and 6 (n = 4). W0 = 
week 0, W3 = week 3, W6 = week6, I10 = IGF at 10 ng/ml, I100 = IGF at 100 
ng/ml, and TGF = TGF-β3 at 20 ng/ml. # = statistically significant difference 
(p < 0.05). @ = statistically significant difference from the TGF-β3 group (p < 
0.05). * = statistically significant difference between growth factor groups and 
the control group at week 6 (p < 0.05). Error bars represent standard 
deviations. 
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Immunohistochemistry  
 
Figure 9.4: Immunohistochemical staining for types I and II collagen, and aggrecan 
(n = 2). CI = type I collagen, CII = type II collagen, W3 = week 3, W6 = 
week6, I10 = IGF at 10 ng/ml, I100 = IGF at 100 ng/ml, and TGF = TGF-β3 
at 20 ng/ml. The scale bar is 500 μm. 
 
Immunohistochemistry revealed positive staining for types I and II collagen 
and aggrecan in all groups through the 6-week period (Fig. 9.4). After exposure to 
chondrogenic medium for 3 weeks, there was a small amount of type II collagen, a 
moderate amount of aggrecan throughout the constructs, and type I collagen was 
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distributed only around the periphery. At week 6, all groups presented a more intense 
staining for types I and II collagen and aggrecan than at week 3. It must be noted that 
type I collagen was the dominant collagen type, and that the 100 ng/ml IGF-I group 
had a stronger staining of type II collagen than other groups, albeit a lower level than 
type I collagen. With the two IGF-I groups, it was clear that the center of the 
constructs were more filled in with collagen than with the TGF-β3 and control 
groups, with type I collagen at both IGF-I concentrations and with type II collagen in 
the 100 ng/mL IGF-I group. 
 
 
Figure 9.5: Gene expression for types I and II collagen, and aggrecan at weeks 3 and 
6 (n = 4). CI = type I collagen, CII = type II collagen, W3 = week 3, W6 = 
week 6, I10 = IGF at 10 ng/ml, I100 = IGF at 100 ng/ml, and TGF = TGF- 3 　
at 20 ng/ml. # = statistically significant difference (p < 0.05). & = statistically 
significant difference from week 3 with specific genes (p < 0.05). Error bars 
represent standard deviations. 
 
  
169
RT-PCR analysis 
From weeks 3 to 6, the mRNA level of type I collagen for all groups and type 
II collagen for the IGF-I groups were up-regulated at week 6 (p < 0.05), whereas 
aggrecan gene expression in all groups remained at the same level (Fig. 9.5). At week 
6, all groups had no statistically significant differences in the gene expression of types 
I and II collagen and aggrecan from the control group, although the IGF-I groups at 
10 and 100 ng/ml had 2.3 and 4.1 times higher gene expression than the control 
group. However, 100 ng/ml IGF-I did promote a type II gene expression that was 4.1 
times higher than with the TGF-β3 group (p < 0.05). 
 
DISCUSSION 
 
In recent years, hUCMSCs have been explored as a fetus-derived source 
alternative to other adult stem cells.196, 200 hUCMSCs have only recently been applied 
in cartilage tissue engineering, with only two full studies conducted by our group.66, 
207 In the first application of these cells for fibrocartilage engineering, hUCMSCs 
outperformed native mandibular condylar cartilage cells, leading to higher cellularity 
and superior matrix production.66 We further optimized the cell seeding density in 
PGA scaffolds and reported that a density larger than 25 million per ml was 
recommended to maintain the scaffold integrity and retain enough cells and 
extracellular matrix for fibrocartilage engineering.207 In the current study, we 
specifically focused on the usage of bioactive signals (TGF-β3 and IGF-I) to better 
promote cell proliferation and enhance cartilage-specific matrix synthesis in a serum-
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free medium. The chondrogenic ability of TGFs is well known and the combination 
of TGFs and IGF-I have been shown to enhance the chondrogenic differentiation and 
the GAG production of stem cells.232, 342 However, there is a paucity of data on the 
sequential treatment of TGFs and IGF-I in the literature. This study revealed that the 
switching from TGF-β3 to IGF-I did promote HYP production and also up-regulated 
the gene expression of type II collagen, which confirmed our hypothesis. 
In the first 3 weeks, the chondrogenic medium containing TGF-β3 induced 
hUCMSCs to differentiate toward a chondrogenic lineage with positive type II 
collagen and aggrecan immunostaining. During this period, the loss of both cells and 
GAGs was observed. The decrease in cell number has been found in our previous 
studies using PGA scaffolds, which degraded rapidly in 2-3 weeks.207, 259 This 
degradation rate did not approximate the rate of extracellular matrix synthesis, which 
caused the contraction of PGA scaffolds and further cell loss into the culture 
medium.207, 259 However, the cell number did not decrease further after 3 weeks, 
indicating that a more stable (confined) construct was achieved. The cell loss might 
be responsible for the GAG loss, given that the GAG content per cell did maintain at 
approximately the same level during the first 3 weeks. Therefore, more slowly 
degrading scaffolds such as poly(L-lactic acid) (PLLA) and poly(lactic-co-glycolic 
acid) (PLGA) would be beneficial in alleviating the cell and GAG loss in the future. 
Collagen content increased during this initial period, containing both types I and II 
collagen as revealed by immunostaining of types I and II collagen. It is interesting 
that the GAG content reached a high level at week 0 only after 2-day cell seeding, 
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although it is possible that these GAGs were non-cartilage-specific. After exposure to 
different medium conditions during the last 3 weeks, the extracellular matrix contents 
increased, which was consistent with stronger collagen and aggrecan staining. 
However, the intense type I collagen staining indicated that the increase of collagen 
mass was mainly due to type I collagen production. 
IGF-I is an anabolic agent that regulates chondrocyte proliferation and 
biosynthesis at all stages of cartilage development.337, 343 Indeed, after exposure to the 
medium containing IGF-I, the constructs were shown to have increased GAG and 
collagen contents compared to the control, while TGF-β3 did not significantly alter 
either of them relative to the control, despite the higher cell number in the TGF-β3 
group. More importantly, in contrast to both the TGF-β3 and control groups, IGF-I 
had more collagen content per cell (and per construct at 100 ng/ml), indicating that 
IGF-I did promote collagen synthesis and/or inhibit collagen breakdown in the 
collagen metabolism process. It was unexpected that IGF-I increased type II gene 
expression, while continuing treatment of TGF-β3 had no effect on type II collagen 
gene expression. In spite of the 8.8-fold increase in type II gene expression in the 100 
ng/ml IGF-I group from week 3 to 6, type II collagen immunostaining was not as 
strong as type I collagen. This may be due to the fact that immunostaining reflects the 
cumulative level of protein synthesized and retained in the construct over time, 
whereas the gene expression merely represents a snapshot of the cellular disposition 
at that point in time. The results could imply that with an extended culture period with 
IGF-I, significantly higher levels of collagen II protein synthesis may have been 
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observed. Therefore, in the future, a longer culture period will be useful to clarify this 
seemingly conflicting result. Nevertheless, in the 100 ng/ml IGF-I group, a stronger 
staining was observed compared to other groups. The up-regulated gene-expression 
of type II collagen due to the anabolic nature of IGF-I perhaps contributed to this 
increase.  
In conclusion, these results indicated that a shift from a chondrogenic signal 
(TGF-β3) to an anabolic agent (IGF-I) in the middle of the culture period produced 
more cartilage-like matrix than continuing with TGF-β3 alone throughout the culture 
period. The IGF-I concentration of 100 ng/ml has been shown to promote 
biosynthesis and type II collagen gene expression with hUCMSCs following TGF-β3 
treatment and is hence recommended for cartilage tissue engineering. This sequential 
signaling strategy is also meaningful for other tissue engineering areas using stem 
cells, as the ability of IGF-I to promote the respective matrix synthesis of a given 
tissue may prove highly advantageous following differentiation strategies in the initial 
culture period. 
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CHAPTER 10: Osteogenic Differentiation of Human 
Umbilical Cord Mesenchymal Stromal Cells for Bone Tissue 
Engineering* 
 
ABSTRACT 
 
Although human umbilical cord mesenchymal stromal cells (hUCMSCs) have 
been shown to differentiate along an osteogenic lineage in monolayer culture, the 
potential of these cells has never before been investigated in 3D scaffolds for bone 
tissue engineering applications. In this 6-week study, we demonstrated the osteogenic 
differentiation of hUCMSCs on polyglycolic acid (PGA) non-woven mesh scaffolds, 
and compared seeding densities for bone tissue engineering. Cells were seeded into 
PGA meshes with densities of 5, 25 or 50 x106 cells/ml scaffold and then cultured in 
osteogenic medium. Cell proliferation, osteogenic differentiation, and matrix 
formation were evaluated at weeks 0, 3, and 6. Osteogenic differentiation was 
observed based on the positive alkaline phosphatase activity (ALP) and an increase of 
collagen production and calcium incorporation into the extracellular matrix, which 
were greater with higher densities. In conclusion, hUCMSCs differentiated along an 
osteogenic lineage in 3D scaffolds, and higher cell density correlated with greater 
expression of osteoblast markers. A density greater than 25 x 106 cells/ml is 
recommended for bone tissue engineering with hUCMSCs. 
 
 
___________________________________________________________________________________ 
*Chapter submitted to Ann Biomed Eng as Wang, Bonewald, and Detamore. “Osteogenic differentiation 
of human umbilical cord mesenchymal stromal cells for bone tissue engineering,” July 2008. 
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INTRODUCTION 
 
Autologous bone grafts are currently the most common clinical treatment of 
critical-sized bone defects.111 However, there remain several drawbacks that limit 
their application, including limited availability, invasive bone tissue harvesting, and 
donor site morbidity.111, 344 Bone tissue engineering, which aims to restore the 
biological and mechanical function of diseased and damaged bone, holds the greatest 
promise for future clinical practice.345, 346 This approach integrates cells, bioactive 
molecules, and biocompatible scaffolds for direct implantation to facilitate bone 
regeneration in vivo or to create a replacement in vitro for implantation. Bone 
marrow-derived mesenchymal stem cells (BMSCs) have been extensively 
investigated as a cell source for bone tissue engineering.347 However, the available 
cell number of BMSCs in bone marrow and their differentiation potential decreases 
significantly with age.248, 348 Moreover, the harvesting procedure is painful, invasive, 
and may lead to complications and morbidity.249 
Recently, umbilical cord mesenchymal stromal cells (hUCMSCs) have been 
explored as a promising cell source for tissue engineering and regenerative 
medicine.196 UCMSCs are extracted through enzyme digestion from Wharton’s jelly 
of umbilical cords,200, 206 which yields 10-50×103 cells per cm of cord, corresponding 
to approximately 2-10×105 primary cells per cord. hUCMSCs express classic surface 
markers identified in BMSCs including CD29, CD44, CD90, CD105, and CD16680, 
195 and markers found in embryonic stem cells including Oct-4, Nanog, and Sox-2 
transcription factors.201 With exogenous signals such as dexamethasone76, 195, 204, 208 or 
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osteoinductive biomaterials such as demineralized bone matrix,239 hUCMSCs have 
been shown to differentiate along the osteogenic lineage, confirmed by positive von 
Kossa staining,76, 195, 204, 208 Alizarin red staining,195 alkaline phosphatase activity 
(ALP),76, 195, 204, 208, 239 osteopontin gene up-regulation,76, 204 and bone-related proteins 
such as osteopontin, osteonectin, osteocalcin, and bone sialoprotein-2.195 Their 
osteogenic ability accompanied by numerous other advantages over hBMSCs 
indicates that hUCMSCs may be a promising candidate as a stem cell source for bone 
tissue engineering. 
Osteogenic differentiation of hUCMSCs in three-dimensional (3D) scaffolds 
is heretofore unexplored in the literature, and is a significant leap forward from 
differentiation studies in monolayer culture. In a 3D environment, many parameters, 
such as the biocompatibility of materials, diffusion parameters, and cell seeding 
methods, are known to affect cell differentiation and proliferation and extracellular 
matrix synthesis.349 In the current study, we focused on the effects of initial cell 
seeding density on hUCMSC differentiation. We have recently shown in a 
chondrogenic application of hUCMSCs that a seeding density above 25 x106 cells/mL 
was optimal.207 In another study, a low cell seeding density resulted in a low seeding 
efficiency in a PLGA scaffold and delayed in vivo mineralization.350 Furthermore, in 
collagen scaffolds, high seeding densities of hBMSCs augmented scaffold 
contraction351 and a specific range of seeding densities (3-30 x106 cells/ml) enhanced 
osteoblastic differentiation of osteosarcoma cell line.349 The present study thus aimed 
to investigate how the seeding density of hUCMSCs affected their osteogenic 
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differentiation and subsequent matrix production in a 3D environment. The 
hypothesis for this study was that a higher seeding density would result in enhanced 
osteogenic differentiation with an increase in bone-related matrix synthesis. 
 
MATERIALS AND METHODS 
 
Cell harvest 
Human umbilical cord collection and cell harvests were approved by the 
University of Kansas human subject board (KU-Lawrence IRB approval no.15402, 
KU Medical Center IRB approval no.10951). One human umbilical cord (Female, C-
section, 26cm long) was collected from the University of Kansas Medical Center and 
processed within 24 hrs. Cords were first cut into 3-5 cm pieces, and then vessels 
were removed from each cord segment. Cord segments were minced and incubated in 
0.75 mg/ml type II collagenase (298 U/mg; Worthington Biochemical; Lakewood, 
NJ) at 37°C. After a 5-hr incubation, a homogenous gelatinous solution was obtained 
and diluted (1:8) in sterile phosphate buffered saline (PBS). The solution was 
centrifuged, the supernatant was discarded, and cells were resuspended in a complete 
culture medium consisting of low-glucose Dulbecco's modified Eagle's medium 
(DMEM-LG; Invitrogen, Carlsbad, CA), 10% MSC-qualified fetal bovine serum 
(FBS; StemCell Technologies, Canada), and 1% penicillin/streptomycin (PS; 
Invitrogen). Cells were plated in cell culture flasks at 8000 cells/cm2 (P0 cells) and 
fed every two to three days. When cells had reached 80-90% confluence, they were 
detached by 1X trypsin (Invitrogen) and resuspended at a density of 1 x106 cells per 
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ml freezing medium, composed of 90% FBS and 10% dimethyl sulfoxide (DMSO; 
Fisher Scientific, Pittsburgh, PA). The cell suspension was transferred into cryotubes 
(Nalgene Labware, Rochester, NY), which were stored in “Mr. Frosty” freezing 
containers (Nalgene) at -80°C overnight, and transferred to a liquid nitrogen 
cryogenic storage system at -196°C for future use. 
 
Cell culture and seeding 
Cells were thawed and expanded to P4 in the complete medium. Non-woven 
PGA meshes (50 mg/cc; > 95% porosity; Synthecon, Houston, TX) were punched 
into 96 cylinder-shape scaffolds with a 5 mm diameter and 2 mm thickness, and then 
sterilized with ethylene oxide. After sterilization, the scaffolds were aired under a 
fume hood for one day, then wetted with sterile filtered ethanol and two washes of 
sterile phosphate buffered saline (PBS). The scaffolds were then soaked in the 
complete medium in 24-well plates for one day and then removed for cell seeding. P4 
hUCMSCs were seeded at 5 (low), 25 (medium) and 50 (high) x106 cells per ml of 
scaffold. 400 μl of cell solution was transferred to well plates and pipetted 10 times 
through the scaffolds. Well plates were then set on orbital shakers at 150 rpm for 24 
hours. In the medium and high density groups, this small amount of medium 
containing a large amount of cells yielded a highly concentrated cell solution, which 
caused the formation of several cell clusters in the medium, some of which attached 
lightly to the peripheral area of PGA scaffolds and detached from the edge when the 
medium was changed during the following culture. After the first 8 hours, the cell 
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clusters in the medium were removed and 400 μl of medium was added. After the 24 
hour orbital shaking period, cells were allowed to attach statically in the culture 
medium for another day. Finally, the complete medium was replaced by 2 ml 
osteogenic medium, which was the complete medium plus 100 nM dexamethasone 
(Sigma, St. Louis, MO), 10 mM β-glycerophosphate (Sigma), 50 μg/ml ascorbic acid 
2-phosphate (Sigma), and 10 nM 1α,25-Dihydroxyvitamin D3 (BIOMOL 
International, Plymouth Meeting, PA). This time point was recorded as week 0. 1.5 
ml of medium was changed every other day for 6 weeks. At weeks 3 and 6, separate 
groups of constructs were analyzed for hydroxyproline content, alkaline phosphatase 
activity, calcium content, and histological analysis. Hydroxyproline content was also 
measured at week 0 to demonstrate minimal initial differences in matrix content 
between groups. 
 
Cell number and hydroxyproline (HYP) content 
Constructs (n = 4) were homogenized in 1.2 ml papain solution (120 μg/ml) 
using a tissue homogenizer (Omni International, Marietta, GA), and incubated in this 
solution at 60 °C overnight, before storing at -20 °C for future biochemical assays. 
The DNA content was determined by using a PicoGreen kit (Invitrogen) according to 
the manufacturer’s protocol. A conversion factor of 8.5 pg DNA/cell was determined 
in preliminary studies and used to convert DNA content to cell number. HYP content 
was determined by using a HYP assay as described previously.311 Briefly, each 
sample was hydrolyzed with sodium hydroxide, neutralized with hydrochloric acid, 
  
179
and then titrated to a pH range from 6.5 to 7.0. This solution was combined with 
Chloramine-T buffer and p-dimethylaminobenzaldehyde in perchloric acid and read 
spectrophotometrically at 550 nm. A conversion factor of 11.5 can be used to convert 
HYP mass to collagen mass, based on our preliminary studies. 
 
Alkaline phosphatase (ALP) activity 
Constructs (n = 4) were homogenized in 500 μl of 0.2% Triton X-100 (Sigma) 
and lysed twice using freeze–thaw cycles. The lysate was used to determine alkaline 
phosphatase activity following a previously described method.352 In brief, 20 μl of 
lysate was combined with 80 μl of 1.5 M 2-amino-2-methyl-1-propanol (AMP; 
Sigma) buffer (pH 10.3) containing 5 mM p-nitrophenol phosphate substrate (Sigma). 
For the standard curve, serial dilutions of 0–20 nM p-nitrophenol (Sigma) were made 
in triton solution. The reaction was stopped by adding 100 μl of 0.5 M NaOH. The 
solution was then read spectrophotometrically at 405 nm. ALP activity was 
normalized to total DNA content. 
 
Calcium content 
Constructs (n = 4) were homogenized, suspended in 1N acetic acid overnight, 
and stored at -20 °C for future assays. An OCPC (ortho-cresolphthalein complexone) 
method was used to measure calcium content as described previously.353 The OCPC 
solution consisted of 1 mg/ml OCPC in a buffer including 0.0063 N KOH and 0.0031 
N acetic acid. The working solution contained 0.05 mg/ml OCPC solution, 0.74M 
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ethanolamine/boric acid buffer (pH 11), and 2% 8-hydroxyquinoline (5 g in 100 mL 
of 95% ethanol). 0–100 mg/ml CaCl2 solution (Sigma) was used as the standard. A 
solution including 50 μl of culture sample and 250 μL of working solution was 
incubated for 10 min at room temperature and then read spectrophotometrically at 
575 nm. 
 
Histology 
Samples were embedded in an OCT compound (Tissue-Tek, Torrance, CA) 
and frozen sections (10 μm) (n = 2) were cut using a cryostat (Micron HM-550 OMP, 
Vista, CA). Sections were incubated with 1% silver nitrate solution in a clear plastic 
Coplin jar, placed under ultraviolet light for 20 minutes and then rinsed in ultra-pure 
water. Finally, the samples were dehydrated through graded alcohol (95% and 100% 
twice each). 
 
Statistical analysis 
All data were expressed as means ± one standard deviation, and analyzed by 
analysis of variance (ANOVA) followed by Tukey’s Honestly Significant Difference 
post hoc tests. Two-way ANOVAs with interaction were used to determine whether 
there were differences among either time-points or seeding densities. A statistical 
threshold of p < 0.05 was used to indicate whether there were statistical significances 
among different groups. 
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RESULTS 
 
Scaffold morphology and cell number 
The shape of the scaffolds changed from cylindrical at week 0 to spherical at 
weeks 3 and 6. Scaffold volume decreased in all groups over the course of the 6-week 
period, with higher density groups being larger than lower density groups (Fig. 
10.1A). There were significant differences among the seeding efficiencies, with 
 
 
Figure 10.1: Construct volume (A) (n = 3) and cell number per construct (B) (n = 4). 
* = statistically significant difference (p < 0.05) from the low density group 
(5M). # = statistically significant difference between the medium density 
(25M) and high density (50M) groups. & = statistically significant difference 
from week 0. @ = statistically significant difference between weeks 3 and 6. 
The symbols in top brackets represent significant differences between the 
different density groups throughout the whole culture period. V in Part A 
represents the scaffold volume. V0 in Part A represents the scaffold volume at 
week 0. Error bars represent standard deviations. A conversion factor of 8.5 
pg DNA/cell was used to convert DNA content to cell number.  
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84.7 ± 8.1% at the low density, 55.1 ± 2.1% at the medium density, and 34.2 ± 5.8% 
at the high density (p < 0.05) (Fig. 10.2). On the whole, cell number decreased with 
time (p < 0.05) throughout the culture period (Fig. 10.1B). The higher density groups 
had more cells than the lower density groups (5M < 25M < 50M) (p < 0.05). The low 
density group maintained cell number over the 6-week culture time, the medium 
density group deceased in cell number only from weeks 0 to 3 (p < 0.05), and the 
high density group decreased in cell number at both weeks 3 and 6 (p < 0.05). It is 
interesting that with the drastic drop in the volume of the low density group, the 
cellularity (cells per volume) in the medium and high density groups was significantly 
lower than in the low density group at week 6 (p< 0.05). There was no significant 
difference in cellularity between the medium and high density groups. 
 
Figure 10.2: Seeding efficiency (n = 4). * = statistically significant difference (p < 
0.05) from the low density group (5M). # = statistically significant difference 
between the medium density (25M) and high density (50M) groups. Error bars 
represent standard deviations. 
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Figure 10.3: Hydroxyproline (HYP) content per construct (A) and per cell (B) (n = 
4). * = statistically significant difference (p < 0.05) from the low density 
group (25M). & = statistically significant difference from week 0. # = 
statistically significant difference between the medium density (25M) and 
high density (50M) groups. The symbols in top brackets represent significant 
differences between the different density groups throughout the whole culture 
period. Error bars represent standard deviations.  
 
HYP content 
The higher density group maintained a higher HYP content per construct 
during the 6-week culture period (5M < 25M < 50M) (p < 0.05) (Fig. 10.3A). The 
high density group had 2.3 and 17 times more HYP content per construct than the low 
density group at weeks 3 and 6 (p < 0.05), respectively, while there was no significant 
difference between the low density and medium density groups at weeks 3 and 6. In 
the high density group, HYP content per construct increased by 2.0 and 2.6 times at 
weeks 3 and 6 relative to week 0 (p < 0.05), respectively. With regard to HYP content 
per cell, the high density group had significantly higher content than the low density 
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group (p < 0.05), while no significant difference was detected between the medium 
and high density groups (Fig. 10.3B). At week 6, the medium and high density groups 
had 6.4 and 9.0 times more HYP content per cell, respectively, than the low density 
group (p < 0.05). Both the medium and high density groups had more HYP content 
per cell at week 6 than at week 0 (p < 0.05), while there were no significant 
differences between weeks 3 and 6. It was interesting that in the low density group, 
the highest HYP content per construct and per cell were observed at week 3, although 
there were no significant difference among weeks 0, 3, and 6.  
 
 
Figure 10.4: Alkaline phosphatase (ALP) activity at weeks 3 and 6 (n = 4). * = 
statistically significant difference (p < 0.05) from the low density group (5M). 
# = statistically significant difference between the medium density (25M) and 
high density (50M) groups. The symbols in top brackets represent significant 
differences between the different density groups throughout the whole culture 
period. Error bars represent standard deviations. 
 
ALP activity 
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The higher density groups had a higher level of ALP activity (measured on a 
per DNA basis) than the lower density groups (5M < 25M < 50M) (p < 0.05) (Fig. 
10.4). At week 6, the medium and high density groups had 38.1% (p > 0.05) and 
53.9% (p < 0.05) more ALP activity than the low density group, respectively. From 
weeks 3 to 6, mean values of ALP activities increased for all three groups, although 
these differences were not statistically significant.  
 
 
Figure 10.5: Calcium content per construct (A) and per cell (B) at weeks 3 and 6 (n = 
4). * = statistically significant difference (p < 0.05) from the low density 
group (5M). # = statistically significant difference between the medium 
density (25M) and high density (50M) groups. @ = statistically significant 
difference between weeks 3 and 6. The symbols in top brackets represent 
significant differences between the different density groups throughout the 
whole culture period. Error bars represent standard deviations.  
 
Calcium content and von Kossa staining 
In general, the higher density constructs had higher calcium content both per 
construct (Fig. 10.5A) and per cell (Fig. 10.5B) than at a lower density (p< 0.05) (5M 
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< 25M < 50M). Only a small amount of calcium (less than 4 μg per construct and 
0.02 ng per cell) was detected in the low density group. Both the medium and high 
density groups at week 6 had 2.9 times more calcium content per construct than at 
week 3 (p < 0.05). Calcium content per cell in the medium and high density groups at 
week 6 was 3.7 and 4.4 times higher than at week 3 (p< 0.05), respectively. The low 
density group maintained calcium content at a low level between weeks 3 and 6, both 
per construct and per cell. von Kossa staining suggested that mineralization increased 
with time and with seeding density (Fig. 10.6), which was consistent with calcium 
quantification. 
 
 
Figure 10.6: von Kossa staining at 3 and 6 weeks (n = 2). The mineralization 
increased with time and seeding density. The scale bar is 50 μm. 5M, 25M, 
and 50M means the low, medium, and high density groups, respectively.  
 
DISCUSSION 
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In this decade, there has been an increasing interest in new cell sources for 
tissue engineering and regenerative medicine. Mesenchymal stem cells (MSCs) with 
multilineage potential have been identified in various tissues including bone 
marrow,318 adipose tissue,188 blood,189, 354 synovial fluid,190 dermis,191 muscle,355 
dental pulp,356 and umbilical cord stroma.80 In the present study, we demonstrated for 
the first time that hUCMSCs harvested from umbilical cord stroma formed bone-like 
tissues in vitro in a 3D biomaterial-based environment. Biochemical assays and 
histological staining revealed the positive ALP activities of hUCMSCs in osteogenic 
medium and the deposition of bone-specific extracellular matrix (calcium and 
phosphate groups) throughout the constructs. We also showed that a higher seeding 
density promoted osteogenic differentiation and matrix production by hUCMSCs in 
PGA scaffolds. These results validated our hypothesis that hUCMSCs can 
differentiate along osteogenic lineage showed that a higher density is results in better 
osteogenic differentiation and matrix biosynthesis than lower densities. 
hUCMSCs are a promising cell source for tissue engineering for numerous 
compelling reasons.200 First, hUCMSCs are developmentally primitive cells that have 
been shown to differentiate along mesenchymal lineages and cross into the 
ectodermal germ layer with neural differentiation.64, 66, 75-77, 80, 195, 202-204, 208, 210, 225 
Second, umbilical cords are in abundant supply and easily accessible, therefore these 
cells have practical advantages over both embryonic stem cells and BMSCs. Thirdly, 
following cell harvesting, hUCMSCs can be expanded 300-fold for over seven 
passages without the loss of differentiation potential.195  The rapid proliferation rate 
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and availability make it possible to obtain a large amount of cells in a short time 
(orders of magnitude larger than BMSCs). Fourthly, there is no donor site morbidity 
and there are no sensitive political issues. hUCMSCs can be frozen at birth (as is 
commonly done with cord blood) as an autologous cell source. Fifth, as an allogeneic 
source, several studies have supported their immunocompatibility and even 
immunosuppressive nature of hUCMSCs.77, 78, 80, 254 In fact, Weiss and colleagues78, 80, 
357 have demonstrated that UCMSCs survived in the extreme case of 
xenotransplantation, with no evidence of a host immune response for up to 12 weeks. 
All of these characteristics make hUCMSCs a suitable, attractive, and potentially 
preferred cell source for tissue engineering. However, the application of hUCMSCs 
for tissue engineering is virtually unexplored with only a few studies conducted in the 
past 3 years, some of which have focused on cardiovascular tissue engineering.65, 205, 
222, 240, 241, 324 Our group has focused on the application of hUCMSCs in cartilage66, 207 
and now bone tissue engineering (the current study). 
In the current study, different seeding densities led to noticeable differences in 
seeding efficiency. The lower seeding efficiency at higher density was explained by 
cell aggregation (the formation of cell clusters) in the medium during the initial 
seeding period. We have improved the seeding efficiency at high densities by 
pipetting the cell solution in two-hour intervals for 8 hours to prevent the formation of 
cell clusters for the future studies. Nonetheless, the higher density groups had more 
cells after seeding and maintained the higher cell numbers compared to the lower 
density groups over the duration of the culture period. The cell number decreased 
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over time in the medium and high density groups. There are several possible 
explanations for this reduction. First, dexamethasone is known to inhibit cell 
proliferation. Second, the degradation rate of PGA scaffolds was faster than the rate 
of matrix production, leading to a decrease in volume over time (the contraction of 
scaffolds). During the contraction, many cells and PGA debris fell into the medium, 
which was observed under a microscope. This cell loss due to degradation has been 
observed in other studies with PGA scaffolds in cartilage tissue engineering207 and 
with collagen scaffolds in bone tissue engineering.138 A scaffold with a slower 
degradation rate (e.g. poly(L-lactic acid) (PLLA), poly(lactic-co-glycolic acid) 
(PLGA)) might help to retain cells in scaffolds. In fact, we have observed in our 
unpublished work that PLLA with hUCMSCs results in over 80% seeding efficiency 
and maintains its original shape in over 6 weeks of culture with hUCMSCs. 
The formation of extracellular matrix and the osteogenic differentiation of 
hUCMSCs were clearly influenced by the initial seeding densities. The constructs in 
the higher density groups had noticeably more HYP and calcium than the lower 
density groups. More importantly, the higher density groups had more HYP and 
calcium content per cell than the lower density groups, indicating that the high 
density promoted extracellular matrix production for the average cell. In addition, the 
high calcium content per cell and ALP activities in the high density group suggest 
that high seeding density improved the osteogenic differentiation of hUCMSCs. It 
was unexpected that the level of ALP activities at week 6 was slightly higher than at 
week 3, since ALP is typically an earlier marker in osteogenic differentiation. 
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However, there were no statistically significant differences between these two time 
points for the different seeding densities. Given that ALP activity is an early 
osteogenic indicator of stem cells,358 we anticipated that ALP activities of hUCMSCs 
before week 3 would be remarkably higher than the ALP level we reported here, 
which illustrates a need for further investigation of ALP activities over time.  
Cell-cell interaction influences cell behavior and extracellular matrix synthesis 
in both 2D359 and 3D349 environments. In this study, cell densities were determined by 
the initial seeding density and scaffold volume. Throughout the 6 weeks of culture, 
the low density group formed a dense pellet with highly packed cells in a small 
amount of extracellular matrix, indicating a high cellularity might hinder extracellular 
matrix synthesis. In contrast, the medium and high density groups with a lower 
cellularity had more active bone-like extracellular matrix synthesis as evidenced by 
the high HYP and calcium content per cell and higher ALP activities. In the future, it 
will be interesting to determine the effect of hUCMSCs cell density on osteogenic 
differentiation by using a more slowly degrading scaffold that provides a fixed 
volume. 
In summary, the osteogenic differentiation of hUCMSCs in a 3D biomaterial-
based environment provides the foundation for future applications of this new cell 
source for bone tissue engineering. A higher seeding density in PGA scaffolds is a 
critically important factor to promote extracellular matrix synthesis and osteogenic 
differentiation. Given the clear advantages of hUCMSCs discussed earlier, and their 
capacity for osteogenic differentiation shown here, we therefore conclude that 
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hUCMSCs are indeed a highly desirable cell source for bone tissue engineering, and 
that a high seeding density is desirable for matrix production and osteogenic 
differentiation in 3D PGA scaffolds. Following this initial proof of concept, the 
optimization of osteogenic culture environment and the use of a scaffold with a 
slower degradation rate should be investigated in the future, with an in depth analysis 
of the quality of mineralization. 
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CHAPTER 11: Signaling Strategies for Osteogenic 
Differentiation of Human Umbilical Cord Mesenchymal 
Stromal Cells for 3D Bone Tissue Engineering* 
 
ABSTRACT 
 
Human umbilical cord mesenchymal stromal cells (hUCMSCs) have recently 
shown the capacity to differentiate into multiple cell lineages in all three embryonic 
germ layers. The osteogenic differentiation of hUCMSCs in monolayer culture has 
been reported, while the differentiation in three-dimensional biomaterials has not yet 
been reported for tissue engineering applications. Thus, the aim of this study was to 
evaluate the feasibility of using hUCMSCs for bone tissue engineering. hUCMSCs 
were cultured in poly(L-lactic acid) (PLLA) scaffolds in either an osteogenic medium 
(OM) or a control medium (CM) for 3 weeks, after which there were five different 
conditions: 1) continuing culture in the CM, 2) continuing culture in the OM, 3) shift 
from culturing in the OM, to a mineralization medium (MM) 4) shift from culturing 
in the OM to the MM with 10 ng/ml insulin-like growth factor (IGF)-I (I10), or 5) 
shift from culturing in the OM, to the MM with 100 ng/ml IGF-I (I100). The 
osteogenic differentiation was confirmed by the up-regulation of Runx2 and OCN, 
calcium quantification, and bone histology. Switching from the OM to the MM 
promoted collagen and calcium per cell, while continuing in the OM retained more 
cells in the constructs and had higher osteogenic gene expression. The addition of 
IGF-I into the MM had no effect on cell proliferation and differentiation and matrix 
synthesis. These results suggest that hUCMSCs seeded on PLLA scaffolds are 
_______________________________________________________________________________ 
*Chapter submitted to J Tissue Eng Regen Med as Wang, Bonewald, and Detamore. “Signaling 
strategies for osteogenic differentiation of human umbilical cord mesenchymal stromal cells for 3D 
bone tissue engineering,” August 2008. 
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suitable for bone tissue engineering and culturing in the OM throughout the entire 
period is beneficial for bone tissue engineering. 
 
INTRODUCTION 
 
Bone tissue engineering is a promising interdisciplinary field, in which cells 
can be integrated into biomaterials to provide a substitute for bone grafts. Indeed, 
human bone marrow mesenchymal stromal cells (hBMSCs) have been translated into 
clinical trials via a tissue engineering approach to treat bone defects successfully in a 
7-year clinical trial. 246, 247 However, there are some known disadvantages associated 
with hBMSCs such as the relative number of hBMSCs in the marrow, a limited 
proliferation ability, and inferior differentiation potential in aged individuals. 248 
Moreover, the invasive and painful harvesting procedure may cause donor site 
morbidity and complications. 249  
Recent evidence has shown that human umbilical cord mesenchymal stromal 
cells (hUCMSCs) are a primitive and multipotent stromal population that shares 
similar characteristics with hBMSCs. 196, 200 hUCMSCs are isolated from the 
Wharton’s Jelly of umbilical cords, a routinely discarded tissue after delivery. They 
are non-hematopoietic cells that can adhere to plastic surfaces for in vitro expansion 
and have many surface markers that are identical to hBMSCs, such as CD73, CD90, 
and CD105. 76, 77, 195, 199, 202, 204 They are multipotent, differentiating along a variety of 
cell lineages in all germ layers such as chondrocytes, osteoblasts, adipocytes, 
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myocytes, neurons, and hepatocytes. 76, 77, 195, 199, 202, 204 Apart from the similarity to 
hBMSCs, hUCMSCs have a number of particular advantages over hBMSCs such as 
extensive availability and supply, no donor site morbidity, fast proliferation, and great 
in vitro expansion ability like other fetus-derived stem cells. All of these features 
render hUCMSCs attractive for tissue engineering as a mesenchymal stromal cell 
(MSC) source. 
hUCMSCs have demonstrated their osteogenic differentiation in two-
dimensional (2D) monolayer culture after exposure to chemical signals containing 
dexamethasone and β-glycerophosphate, 76, 77, 195, 204, 208, 225 and osteoinductive 
biomaterials such as demineralized bone matrix. 239 However, most studies regarding 
osteogenic differentiation of hUCMSCs are reported briefly in a qualitative way with 
histological stains such as Alizarin Red S staining and von Kossa staining. 76, 77, 195, 
204, 208, 225 In addition, osteogenic differentiation of hUCMSCs in three-dimensional 
(3D) biomaterials is still unexplored in the literature. In our group, we have 
previously revealed that osteogenic differentiation can be achieved in polyglycolic 
acid (PGA) scaffolds, although the rapid degradation rate of PGA led to a loss of cells 
and construct integrity (unpublished data). Like PGA, poly(L-lactic acid) (PLLA) has 
been extensively investigated in tissue engineering applications with good 
biodegradability, biocompatibility, and mechanical properties, but is more slowly 
degraded. In a phosphate-buffered solution (PBS) at 37 °C, quenched PGA 
demonstrated a rapid decrease in mass after 10 days, 325 while in another study, 360 
PLLA meshes almost had no loss of mass after 35 weeks in the same buffer. 
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Therefore, non-woven PLLA meshes were used in the current study as support for 
cell growth and bone formation during the in vitro osteogenesis of hUCMSCs.  
The majority of bone tissue engineering studies using BMSCs have been 
conducted with an osteogenic medium (OM) throughout the entire culture period (up 
to 6 weeks), 138, 361 although osteogenic differentiation of BMSCs can be 
accomplished in 2-3 weeks with extensive mineralization. 58, 351, 358 However, it is 
unknown how the OM affects the differentiated MSCs. Thus, in the current study, we 
cultured hUCMSCs with the OM in slowly degrading PLLA scaffolds for 3 weeks, 
and then removed osteogenic components (dexamethasone and Vitamin D3) to expose 
pre-differentiated hUCMSCs to a mineralization medium (MM) and an insulin-like 
growth factor (IGF)-I-containing MM for another 3 weeks. The negative and positive 
controls were no and continued exposure to osteogenic components, respectively. The 
goal of this study was to examine in vitro osteogenesis with both qualitative and 
quantitative data and determine the effects of the medium shift on osteogenically-
induced hUCMSCs.  
 
MATERIALS AND METHODS 
 
Isolation and culture of hUCMSCs 
IRB approval was obtained for human umbilical cord collection and hUCMSC 
isolation from KU-Lawrence (no. 15402) and the KU Medical Center (no. 10951). In 
this study, two human umbilical cords (both female, 15 and 23 cm long) were first cut 
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into 3-5 cm segments, from which vessels were then removed. Cord segments were 
cut into 1-2 mm3 pieces and incubated at 37°C in 0.75 mg/ml type II collagenase (298 
U/mg; Worthington Biochemical; Lakewood, NJ). A 5-hr incubation yielded a 
homogenous gelatinous solution, which was then diluted (1:8) in sterile phosphate 
buffered saline (PBS). hUCMSCs were obtained by centrifugation and then 
resuspended in an expansion medium containing low-glucose Dulbecco's modified 
Eagle's medium (DMEM-LG; Invitrogen, Carlsbad, CA), 10% MSC-qualified fetal 
bovine serum (FBS; StemCell Technologies, Vancouver, BC, Canada), and 1% 
penicillin/streptomycin (PS; Invitrogen). Cells were plated in cell culture flasks at 
8000 cells/cm2, expanded to 80-90% confluence (recorded as P0 cells) and detached 
by 1X trypsin (Invitrogen). Following a previously described procedure, 207 P0 cells 
were cryogenically stored in liquid nitrogen at -196°C for future use. 
 
Scaffold preparation, cell seeding and differentiation 
hUCMSCs were thawed and expended in the expansion medium to P4 for cell 
seeding. Cylinder-shaped scaffolds (n = 83), 5 mm in diameter and 2 mm in 
thickness, were cut out of non-woven PLLA meshes (> 95% porosity and 45–55% 
crystallinity; Biomedical Structures, Warwick, RI, USA). The scaffolds were 
sterilized in a sterile pouch using ethylene oxide and then placed in a fume hood. 
Before seeding, scaffolds were wetted with sterile-filtered ethanol followed by two 
PBS washes, and then immersed for one day in the expansion medium. P4 hUCMSCs 
were resuspended in the expansion medium and then seeded at 25 x106 cells per ml of 
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scaffold into PLLA scaffolds using an orbital shaker at 150 RPM according to a 
previously described protocol 340. The expansion medium was referred as to the 
control medium (CM) over the following culture period. After a 2-day seeding period 
(week 0), some of the scaffolds were continually cultured in the CM and the 
remaining were cultured in the OM by replacing the CM with 1.5 ml of the OM, 
consisting of the CM supplemented by 100 nM dexamethasone (DEX; Sigma, St. 
Louis, MO), 5 mM β-glycerophosphate (β-GP; Sigma), 10 nM 1α,25-
Dihydroxyvitamin D3 (VD3; BIOMOL International, Plymouth Meeting, PA), and 50 
μg/ml ascorbic acid 2-phosphate (AA2P; Sigma). After 3 weeks, there were five 
different culture conditions: (1) continue culture in the CM, (2) continue culture in the 
OM, (3) change culture from the OM to the MM, which consisted of the OM without 
DEX and VD3, (4) change culture from the OM to the MM with 10 ng/ml IGF-I 
(I10), or (5) change culture from the OM to the MM with 100 ng/ml IGF-I (I100). 1 
ml of medium was changed every other day, except for the complete replacement at 
weeks 0 and 3. 
 
Biochemical assays 
Constructs (n = 4) were homogenized in 1.2 ml papain solution (120 μg/ml) 
and then incubated at 60 °C overnight. A PicoGreen kit (Invitrogen) was used to 
determine DNA contents according to the manufacturer’s protocol. A hydroxyproline 
(HYP) assay was used to obtain HYP content by using as described previously. 207 A 
conversion factor of 8.5 pg DNA/cell was used to convert DNA content to cell 
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number, and a conversion factor of 11.5 can be used to convert HYP mass to collagen 
mass, based on our preliminary studies. 
Calcium content was quantified by an OCPC (ortho-cresolphthalein 
complexone) method as described in the literature. 353 Constructs (n = 4) were 
homogenized and suspended in 1N acetic acid (Sigma) overnight. 50 μl of this culture 
sample or a standard solution (0–100 mg/ml CaCl2; Sigma) was added into 250 μL of 
working solution. The working solution contained 0.05 mg/ml OCPC solution (1 
mg/ml OCPC, 0.0063 N KOH and 0.0031 N acetic acid) (Sigma), 0.74M 
ethanolamine/boric acid buffer (pH 11; Sigma), and 2% 8-hydroxyquinoline (5 g in 
100 mL of 95% ethanol; Sigma). This mixture was incubated at room temperature for 
10 min and then read at 575 nm. 
 
Histology 
Frozen sections (10 μm, n = 2) were used for histological analysis. Alizarin 
Red S and von Kossa staining were used to visualize the mineralization. Sections 
were fixed in 10% phosphate-buffered formalin for 20 min and then rinsed in 
ultrapure water before staining. For Alizarin Red S staining, sections were incubated 
with 2% Alizarin Red S reagent (PH = 4.1 - 4.3; Sigma) for 5 min. For von Kossa 
staining, sections were incubated with 1% silver nitrate solution (Sigma) under 
ultraviolet light for 20 minutes and then with 5% sodium thiosulfate (Sigma) for 5 
minutes to remove un-reacted sliver. Finally, all sections were rinsed in ultrapure 
water and dehydrated through graded alcohol (95% and 100% twice each). 
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RNA isolation and real-time RT-PCR 
Total RNA was extracted from cells using 1 ml of Trizol reagent (Invitrogen) 
following the manufacturer’s instructions (n = 4). Total RNA concentration and 
purity were determined on a spectrophotometer (Nanodrop; Wilmington, DE). The 
mRNA samples were then converted to cDNA using a High-Capacity cDNA Archive 
kit (Applied Biosystems, Foster City, CA) following the supplier’s procedure. 
TaqMan gene expression assay kits (Applied Biosystems) were used for transcript 
levels of type I collagen (CI), runt-related transcription factor 2 (Runx2), and 
osteocalcin (OCN) using a real-time reverse transcriptase polymerase chain reaction 
(real time RT-PCR) in an Applied Biosystems 7500 System. TaqMan gene expression 
assay kits (Applied Biosystems) were Hs00164004_m1 for type I collagen, 
Hs00231692_m1for Runx2, Hs01587813_g1 for OCN, and Hs99999905_m1 for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). A 2−ΔΔCt method was used to 
evaluate relative the mRNA expression level for each target gene. 312 Briefly, ΔCt 
values were obtained by the difference between the Ct values of target genes and the 
GAPDH gene. They were then normalized by subtracting the ΔCt value of the 
calibrator sample, their respective Ct values in the CM groups, to obtain ΔΔCt values. 
 
Statistical analysis 
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All data were expressed as means ± one standard deviation, and analyzed by 
one-way ANOVAs followed by Tukey’s Honestly Significant Difference post hoc 
tests. Statistical significance was determined by a statistical threshold of p < 0.05. 
 
RESULTS 
 
Cell number 
Over the 6-week culture period, cell number decreased in all groups (p < 0.05) 
compared to week 0 (Fig. 11.1). Despite the cell loss throughout the culture period,  
 
 
Figure 11.1: Cell number per construct (n = 4). CM = control medium, OM = 
osteogenic medium, MM = mineralization medium, I10 = MM containing 10 
ng/ml IGF-I, and I100 = MM containing 100 ng/ml IGF-I. * = statistically 
significant difference (p < 0.05) from week 0. # = statistically significant 
difference (p < 0.05) from the OM group at weeks 3 or 6. @ = statistically 
significant difference (p < 0.05) in the OM group between weeks 3 and 6. 
Error bars represent standard deviations. A conversion factor of 8.55 pg 
DNA/cell was used to convert DNA content to cell number.  
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 the OM groups at weeks 3 and 6 retained 1.67 and 1.50 times more cells in the 
constructs than the CM groups, respectively (p < 0.05). From weeks 0 to 3, the cell 
number decreased by 46% in the CM group (p < 0.05), while only decreasing by 10% 
in the OM group without statistical significance. In contrast, from weeks 3 to 6, the 
cell number decreased in the CM group only by 10% without statistical significance, 
while decreasing by 19% in the OM group (p < 0.05). The medium change at week 3 
(from OM to MM, I10, and I100) caused a decrease in cell number (p < 0.05) and 
there were no significant differences in cell number between the MM, I10, and I100 
groups. 
 
HYP content 
In all groups but the CM group, the HYP content per construct and per cell 
increased over time, with a substantial leap from weeks 0 to 3 (p < 0.05) (Fig. 11.2). 
In the CM groups, the HYP content per construct did not vary over the 6-week culture 
period and the HYP content per cell had a slight increase without statistical 
significance. The OM group had 4.2 and 3.5 times more HYP per construct than the 
CM group at weeks 3 and 6, respectively (p < 0.05), and had 2.5 and 2.4 times more 
HYP per cell than the CM group at weeks 3 and 6, respectively (p< 0.05). The shift 
from OM to MM, I10, or I100 did not affect the total HYP content per construct, 
while this change did lead to an up-regulation of HYP synthesis, given that the HYP 
content per cell was approximately 50% greater in the MM, I10 and I100 groups 
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compared to the OM group at week 6 (p< 0.05). Like the cell number, HYP synthesis 
was not influenced by the addition of IGF-I into the MM. 
 
 
Figure 11.2: Hydroxyproline (HYP) content per construct (A) and per cell (B) (n = 
4). CM = control medium, OM = osteogenic medium, MM = mineralization 
medium, I10 = MM containing 10 ng/ml IGF-I, and I100 = MM containing 
100 ng/ml IGF-I. * = statistically significant difference (p < 0.05) from week 
0. # = statistically significant difference (p < 0.05) from the OM group at 
weeks 3 or 6. Error bars represent standard deviations. 
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Figure 11.3: Calcium content per construct (A) and per cell (B) (n = 4). CM = 
control medium, OM = osteogenic medium, MM = mineralization medium, 
I10 = MM containing 10 ng/ml IGF-I, and I100 = MM containing 100 ng/ml 
IGF-I. * = statistically significant difference (p < 0.05) from week 0. # = 
statistically significant difference (p < 0.05) from the OM group at weeks 3 or 
6. @ = statistically significant difference (p < 0.05) between weeks 3 and 6. 
Error bars represent standard deviations. 
 
Calcium content  
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There was a considerable increase in calcium content per construct and per 
cell with time in all groups over the culture period (p < 0.05) (Fig. 11.3). Calcium 
deposition was also observed in the CM group, albeit at a low level. However, the 
OM group did exhibit more calcium per construct and per cell than the CM group at 
weeks 3 and 6 (p < 0.05). At week 6, there was no significant difference in calcium 
content per construct among the OM, MM, I10, and I100 groups, while the MM and 
I100 groups had 1.32 and 1.29 more times calcium content per cell than the OM 
group, respectively (p< 0.05). No significant differences were observed in calcium 
content per cell among the MM, I10, and I100 groups. 
 
 
Figure 11.4: Alizarin Red S staining and von Kossa staining at 3 and 6 weeks (n = 2). 
CM = control medium, OM = osteogenic medium, MM = mineralization 
medium, and I100 = MM containing 100 ng/ml IGF-I. The scale bar is 500 
μm.  
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Histology 
Alizarin Red S staining was consistent with von Kossa staining, both of which 
revealed a positive mineral deposition that increased with time (Fig. 11.4). The CM 
groups had weaker staining than the OM groups, which was consistent with the 
calcium quantification. It must be noted that there was a stronger staining at the 
peripheral area of the constructs than inside the constructs. There were no discernible 
differences among the OM, MM, and I100 groups. 
 
 
Figure 11.5: Gene expression (normalized to the CM group) for type I collagen (CI), 
runt-related transcription factor 2 (Runx2), and osteocalcin (OCN) at week 6 
(n = 4). CM = control medium, OM = osteogenic medium, MM = 
mineralization medium, I10 = MM containing 10 ng/ml IGF-I, and I100 = 
MM containing 100 ng/ml IGF-I. # = statistically significant difference in 
Runx2 gene expression between the OM and CM groups (p < 0.05). & = 
statistically significant difference in OCN gene expression between the OM 
group and all other groups (p < 0.05). Error bars represent standard deviations. 
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Gene expression levels of CI, Runx2, and OCN 
Runx2 and OCN gene expression was up-regulated in the OM group (p < 
0.05) (Fig. 11.5). There were no statistically significant differences in type I collagen 
gene expression among all groups. After a change from the OM, the MM group had a 
lower gene expression of CI, Runx2 (p < 0.05), and OCN when compared to 
continuing treatment with the OM medium. The addition of IGF-I into the MM did 
not statistically affect the gene expression level of Runx2, OCN, or type I collagen. 
 
DISCUSSION AND CONCLUSION 
 
 
In the field of tissue engineering, it is critical to select a promising cell source 
that is easy to obtain, and provides sufficient cell numbers. hUCMSCs undoubtedly 
meet these requirements. There is an abundant supply of umbilical cords, with 4.1 
million births in the United States alone in 2005. 257 After cell isolation, hUCMSCs 
can achieve a 300-fold cell increase in 7 passages while maintaining differentiation 
potential. 195 In vivo transplantation of these cells has demonstrated their regenerative 
effects on brain injuries and retinal disease in animal models, while immunorejection 
was not observed in these studies. 213, 214 All previous osteogenic differentiation 
studies with hUCMSCs have been performed in monolayer (2D). 76, 77, 195, 204, 208, 225 In 
the current study, we presented the osteogenesis of hUCMSCs in vitro in a 3D 
biomaterial-based environment, thus supporting the use of hUCMSCs for bone tissue 
engineering. 
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The Runx2 gene is known to play an essential role in osteoblast differentiation 
and bone formation. 362, 363 The disruption of Runx2 leads to the termination of 
intramembranous and endochondral ossification due to the maturational arrest of 
osteoblasts.364 The in vitro osteogenic differentiation of MSCs is accompanied by the 
up-regulation of Runx2 gene expression at the early stage. 365 The OCN gene is 
mainly expressed by mature osteoblasts and responsible for the mineralization at the 
late stage of differentiation. Exposed to the OM, hUCMSCs did show an up-
regulation of the gene expression of Runx2 and OCN compared to the CM group, 
indicating osteogenic differentiation of these cells. Compared to the MM, I10 and 
I100 groups, the OM is also beneficial for the osteogenic differentiation due to the 
higher Runx2 and OCN gene expression. The positive staining of Alizarin Red S and 
von Kossa staining confirmed the presence of mineralization, suggesting that the 
hUCMSCs were progressing down an osteogenic lineage. In contrast to 
mineralization, collagen content increased mainly between weeks 0 to 3 and was 
maintained between weeks 3 to 6. In native normal bone, the nucleation and 
development of mineral crystals interacts principally with collagen. 366 The abundant 
collagen production may have contributed to the boost of mineralization between 
weeks 3 and 6. 
The OM also promoted cell proliferation and/or inhibited cell loss compared 
to other media. This effect was mainly due to the presence of DEX and VD3 in the 
OM, rather than AA2P and β-GP, based on the observation that the MM group had a 
comparable cell number range with the CM group after switching the medium at 
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week 3. A few studies have demonstrated an inhibitory effect of either DEX or 
Vitamin D3 on cell proliferation, 367-369 although they can induce osteogenic 
differentiation. 358, 370, 371 In monolayer culture, we also observed in a previous study 
that DEX inhibited hUCMSC proliferation (unpublished data). Thus, the increase in 
cell number with the OM group in the current study indicated that the combination of 
DEX and VD3 might have a synergetic effect on hUCMSC proliferation and/or 
survival. It must be noted that this stimulation decreased with time (Fig. 11.1) and 
might achieve a plateau in cell number similar to the CM group after a longer culture 
period, which would be of interest to investigate in the future. 
The MM had no impact on the total collagen and calcium content in the 
constructs, although they had a slight higher collagen and calcium per cell. Moreover, 
the shift from the OM to the MM led to a decrease in osteogenic gene expression 
including CI, Runx2 and OCN. IGF-I plays an important role as an anabolic agent in 
bone development at all stages, 337, 338, 372 and regulates MSC proliferation and 
biosynthesis. 373, 374 In the current study, the addition of IGF-I into the MM had no 
beneficial effects on cell proliferation, matrix production or gene expression. In the 
future, the incorporation of IGF-I at an earlier stage, and/or in addition to osteogenic 
signals as opposed to in lieu of them, might facilitate the osteogenic differentiation of 
MSCs. 374 
In summary, the results demonstrated the osteogenic differentiation of 
hUCMSCs in PLLA scaffolds with the up-regulation of bone-specific genes and 
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mineral deposition, thus supporting the feasibility of applying hUCMSCs to bone 
tissue engineering. Therefore, given the numerous advantages over adult stem cells 
and the successful osteogenesis in 3D biomaterials, hUCMSCs may be a promising 
alternative for bone tissue engineering. A future side-by-side comparison between 
hUCMSCs and hBMSCs in a 3D biomaterial environment will be interesting and 
meaningful to further evaluate the potential of hUCMSCs in bone tissue engineering. 
In the current study, there was no advantage to removing DEX and VD3 after 3 
weeks, as in fact the only group to retain these factors (i.e., the OM group) produced a 
greater number of cells and expressed the highest level of osteogenic genes. Future 
strategies may include earlier introduction of IGF-I and/or extended exposure of DEX 
and VD3. 
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CHAPTER 12: Conclusion 
 
This thesis was motivated by the need for new cell sources for TMJ condyle 
tissue engineering. The osteochondral structure of the TMJ condyle necessitates 
engineering cartilage and bone tissue concurrently, and hUCMSCs provide a single 
cell source to fulfill that task. Indeed, this thesis presented evidence of the successful 
differentiation of fibro-chondrocytes and osteoblasts in 3D biomaterials, which filled 
a major void in the literature regarding the use of hUCMSCs for musculoskeletal 
tissue engineering. The refinement of cell-scaffold culture parameters, including 
seeding densities and signaling strategies, resulted in a biologically and mechanically 
closer substitute for native TMJ tissues that provides more cells, better differentiation, 
and a more abundant extracellular matrix. These results undoubtedly validated the 
overall hypothesis that TMJ condyle tissue engineering would be achieved in vitro 
using hUCMSCs. 
hUCMSCs differentiated along chondrogenic and osteogenic lineages in 
scaffolds, as evidenced by the existence of type II collagen and aggrecan with 
chondrogenesis and the presence of mineralization, ALP activity, and up-regulation 
of osteogenic gene expression with osteogenesis. hUCMSCs surpassed mature TMJ 
cells and hBMSCs for TMJ cartilage regeneration with more cells and matrix content. 
In addition, as a mature cell source, in vitro culture of hyaline cartilage cells formed a 
TMJ-like fibrocartilage tissue with superior biosynthesis. Therefore, both hUCMSCs 
and hyaline cartilage cells provided superior alternatives to TMJ cells themselves. In 
the future, the comparison between hyaline cartilage and hUCMSCs can be made. An 
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advantage that mature cells possess over various types of stem cells is the absence of 
the variable of differentiation and the reduced possibility of metaplasia. However, 
even if hUCMSCs have a performance that is comparable to that of hyaline cartilage 
cells, hUCMSCs will be preferred because of their extensive availability and their 
non-invasive harvest among other reasons. 
A higher cell seeding density (> 25M) was recommended for both cartilage 
and bone tissue engineering. Higher densities promoted greater cell proliferation and 
differentiation and extracellular matrix synthesis than the lower densities and, more 
importantly, helped to retain the mechanical integrity of scaffolds. In both studies, 
PGA scaffolds experienced massive degradation and caused cell and matrix loss into 
the medium from the constructs. Therefore, in the future, more slowly degrading 
scaffolds, such as PLLA and PLGA, will need to be investigated for maintaining the 
original shape of the scaffolds, which will facilitate the integration of cartilage and 
bone to create an osteochondral TMJ condyle. In fact, PLLA scaffolds did maintain 
their initial shape during osteogenic differentiation over a 6-week period (Chapter 
11). 
Switching from differentiation media to anabolic media containing (IGF-I) 
was beneficial for cartilage tissue engineering using hUCMSCs, while it was not 
rewarding when attempting bone tissue engineering. When compared to the continued 
use of TGF-β3 for cartilage tissue engineering, switching to IGF-I increased collagen 
production and type II collagen gene expression and immunostaining. However, in 
bone tissue engineering, IGF-I did not affect the osteogenic differentiation and matrix 
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synthesis with hUCMSCs. Continuing in osteogenic media resulted in more cells, 
comparable matrix content, and a higher gene expression level of bone-specific 
markers than switching to mineralization media containing IGF-I or no IGF-I. In the 
future, an IGF-I concentration larger than 100 ng/ml may be warranted to investigate 
the manifestation of its anabolic effects on osteogenically induced hUCMSCs. 
Moreover, the incorporation of IGF-I at an earlier stage, and/or in addition to 
osteogenic signals as opposed to in lieu of them, might facilitate the osteogenic 
differentiation of MSCs. Finally, the sequential signaling strategy of initial 
differentiation followed by anabolic signaling might be beneficial for any other tissue 
engineering area involving the use of stem cells. 
In summary, tissue engineering of TMJ condylar cartilage and bone was 
accomplished in vitro separately with refined culture parameters. The immediate next 
step will be to integrate tissue-engineered cartilage and bone to create an 
osteochondral construct that mimics the native structure of TMJ condyle. It must be 
noted that the application of these findings includes, but is not limited to, TMJ 
condylar cartilage and bone and can be translated to a broader area in orthopedic 
research, including other fibrocartilage tissues, such as TMJ discs, intervertebral 
discs, knee menisci, tendons and ligaments, and bone tissue in other joints, such as 
the knee, shoulder, and hip. In addition, with the modification of bioactive signals in 
chondrogenic differentiation, hUCMSCs can be used for hyaline cartilage tissue 
engineering and osteochondral tissues consisting of hyaline cartilage and bone tissues 
(e.g., femoral and tibial condyles). 
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